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 The glmS riboswitch undergoes self-cleavage upon binding its metabolic product 
GlcN6P, thereby providing a negative feedback mechanism limiting translation of the 
glmS protein when GlcN6P is abundant.  As a first step toward the development of novel 
antimicrobials, we have synthesized a series of GlcN6P analogues bearing phosphatase-
inert surrogates in place of the natural phosphate ester functionality. The self-cleavage 
assay identified two such compounds that display significant riboswitch actuator activity; 
namely those bearing a 6-phosphonomethyl group or a 6-O-malonyl ether.  These two 
analogues exhibit a 22-fold and a 27-fold higher catalytic efficiency, respectively, than 
does glucosamine. Docking experiments were conducted to provide insight into the 
structural basis for SAR (Structure/Activity Relationship) seen across this battery of 
GlcN6P analogues and directions for future design of such small molecule actuators.  
M6P/IGF2R regulates intracellular sorting of lysosomal enzymes, as well as 
endocytosis of extracellular ligands. To explore the possibility of multivalent receptor-
ligand interactions, we have utilized novel chemistries to synthesize “tailored” bivalent 
ligands. A “linker diversification” approach has been recently developed. It emanates 
from a monomer with a terminal azide. Five different chemistries were exploited to 
connect two monomers together, leading to five structurally and functionally distinct 
linkages. The assay showed that when the angles between two linking bonds are acute 
rather than obtuse, the corresponding ligands present higher binding affinity, suggesting 
the three dimensional shape of the ligand is crucial for achieving multivalency.  
The ISES technique has proven to be a useful technique for catalyst screening. In 
this procedure, an organic reaction product or byproduct diffuses into an aqueous layer, 
wherein an enzymatic transformation leads to signal that can be monitored by UV/vis 
spectroscopy.  Herein, we describe proof of principle of a miniaturized ISES assay, in 
which volumes are significantly reduced by utilizing a quartz micromulticell. This 
miniaturized ISES platform is used to examine a 4  4 combinatorial library of salen 
ligands, that is derived from both oxa- and carbacyclic D-fructopyranosyl-1,2-diamines. 
The Co(III)-salen derived from 3’,5’-diiodo-salicylaldehyde and -D-
carbafructopyranosyl-1,2-diamine shows the highest chiral bias. X-ray crystallographic 
analysis reveals important structural differences between the more selective 
carbofructopyranosyl-1,2-diamine-derived salens and their oxacyclic counterparts. 
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Chapter 1  
Overview of Phosphonates in Bioorganic Chemistry 
Phosphonic acids, sometimes termed C-P compounds are a type of compound that 
contain the C-P(O)(OH)2 moiety. The acid, salt and ester forms are generally referred to 
as phosphonates. Perhaps organic chemists encounter phosphonates more often when 
using them in the Horner–Wadsworth–Emmons reaction. However, this overview will 
focus on the phosphonates that are produced either in nature or in laboratories, to imitate 
biologically relevant phosphates or carboxylates. 
I. Naturally Occurring Phosphonates  
The first report of a phosphonate in a living system was in 1959, published in 
Nature by Horiguchi and Kandatsu.1 While examining the amino acid composition of 
rumen protozoa from sheep, they observed a ninhydrin-positive substance which was 
later crystallized and determined to be 2-aminoethanephosphonic acid (AEP). This 
discovery opened a new chapter in the chemical biology of phosphorus metabolism. The 
unprecedented naturally-occurring C-P bond inspired biochemists in the years that 
followed to search for new phosphonates and novel enzymes in their biosynthetic 
pathways. After 55 years of exploration, a wealth of novel structures containing C-P 
bonds have been unveiled from various natural sources (Fig. 1.1).2 Most of these 
compounds possess potent biological activities due to their structural similarities with the 
native carboxylates or phosphates. Herein, a few examples are elaborated to demonstrate 
the importance and the rising interest of these underexplored compounds in recent years.  
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Figure 1.1: Structures of naturally-occurring phosphonates 
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A. Fosfomycin/Fosphonomycin 
The discovery of fosfomycin was announced in 1969 by Hendlin and colleagues, 
under its former name fosphonomycin.3 This “new antibiotic” from strains of 
Streptomyces combines two unusual features: an epoxide ring and a carbon-phosphorus 
bond. In 1974, Kahan and colleagues studied the mechanism of action for its 
antimicrobial activities. They proposed that fosfomycin is an irreversible inhibitor of 
bacterial cell wall biogenesis.4 More specifically, analogous to phosphoenolpyruvate 
(PEP), fosfomycin competes for binding to UDP-N-acetylglucosamine enolpyruvyl 
transferase (or MurA). MurA catalyzes the first committed step in peptidoglycan 
biosynthesis, ligating PEP to the 3’-hydroxy group of UDP-N-acetylglucosamine (Fig. 
1.2).5 An active site cysteine residue opens the epoxide ring of fosfomycin, resulting in 
the irreversible inactivation of the enzyme. Today, in the United States, fosfomycin 
tromethamine salt is used to treat urinary tract infections under the trade name Monurol®. 
Recently, the combination of fosfomycin and tobramycin was also used in clinical studies 
for treatment of cystic fibrosis.6  
Figure 1.2: Irreversible inactivation of Fosfomycin on MurA 
4 
 
B. 2-Amino-5-Phosphono-3-Pentenoic  Acid (APPA)  and  APPA-Containing 
Peptides: Plumbemycins and Rhizocticins  
In 1977, Park, Hirota and Sakai isolated two peptide antibiotics from 
Streptomyces plumbeus: Plumbemycin A [(L)-Ala-(L)-Asp-(L,Z)-APPA] and 
Plumbemycin B [(L)-Ala-(L)-Asn-(L,Z)-APPA].7 The non-proteinogenic amino acid (L, 
Z)-APPA8 was later found at the C-terminus of the antifungal agents, Rhizocticins, as 
well.9 It is believed that both plumbemycins and rhizocticins enter the cells through 
oligopeptide transport systems (Fig. 1.3).10-11  
 
 
 
 
 
 
 
Host oligopeptidases cleave the peptides, releasing the warhead (L,Z)-APPA 
which inhibits the pyridoxal 5’-phosphate dependent enzyme, threonine synthase (TS).12 
TS catalyzes the last step of threonine biosynthesis, which converts homoserine-O-
phosphate to L-threonine. Structurally resembling the substrate homoserine-O-phosphate, 
(L,Z)-APPA competes for binding to TS, thereby interfering with the biosynthesis of 
Figure 1.3: Mechanism of action for the APPA-Containing Peptides 
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threonine, ultimately leading to the inhibition of cell growth.13 It is noted that the 
selectivity of these antimicrobials is determined by the proteinogenic amino acids 
attached to the (L,Z)-APPA. The specific sequences of these peptides can be 
differentiated by oligopeptide transporters from varied organisms.14 This is a nice 
prodrug strategy, demonstrated by Nature, that exploits a short peptide to deliver an 
active agent and selectively target a particular organism. In addition to the naturally-
occurring Z-APPA, synthetic E-APPA has been studied, as well, mostly as a reversible 
inhibitor of cystathionine -synthase (synthesizes cystathionine from cysteine and 
homoserine phosphate).15 
C. FR-900098 and Fosmidomycin 
 
 
 
 
 
 
 
Figure 1.4: Inhibition of DOXP reductase by FR-900098 and 
fosmidomycin  
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FR-900098 and fosmidomycin were isolated from strains of Streptomyces 
rubellomurinus and Streptomyces lavendulae, respectively, by researchers at Fujisawa 
Pharmaceutical Co..16-17 These compounds inhibit isoprenoid biosynthesis by blocking 1-
deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase (Fig. 1.4).18 This enzyme 
catalyzes the first committed step in the non-mevalonate pathway for biosynthesis of 
isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), the 
fundamental building blocks for isoprenoid biosynthesis.19-21 Probably because both IPP 
and DMAPP are biosynthesized via the mevalonate pathway in animals and humans, 
FR900098 and fosmidomycin displays limited toxicity for mammalian cells. In addition 
to their antibacterial activities, FR900098 and fosmidomycin also display potent 
antimalarial activity, owing to the unexpected presence of the non-mevalonate pathway in 
Plasmodium falciparum, the most common causative agent of malaria. Indeed, 
fosmidomycin and its clindamycin combination have already shown great promise in 
early human trials for treating malaria, including showing activity against drug-resistant 
strains.22-24 
D. Latest Discoveries 
 
 
 
 
 
 
Figure 1.5. The essential enzyme pepM in phosphonate 
biosynthesis  
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The majority of phosphonate natural products were isolated in the 20th century. 
However, new phosphonates continue to be discovered thanks to newly developed 
detection technologies and recent advances in genome mining. In the last two years, a 
number of novel phosphonates have been uncovered from various organisms. 
Phosacetamycin is N-acetylated Z-APPA that inhibits growth of both bacteria and 
fungi.25 Furthermore, Phosphoiodyn A bears a polyacetylene chain that is terminated with 
an unprecedented vinyl iodide.26 Phosphoiodyn A exhibited significant agonistic activity 
toward human peroxisome proliferator-activated receptor delta (hPPAR). It displayed an 
EC50 of 23.7 nM for hPPAR activation and over 200-fold selectivity compared with 
other subtypes (hPPAR and hPPAR).  
Recently, Metcalf et al conducted a large-scale genome mining for the presence 
of pepM,27 which encodes the essential enzyme phosphoenolpyruvate phosphonomutase 
found in most phosphonate biosynthetic pathways (Fig. 1.5). From one of the pepM 
positive strains, Streptomyces regensis strain WC-3744, a unique cyanohydrin-containing 
phosphonate, cyanophos, was isolated.28 Considering the rarity of nitrile compounds in 
Nature,29 the discovery of this phosphonate is particularly exciting, and it certainly 
expands the structural diversity of known naturally occurring phosphonates. 
In summary, recent years have seen a renewed interest in the study of naturally 
occurring phosphonates. Nevertheless, natural C-P compounds remain understudied 
metabolites. The enzymes involved in their biosynthetic pathways represent even more 
intriguing subjects for biochemical studies. Given the great potential associated with 
these compounds, more effort and resources will be devoted to this topic.  
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II. Synthetic phosphonates  
Synthetic phosphonates have played important roles in the pharmaceutical and 
agrochemical industries.30 It is not an exaggeration to say that these molecules have 
changed our world. In this overview, three examples are discussed in detail to 
demonstrate the great impact that these compounds have brought to our lives.  
A. Glyphosate/Roundup 
Under the tradename “Roundup”, glyphosate is a broad-spectrum herbicide that 
was discovered by Monsanto in the 1970s.31 It kills weeds by blocking the shikimate 
pathway of aromatic amino acid biosynthesis.32 Glyphosate targets 5-
enolpyruvylshikimate 3-phosphate (EPSP) synthase (EC 2.5.1.19), which converts 
shikimate-3-phosphate (S3P) and phosphoenolpyruvate (PEP) into EPSP via a ternary 
enzyme-substrate complex.33 Analogous to the transient PEP oxonium ion, glyphosate 
occupies the PEP binding site to form a more tightly bound ternary complex with S3P 
which slowly decrease the enzyme activity (Fig. 1.6). The formation of an EPSP 
synthase-S3P-glyphosate complex has been confirmed by X-ray crystallography.34 In 
addition, kinetic studies have shown that glyphosate inhibits EPSP synthase in an 
uncompetitive manner.35 Hence, glyphosate is a textbook example of uncompetitive 
inhibitors that bind not to the free enzyme, but rather, to the enzyme-substrate complex.  
After its introduction to the market in 1974, glyphosate was quickly adopted by 
farmers due to its broad spectrum of activity and relatively low toxicity compared with 
other herbicides. It has grown even more popular since Monsanto induced genetically 
modified crops (termed “Roundup Ready System”) that resist the herbicide. In 2007, 
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glyphosate became the most used herbicide in the United States agricultural industry, 
with 180 to 185 million pounds applied that year.36 Nevertheless, recent years have seen 
rising concerns over the effect of glyphosate on the environment and human health. A 
2014 article published in Food Chemistry implies that Roundup Ready soybeans have a 
high residual level of accumulated glyphosate, that could have “potential consequences 
for human and animal health”.37 
 
 
 
 
 
 
 
 
 
B. Bisphosphonates 
Bisphosphonates are hydrolytically stable analogs of pyrophosphate (Fig. 1.7). 
The first reported synthesis of a bisphosphonate dates back to 1865 by German chemist 
Menschutkin.38 However, in the following century, bisphosphonates were only developed 
Figure 1.6: EPSP synthase and its inhibition by glyphosate  
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for industrial uses, mainly in the textile, fertilizer and oil industries.39 In 1968, following 
the discovery that inorganic pyrophosphate inhibits both precipitation and dissolution of 
calcium phosphate,40 analogous bisphosphonates were used in the studies of calcium 
metabolism.41 This represents the first biological study of bisphosphonates. One year 
later, the collaboration between the Fleisch group (University of Berne, Davos, 
Switzerland) and David Francis (Procter & Gamble, Ohio, US) led to two seminal papers, 
published back to back in Science, which demonstrated for the first time that 
bisphosphonates are powerful inhibitors for both tissue calcification and bone 
resorption.42-43 It is clear that, as is the case for the native pyrophosphate, 
bisphosphonates inhibit the formation of calcium phosphate crystals through calcium-
chelating abilities, thereby preventing the calcification of soft tissues.42 However, the 
mechanisms are more complicated for their use to prevent loss of bone mass.  
The originally conceived theory that bisphosphonates inhibit dissolution of 
calcium phosphate appears unlikely in vivo.39 Instead, most bisphosphonates are believed 
to decrease the numbers of osteoclasts (cells that break down bone tissue) by promoting 
their apoptosis.44 Some non-N-containing bisphosphonates replace the terminal 
pyrophosphate of ATP through intracellular metabolism, leading to toxic ATP analogues 
which ultimately prompt osteoclasts apoptosis.45 In contrast, most N-containing 
bisphosphonates bind to and inhibit farnesyl pyrophosphate synthase (FPPS) in the 
mevalonate pathway (Fig 1.8).46-49 The disruption of FPP biosynthesis will block 
prenylation of proteins, including GTP-binding proteins, Ras, Rho and Rac.49 Interfering 
with their cellular function could result in increased cellular death by apoptosis. Hence, 
by mechanism of action, bisphosphonates can be divided into two different classes. 
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Bisphosphonates have very high affinities for bone tissues and can be rapidly 
absorbed onto the bone surface. Thus, they are very specific for bone diseases. Currently 
there are about 9 bisphosphonates used worldwide to treat osteoporosis, osteitis 
deformans (Paget’s disease), bone metastasis and other conditions that feature bone 
fragility.  
                   Figure 1.7: Structures of bisphosphonates  
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C. Acyclic Nucleoside Phosphonates (ANPs)  
Since its first clinic observation in 1981, human immunodeficiency virus 
infection/acquired immunodeficiency syndrome (HIV/AIDS) has caused an estimated 39 
Figure 1.8. N-bisphosphonates inhibit the Mevalonate Pathway by  
targeting FPPS 
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million deaths worldwide.50 The retrovirus mainly infects the human immune system, 
reversely transcribing its RNA genome into double-stranded DNA in the host cells.51  
 
 
  
Figure 1.9:  Inhibition of HIV-1 reverse transcriptase by AZT and tenofovir 
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Antiviral agents that target reverse transcriptases (RTs) have become crucial in 
management of the retroviral infections. 3′-Azido-3′-deoxythymidine (AZT, Zidovudine) 
was the first FDA-approved drug for HIV treatment.52 AZT is a nucleoside analogue that 
needs to be converted to AZT- triphosphate (AZT-TP) that then acts as a chain terminator 
in RT-catalyzed DNA synthesis. The first phosphorylation of AZT, or other nucleoside 
analogues, has been identified as the bottleneck of the deactivation process. Addressing 
this, De Clercq and Holy have developed a number of acyclic nucleoside phosphonates 
(ANPs) that only need two phosphorylation steps to be activated to the chain-terminating 
metabolites (Fig. 1.9).53-55 And then the ANP diphosphates are incorporated into the 
DAN chain, either by RNA reverse transcriptase or DNA polymerase. This mechanism is 
supported by a meticulous study with cidofovir diphosphate using gel electrophoresis.56 
Thus far, three of these nucleotide analogue/reverse transcriptase inhibitors (NtRTIs) 
have entered the pharmaceutical market. Tenofovir, in its oral prodrug form tenofovir 
disoproxil fumarate (TDF or PMPA), has been approved for treatment of HIV infection 
under the trade name Viread. Cidofovir (Vistide, which targets viral DNA polymerase) is 
administrated intravenously to treat CMV retinitis in AIDS patients. Adefovir has been 
approved in its prodrug form, adefovir dipivoxil (Hepsera), to treat chronic hepatitis B 
virus (HBV) infections. 
In addition to these well-established classes, there are other phosphonates that 
have reached pre-clinical or clinical studies. For example, Perzinfotel (EAA-090), a 
potent NMDA antagonist, has been investigated for treatment of stroke; however, it was 
shown to lack an analgesic effect. Taken together, the phosphonate motif has been an 
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important group in modern drug discovery, and it will continue to serve as a non-
hydrolyzable bioisotere for numerous phosphate and carboxylate metabolites.  
III. Sugar Phosphonates in Bioorganic Chemistry 
Carbohydrate phosphates play critical roles in cell survival and proliferation. As 
one of the most common metabolic intermediates, glucose 6-phosphate (G6P) lies in two 
major metabolic pathways, namely glycolysis and the pentose phosphate pathway.57 The 
former converts G6P to pyruvate and releases free energy in the form of adenosine 
triphosphate (ATP). The latter converts G6P to ribose 5-phosphate (R5P) and erythrose 
4-phosphate (E4P) which are utilized in biosynthesis of nucleic acids and aromatic amino 
acids, respectively. In addition, fructose 6-phosphate (F6P), mannose 6-phosphate (M6P), 
glucosamine 6-phosphate (GlcN6P) all emanate from G6P and are all essential 
intermediates in carbohydrate metabolism, influencing various cellular processes. 
Like other phosphonates, replacing enzyme-lable O-P bonds with stable C-P 
bonds in carbohydrate scaffolds, generates sugar phosphonates.  These compounds are 
resistant to phosphatase cleavage and, as such, exhibit a sort of “constitutive 
phosphorylation” phenotype and as such be able to block  or articifially stimulate a 
metabolic pathway of interest, resulting in a desired cellular response. The first synthesis 
of sugar phosphonates dates back to the 1950s. Burger et al. synthesized a nonisosteric 
(one carbon unit shorter) phosphonate analogue of G6P via the Arbuzov reaction.58 Later, 
the Syntex group claimed the synthesis of the isosteric phosphonate analogues of G6P, 
R5P, and M6P, exploiting a stabilized Wittig reagent.59 However, these protocols had 
limited applications due to the inconvenient process and harsh conditions. Despite their 
16 
 
great potential in biosystems, sugar phosphonates have been incompletely investigated 
and underutilized in biochemical investigations.    
In 1994, our group reported a direct displacement of sugar triflates with diethyl 
lithiomethylphosphonate, providing an expedient entry into valuable, sought after sugar 
phosphonates.60 From the corresponding alcohols, the primary triflates can be easily 
synthesized, purified and stored under argon. At – 78 °C in THF, the triflates are rapidly 
displaced by the phosphonate anion in an SN2 manner. Reactions are typically complete 
within 10 min following substrate addition. This reaction proved to be widely applicable 
toward various triflates, offering a general approach to the isosteric phosphonate 
analogues of sugar phosphates.  
Most importantly, this protocol is quite compatible with a variety of different C-
nucleophiles, especially the -fluorinated phosphonate anions.60-65 As a matter of fact, 
the triflate displacement was originally applied with diethyl (,-
difluoromethy)phosphonate anion, to give the acclaimed difluorinated phosphonate 
analogues of sugar phosphates.61 In the 1980s, Blackburn pointed out that while 
Figure 1.10. Three types of phosphonates vs native phosphates 
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phosphonates sterically resemble phosphates, the replacement of an O-P bond with a C-P 
bond will largely change the polarity of the group.66-68 This could be a crucial factor in 
the ability of phosphonates to bind to proteins as the deleted oxygen may have been 
involved in significant dipole-dipole interactions in the protein active site.69-70 In such 
cases, -halogenation, particularly -fluorination, could potentially compensate for the 
removal of the oxygen eletronegative  atom, and in this way provide a more effective 
surrogates for the native phosphate (Fig. 1.10).71  
Mostly promoted by Blackburn and McKenna, the -CF2-  moiety has been 
employed as an isopolar replacement of  the bridging oxygen. Indeed, in a number of 
notable cases, , -difluorinated phosphonates have been observed to be superior 
analogues to their non-fluorinated counterparts.72-81 Perhaps the most impressive case 
was a series of hexapeptides, developed by Burke and coworkers, utilizing non-
hydrolyzable analogues of phosphotyrosine to inhibit protein phosphotyrosine 
phosphatase PTP1B. The Burke group chose to use a hexapeptide (Ac-Asp-Ala-Asp-Glu-
pTyr-Leu-C(O)NH2) that represents the sequence at the EGFR (epidermal growth factor 
receptor) phosphorylation site, an excellent substrate for rat PTP1. The peptide 
 Figure 1.11: Peptides containing non- and difluorophosphonate  
 analogues of phosphotyrosine are PTP1B inhibitors 
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containing the difluorophosphonotyrosine in place of pTyr exhibited 2000-fold greater 
inhibition than the non-fluorinated congener (Fig. 1.11).82  
Nonetheless, an extensive SAR study from our group showed that the -CH2- 
analogue of G6P is a better substrate for G6P dehydrogenase (G6PDH) than the 
difluorinated counterpart.83 More importantly, the two diastereomeric -monofluorinated 
phosphonates have also been synthesized through the addition of a phosphite anion to the 
appropriate aldehyde, followed by deoxyfluorination. Interestingly, out of the four 
synthetic substrates examined, (7S)-glucose-CHF-phosphonate displayed the best 
substrate activity with kcat/Km = 922 mM-1S-1, 11-fold higher than its (7R)-diastereomer 
(Fig. 1.12). Together with other cases,74, 77 this study suggests that any of the non-, mono- 
and difluoro-phosphonates could have the best fit for an active site. The activity of these 
analogues is determined by assaying binding to the targeted macromolecule.  And, as can 
be seen from the discussion above,  this is clearly an experimental science, i.e. for a given 
Figure 1.12: Phosphonate analogues are examined as pseudosubstrates for 
Glc6P dehydrogenase 
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active site, it is generally best to synthesize all phosphonate analogues and examine these 
for binding to the target macromolecule.  
A year after our 2000 JOC article describing the importance of monofluorinated 
phosphonates based upon their tunability for binding to G6PDH, our group reported a 
triflate displacement approach to the monofluorinated phosphonates.84 This is realized by 
using a McCarthy reagent as the nucleophile, followed by reductive removal of the 
phenylsulfonyl group.  Emanating from a common precursor, one can thus access all 
three types of phosphonate in a divergent, late stage value-added manner (Fig. 1.13). This 
feature renders the triflate displacement one of the more useful methods for the synthesis 
of biologically relevant  phosphonates. Applying this strategy, we have carried out 
several case studies and discovered  a variety of interesting  phosphonates, mostly as 
analogues of sugar phosphates. For instance,  the nonfluorinated phosphonate analogue of 
M6P is shown to be excellent monodentate ligand for the M6P receptor, while the 
difluorinated congener showed significantly lower binding affinity.85 The ,-
difluorinated phosphonate analogue of fructofuranose 6-phosphate has been seen to be a 
slow-binding inhibitor of glucosamine 6-phosphate synthase.86 Furthermore,  the 
Berkowitz group was the first to synthesize the ,-difluorophosphonate analogues of 
serine-O-phosphate and threonine-O-phosphate.64 The former has since been extensively 
utilized in chemical biology to understand the role of protein phosphorylation at specific 
loci.87  
Chapters two and three of this thesis will discuss the use of the triflate 
displacement chemistry to probe two distinct biological systems, targeting both a protein 
(M6P/IGF2R) and an RNA target (the glmS riboswitch).  In these sections, detailed 
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syntheses of the relevant phosphonate analogues are presented and their corresponding 
biochemical characterization is also described.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13: A divergent approach to three types of phosphonates 
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Chapter 2  
Phosphatase-Inert Actuators for the glmS Riboswitch  
I. Introduction 
A. Background of Riboswitches 
 
 
 
 
 
 
 
 
 
 
 
At any given time, a typical human or bacterial cell only expresses a fraction of its 
genes (~3% to 5%). “The fundamental problem of chemical physiology and of 
embryology is to understand why tissues cells do not all express, all the time, all the 
Figure 2.1: Regulation of gene expression could occur in any 
step of  its process 
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potentialities in their genome,” commented Jacob and Monod.1 Indeed, gene expression 
is controlled by an extremely sophisticated system that coordinates numerous tasks to 
respond to developmental needs and environmental stimuli.2 Essentially, any step of the 
expression process can be recruited to modulate levels of gene products in a cell (Fig. 
2.1). The most well-characterized mechanism is the protein-based modulation of 
transcription initiation.3 Numerous transcription factors have been uncovered since the 
initial discovery of the lactose repressor (Lacl), which interacts with the lac operon to 
ultimately control the production levels of lactose-metabolism enzymes.4 In addition to 
their interactions with DNA, protein factors can bind to mRNA to regulate either 
transcription termination (e.g. the PyrR protein5) or translation (e.g., TRAP protein6 and 
CUGBP17). Because proteins can adopt different conformations to respond to cellular 
and environmental cues, they can carry out a variety of regulatory activities. In contrast, 
nucleic acids were considered to be merely responsible for storing and transferring 
genetic information.2  
Discoveries made in recent decades have proven that RNA plays a far more 
sophisticated role than originally believed. Notable examples include the discoveries of 
small interfering RNA (siRNA) and micro RNA (miRNA) which are central to RNA 
interference (RNAi).8-9 These small non-coding RNAs exert posttranscriptional gene 
control, either through protein-associated RNA cleavage (siRNA)10 or sequence specific 
RNA binding (miRNA)11-12. RNAi mechanism has been found in many eukaryotic cells 
including plants and animals. In 2006, the Nobel Prize in Physiology or Medicine was 
awarded to Fire and Mello for their discovery of RNA interference.13  
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Within the last 12 years, a new gene-control mechanism has emerged in which 
mRNA self-regulates its own translation, with no obligate needs for protein factors.14-20 
Termed riboswitches, these 5’-untranslated regions (UTRs) sense specific secondary 
metabolites. Upon binding RNA,these small molecules typically induce allosteric 
changes in the conserved structures, which ultimately leads to the termination of  gene 
expression.21 Prior to the discovery of the existence of riboswitches in nature, the 
regulation of some essential genes in bacterial metabolism remained enigmatic. For 
example, thiamin (Vitamin B1) is a crucial coenzyme for bacterial cell growth. However, 
when bacteria are in thiamin-adequate media, they will exploit exogenous thiamin rather 
than produce their own. Therefore, there must be a regulatory factor that senses the 
concentration of the product and controls the expression of the biosynthetic genes. This 
led to the postulate that a thiamin pyrophosphate (TPP) sensing protein was involved in 
the modulation of thiamin biosynthetic genes.22 However, such a regulatory protein has 
not been discovered in nature thus far.  
Alternatively, in 2001, Miranda-Rios and Soberon disclosed that the conserved 
structure (thi box) of the mRNAs encoding thiamin biosynthetic enzymes is 
indispensable for thi gene expression, implying the presence of a RNA-dependent gene 
regulating system.23 In 2002, Breaker et al. confirmed that the mRNAs (thiM and thiC) 
indeed regulate thi gene expression via an allosteric mechanism.24 Namely, the 5’-UTRs 
of thiM and thiC bind thiamin or its pyrophosphate derivative, ultimately leading to the 
reduction of gene expression. The resultant/resulting complex is shown to take on a 
conformation than is distinct from that of the unbound RNA structure, which is proposed  
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Table 2.1: Known riboswitches in the nature and their cognate ligands 
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Table 2.1 (Continued). 
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as the mechanism underlying the translation inhibition.25  In the same year, the Breaker 
group unveiled two more riboswitches that sense flavin mononucleotide (FMN, Vitamin 
B2)26 and cobalamin (Vitamin B12),27 respectively. Since then, this mRNA self-regulating 
mechanism has been found be widely used in prokaryotic cells (Table 2.1).18 To date, 
there are approximately two dozen riboswitches that have been experimentally validated 
to sense 17 different metabolites, one secondary messenger (cyclic di-GMP) and one 
divalent cation (Mg2+).28  
B. Background of the glmS riboswitch 
In 2004, a unique riboswitch was disclosed by the Breaker group by exploiting 
bioinformatics in bacterial genomes. Riboswitches have conserved sequence and 
secondary structures, typically located in the noncoding or intergenic regions (IGRs). 
Using the database known as the Breaker Laboratory Intergenic Sequence Server 
(BLISS), they examined the IGRs of 91 microbial genomes, that led to a variety of 
conserved RNA motifs.29 The glmS element was found to be highly conserved in 18 
gram-positive bacteria (Fig 2.2). It resides upstream of the glmS gene which codes for the 
enzyme glucosamine 6-phosphate synthase or synthetase (glmS). GlmS lies at the 
beginning of the cell wall biosynthesis. It converts fructose 6-phosphate to glucosamine 
6-phosphate, exploiting glutamine as the amine source. Along the biochemical pathway, 
several metabolites could serve as the signaling molecule for the putative glmS riboswitch.  
To identify effective ligands for riboswitches, an “in line probing” assay was 
previously developed.27 This assay relies on the structure-dependent RNA self-cleavage. 
Single strand RNA is relatively unstable and can be cleaved spontaneously over time. 
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The rate of the cleavage is found to be closely related to the secondary and tertiary 
structure. The spontaneous cleavage only occurs at a substantial rate when the  
  
Figure 2.2: Secondary structure of the Bacillus cereus glmS 
riboswitch/ribozyme. The highly conserved core sequence of the glmS ribozyme is 
shown in red (P2.1 and P2.2), while requisite structural elements (P1 and P2) and 
peripheral structural elements (P3-P4) are also displayed with nucleotide detail. The 
arrowhead denotes the site of self-cleavage. 
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nucleophilic 2’-oxygen, phosphorus, and the leaving 5’-oxygen are in the proper position. 
Thus, regions with stable base-paired structures rarely undergo cleavage, while the 
nucleotides in some tertiary structures are particularly vulnerable to adjacent nucleophilic 
attack. Therefore, by incubating a messenger RNA in the presence or absence of potential 
ligands and examining the change in cleavage patterns, one can identify small molecule 
effectors as well as their binding regions on the RNA.  
Prior to the discovery of GlcN6P as a riboswitch ligand, the “in line probing” 
assay had successfully recognized cobalamin27, thiamin24, FMN26, SAM30, glycine31 and 
lysine32 for binding their corresponding riboswitches. Consequently, Breaker et al. 
subjected a 246-nucleotide glmS mRNA from Bacillus subtilis to the assay with various 
metabolite candidates. Gel electrophoresis revealed that the mRNA was mostly cleaved 
within 1 min in the presence of 200 M GlcN6P, while the same cleavage fragment in the 
absence of GlcN6P was almost negligible. Such an observation experimentally confirms 
the existence of the glmS riboswitch in bacteria, and divulges that GlcN6P serves as a 
handle, exerting a genetic switch to regulate glmS gene expression.33  
More interestingly, single-site cleavage is 1000-fold faster than the spontaneous 
cleavage of a typical unconstrained RNA linkage, and 10-fold faster than any known 
constrained RNA structure that favors the phosphodiester transesterification.34 This made 
Breaker and others wonder whether this “spontaneous cleavage” is really spontaneous or 
actually catalytic. The extensive kinetic characterization and x-ray crystal structures have 
now led to the conclusion that the glmS RNA is indeed a novel class of ribozyme.35 In the 
presence of GlcN6P, it accelerates its self-cleavage by 106-8 fold.33, 36-37 This feature 
makes the glmS riboswitch/ribozyme unique in both categories. As a riboswitch, it 
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undergoes a self-cleavage rather than a conformational change to regulate gene 
expression. As a catalytic RNA, it is the first known natural ribozyme that requires a 
small molecule cofactor for the catalysis.35 Together with the other 13 classes of 
naturally-occurring ribozymes, the glmS ribozyme supports the “RNA world” theory 
which hypothesizes that life begins from self-replicating RNA, rather than the DNA-
RNA-protein system in current biology.38  
 
 
 
 
 
 
There has been debate about the role of GlcN6P in the mechanism of glmS self-
cleavage. Previously, it was proposed that GlcN6P only acts as a general acid which 
protonates the leaving oxygen of the phosphate group. This was supported by the crystal 
structure that shows a nearby guanine (G33) posed to deprotonate the 2’-OH of the 
attacking nucleotide A-1.39-40 Furthermore, a G33A mutation deactivates the glmS self-
cleavage, which validates that the guanine is essential for the catalysis.40 However, in 
2011, Fedor et al. conducted a pH-fluorescence profiling using a fluorescent guanosine 
analogue, 8-azaguanosine. The microscopic pKa of the active site guanine was measured 
Figure 2.3: Plausible mechanism for the GlcN6P activated RNA 
cleavage 
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to be around 8.9, which suggests the guanine (N1) should be protonated under the assay 
pH (~7.3).41  
Furthermore , it has been demonstrated that the cleavage rate has a dependence on 
the pKa of the amino group of GlcN6P.37 The Brønsted -value for GlcN6P was recently 
determined to be 0.7 in Fedor’s group, suggesting a general base role in the catalysis.36 
GlcN6P analogues that lack the base function of the 2-amino group also failed to catalyze 
the cleavage.42 Therefore, the mechanistic most consistent with all available data appears 
to be on in which GlcN6P serves as a general base and a general acid in the activation of 
the glmS self-cleavage. As shown in Fig. 2.3, in this view, the GlcN6P-2-amino group 
deprotonates the 2’-OH of A-1 through a proton hopping mechanism. The 2’-oxygen 
attacks the phosphodiester linkage, forming the 2’-3’ cyclic phosphodiester. The 2-amino 
group protonates the leaving oxygen of  G1, facilitating the cleavage. This proposed 
mechanism is supported by Raman difference crystallography studies43 and 
computational simulations44. These studies suggest that the glmS active site tunes down 
the GlcN6P (-NH2) pKa to align with the optimal reaction pH. 
C. GlmS riboswitch as an antimicrobial target 
In addition to being a great study subject, the glmS riboswitch also represents a 
potential new target for antimicrobial drug development. Bacterial resistance is emerging 
at an alarming rate. A 2014 WHO report reveals that “this serious threat is no longer a 
prediction for the future, it is happening right now in every region of the world and has 
the potential to affect anyone, of any age, in any country.”45 However, most academic 
groups and companies are working on known scaffolds and known targets.46 To 
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sustainably battle bacterial pathogens, especially the multidrug-resistant “superbugs”, 
new targets in the bacterial life cycle are in great demand. Riboswitches have emerged as 
attractive alternatives for the development of new antibiotics.47-48 These metabolite-
sensing RNAs regulate expression of genes that are essential in bacterial metabolism. In 
addition, most riboswitches are present in prokaryotic cells. No natural riboswitch has 
been detected in mammalian cells to date. This reduces the potential toxicity issues that 
are affecting many antibiotic candidates.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: A negative feedback mechanism exerted by the glmS 
riboswitch to regulate glmS gene expression 
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In addition, the glmS riboswitch is found in a number of pathogenic bacteria, 
including high profile ones such as S. aureus, Clostridium difficile, and B. anthracis.49 In 
the life cycle of these bacteria, proper control of glmS gene expression is critical for the 
production of GlcN6P, an essential metabolic precursor for bacterial cell wall synthesis.50 
As GlcN6P accumulates in the cell, it facilitates the self-cleavage of glmS RNA, 
unleashing a new 5’-end as a marker for Ribonuclease J1 (RNase J1).51 Further 
degradation destroys the coding region of glmS RNA, decreasing the production of 
GlcN6P synthase and therefore the product of GlcN6P in the cell. Thus, a small molecule 
that artificially actuates the glmS riboswitch could lead to significant reduction of glmS 
gene expression, consequently disrupting the cell wall biosynthesis (Fig. 2.4). This idea 
has prompted several efforts to develop artificial actuators for the glmS riboswitch. 
In a 2004 Nature paper, the Breaker group demonstrated that the glmS RNA 
strongly favors GlcN6P against even closely related analogues.33 This was later 
reinforced by several other SAR characterizations from Breaker and other groups.36-37, 42 
From these  studies, along with x-ray crystal structures, a series of key molecular 
components were proposed for GlcN6P-actuator activity: i) the 6-phosphate is the 
anchoring element that binds one of two Mg2+ ions in the active site; ii) the 4-hydroxyl 
group is considered as an indispensable hydrogen-bond donor for the binding; iii) the fact 
that glmS RNA binds only the -anomer GlcN6P suggests that the anomeric -OH is also 
involved in molecular recognition; iv) the free 2-amino group has proven to be essential 
for the actuation, and in the Soukup model, this amino group serves the role of a general 
base and a general acid (in the ammonium form) for the catalytic RNA-cleavage. 
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In 2006, Mayer and Famulok developed a “high throughput compatible” assay to 
identify artificial actuators of the glmS riboswitch.52 They derivatized the 5’-end of an 81-
nucleotide glmS RNA with a fluorescent label. Utilizing fluorescence polarization (FP), 
Figure 2.5: Ligand characterization for the glmS riboswitch 
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they were able to estimate binding affinity between the nucleic acid and the small 
molecules. The modified RNA responded well to GlcN6P, as the intensity of FP showed 
strict dependence on GlcN6P’s concentration. However, to their disappointment, the 
screening of an initial 88-membered library, and  later over 5000 compounds53 did not 
yield any compounds that could actuate the glmS riboswitch.  
In 2011, Mayer et al. went back to the structure-based approach. They 
synthesized and tested 9 analogues of GlcN6P.53 Interestingly, the replacement of the ring 
oxygen with -CH2- only resulted in a modest loss of activity. At a concentration of 200 
M, the carba-GlcN6P promotes the RNA self-cleavage with a reported rate constant of 
0.153 min-1, comparable to that of 0.177 min-1 from the natural metabolite. Other 
modifications of the sugar phosphate, however, were much less tolerated in the glmS-
riboswitch active site. It is noted that this carbocyclic glucosamine 6-phosphate was later 
included in another SAR characterization. In this study, a different group also synthesized 
a pair of nonisosteric -hydroxyl phosphonate analogues.54 Nonetheless, these shortened 
phosphonate analogues showed no activity for the cleavage assay. Recently, Posakony 
and Ferré-D’Amaré synthesized a series of GlcN6P and GlcN analogues as well; however, 
the activities of these were not disclosed in the report.55  
II. Results and Discussion 
A. Synthesis of GlcN6P Analogues 
As a group that excels in synthesizing phosphonate analogues, we embarked on 
the glmS project in collaboration with Prof. Julianne Soukup from Creighton University. 
Perhaps,  the most obvious such analogue to target was the isosteric phosphonate 
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surrogate for GlcN6P. However, phosphonate analogues of aminosugar 6-phosphates had 
not been reported prior to this work. A synthetic strategy remained to be established. To 
adopt our triflate displacement methodology, we needed to design and synthesize a viable 
glucosamine 6-O-triflate. And one significant challenge was to find a proper protecting 
group, that would be compatible for both the triflate installation step and the 
displacement step. The initial effort using an acetyl group met with little success in the 
triflate installation stage, while the trifluoroacetyl group proved to be incompatible with 
the displacement conditions. One the other hand, sulfonyl protecting groups were well 
tolerated under such conditions, with the (2-trimethylsilyl)ethanesulfonyl (SES) group 
being optimal.  
The key step in our synthetic route involves an iodonium-mediated 
sulfonamidoglycosylation of glycals. This chemistry was discovered in 1990s by Griffith 
and Danishefsky, and has been broadly employed to assemble glucosamine-containing 
oligosaccharides.56-57 This particular iodonium salt, iodonium di(sym-collidine) 
perchlorate (IDCP) was shown to be critical for the success of the initial alkene 
iodination reaction. Therefore, staring from the glucal 1, we first introduced the 
sulfonylamino functionality to the 1-position using freshly prepared IDCP. Upon 
treatment with an alcohol, in the presence of a silver salt and base, the amino group “rolls 
over” to the 2-position of the sugar, via a presumed N-sulfonyl aziridine intermediate, 
that is opened on the anomeric side by the alkoxide present. Following the successful 
application of this N-rollover reaction with benzyloxy-anion opening of the putative 
sulfonyl aziridine intermediate, the sulfonyl nitrogen was further protected via N-
benzylation. Fluoride deprotection of the TBDPS group then gave the free alcohol 3 
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which proved to be a convenient stage at which to store significant quantities of material,  
as a key intermediate. 
. The reaction between 3 and triflic anhydride provided the glucosamine 6-O-
triflate in over 90% yield. This triflate intermediate displayed only modest stability under 
argon. Its DCM solution (concentration < 1 g/L) was stored in a -40 C freezer for 3 days, 
with no significant degradation using NMR analysis. However, when being dried under 
vacuum, the compound turned to a brown color within 1 h at rt. A TLC analysis showed 
that multiple degradation products were generated from the triflate. Consequently, 
compound 4 was normally freshly prepared and immediately subjected to the 
displacement reaction. The displacement of 6-O-triflate with excess di-O-benzyl 
phosphonomethyl lithium gave the phosphonate product 5 in up to 62% yield. Additives 
such as HMPA were explored in effort to increase the reaction yield, however, no 
appreciable improvement was observed. Following the SES deprotection with CsF, the 
global deprotection of six benzyl groups proceeded smoothly in 86% yield. The fully 
Figure 2.6: Synthesis of phosphonate 6  via triflate 
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deprotected phosphonate was then purified by trituration with methanol, to a purity of 
over 95% (estimated from NMR analysis). Lyophilization finally afforded the desired 
phosphonate surrogate of GlcN6P 6 as a white foam (Fig. 2.6). 
Motivated by this synthetic achievement, we set out to exploit this route for 
synthesis of a series of GlcN6P analogues. First, we decided to explore tether length in 
the phosphonate-based analogues. Phosphite anions are known as better nucleophiles 
than phosphonoalkyl anions.58 The C-P bond can be constructed via substituting a variety 
of electrophiles with phosphite anions. Herein, we reacted the key triflate intermediate 4 
with dibenzyl phosphite anion to provide the one-carbon “truncated” phosphonate 7 in 80% 
yield. Standard deprotection procedures were then followed to give analogue 8. This 
strategy was subsequently adopted to synthesize the “elongated” phosphonate analogue. 
The requisite alcohol 10 was prepared from the displacement of 4 with a malonate anion, 
Figure 2.7: Synthesis of the “truncated” (8) and “elongated” 
phosphonate (12) analogues  
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followed by a mono-decarboxylation/reduction sequence. Nevertheless, the extended 
triflate, built on the alcohol 10, was highly unstable even at low temperature (- 40 C). 
Therefore, the corresponding iodide was employed as an alternative electrophile for the 
displacement reaction with dibenzyl phosphite anion. After removal of SES and benzyl 
groups, the phosphonate compound 12 was obtained as an “elongated” phosphonate 
analogue.  
 
 
 
 
 
 
 
 
 
 
Additionally, we set out to explore other phosphate isosteres that have been used 
in bioorganic chemistry. In particular, we were inspired by the use of the malonate motif 
in phosphate mimics. For instance, the Frost group had synthesized a set of 3-deoxy-D-
Figure 2.8: Synthesis of the malonyl ether, malonate and carboxylate 
analogues 
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arabino-heptulosonic acid 7-phosphate (DAHP) analogues that competitively inhibit 3-
dehydroquinate (DHQ) synthase.59 Malonate, -hydroxyl malonate and malonyl ether 
functional groups were utilized to replace the phosphate in binding to that enzyme. These 
carbocyclic inhibitors displayed excellent inhibition, with Ki =  0.7, 0.3, 7 M 
respectively, compared with a Km = 3.6 M for DAHP. Recently, a malonate analogue of 
mannose 6-phosphate, which was first synthesized in our group for the M6P receptor60, 
was found to be a strong inhibitor of S. cerevisiae M6P isomerase (IC50 = 18.1 M, Ki = 
10.5 M).61  
Hence, malonate and malonyl ether analogues of GlcN6P were considered 
reasonable candidates for glmS riboswitch binding/self-cleavage . The malonate 
functionality was installed by displacement of the triflate 4 with dibenzyl malonate anion, 
in 82% yield. However, in the SES deprotection step , a major byproduct was obtained, 
namely the moncarboxylate resulting from Krapcho de-alkoxycarboxylation.62 
Subsequently, both products were further deprotected to afford malonate analogue 18 and 
carboxylate analogue 19. In the meantime, the malonyl ether analogue 14 was also 
synthesized via a Rh(II)-mediated insertion into the O-H bond at the 6-position of the 
sugar by the Rh(II)-carbenoid species derived from dibenzyl diazomalonate. Standard 
deprotection procedures were employed for all three carboxylate-based phosphate mimics 
(Fig 2.8). 
 Next, the phosphoramide analogue was targeted as a novel mimic for GlcN6P. 
The triflate 4 was again employed in a SN2 reaction with TMSN3. Sequential SES-
removal and Staudinger reduction then resulted in the 2,6-diamino-2-deoxy glucoside 21. 
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This diamine was then subjected to the reaction with dibenzyl chlorophosphate. 
Pleasingly, the N-phosphorylation exclusively proceeded on the primary amino group. 
Finally, the global Bn-deprotection gave the sought-after glucosamine 6-phosphoramide 
23 (Fig. 2.9).  
The 2-amino group plays a significant role in catalysis. Modulation of its pKa and 
spatial hindrance are expected to potentially influence the RNA self-cleavage reaction, 
potentially also providing insight into the mechanism of this reaction. Consistent with 
this picture, the N-acetyl GlcN6P had already been shown to be inactive toward glmS 
riboswitch actuation. N,N,N-trimethylation also completely deactivates the cofactor. In 
contrast, N-methylation of GlcN6P only led to a 16-fold loss of activity in terms of 
observed rate constant (kobs).42 This is consistent with the postulate that the 2-amino 
group serves as a general base in catalyzing the self-cleavage reaction.. In this case, we 
slightly modify the synthetic route to analogue 6, and synthesized two N-methylated 
phosphonate analogues of GlcN6P. After the “roll-over” reaction, the silyl ether 2 was 
methylated using MeI and NaH in DMF, followed by the TBDPS deprotection. The 
alcohol intermediate was then conveniently transformed into the phosphonate 25, 
following standard triflate displacement procedures. Interestingly, a significant 
Figure 2.9: Synthesis of phosphoramide analogue 23 
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improvement of yield was observed for the displacement of the N-methyl glucosamine 6-
O-triflate (75%), compared with the N-benzyl glucosamine 6-O-triflate (62%). This is 
probably because the N-methyl intermediate is more stable than the N-benzyl compound. 
As a result, the former is less likely to undergo side reactions such as hydrolysis or 
elimination reactions. Following SES removal, compound 26 was either hydrogenated to 
give the N-mono-methylated phosphonate 27, or methylated again to yield the N,N-
dimethyl analogue 29, after debenzylation (Fig. 2.10).   
 In summary, nine analogues of GlcN6P have been synthesized (Fig 2.11). All but 
one of the syntheses proceed through displacement of a protected amino sugar triflate 
intermediate, attesting to the value of this synthetic strategy.  
Figure 2.10: Synthesis of the N-methyl (27) and N,N-dimethyl (29) 
phosphonate analogues  
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B. Self-Cleavage Assays with the glmS Riboswitch 
The self-cleavage assay was conducted in the Soukup Laboratory at Creighton 
University. A 154-nucleotide Bacillus cereus glmS riboswitch was utilized in the assay. 
The RNA was prepared through in vitro transcription from the amplified glmS DNA 
using T7 RNA polymerase. 32P-Labelled UTP (the  phosphate) was utilized in this 
process to radiolabel the RNA, which was then purified by polyacrylamide gel 
electrophoresis.37 During this research, I was able to participate by conducting some of 
the self-cleavage assays.  The glmS RNA was incubated with different analogues, and 
aliquots were taken to measure the intensity of the cleaved and the uncleaved fragments.  
From the percentage of the cleaved fragments, apparent rate constants could be 
determined. All nine analogues were tested for their ability to support glmS self-cleavage. 
Figure 2.11: Structures of all the nine GlcN6P analogues  
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Compounds 12 and 19 were tested at 1 mM owing to their limited quantities, while the 
remaining seven compounds were assayed at 10 mM concentration. Glucosamine (GlcN) 
was chosen as the control in these assays, as it was shown to facilitate the glmS 
riboswitch self-cleavage at rates that can be readily measured under such conditions.37 
Although GlcN6P is the native cofactor for the glmS ribozyme and should be the direct 
compound of reference here, it is very difficult to measure its cleavage rate accurately. It 
is claimed that the reactions are extremely fast, even in the presence of low GlcN6P 
concentration. The reactions need to be quenched within seconds after initiation. 
Currently, there is ambiguity in the literature as to the  value of kobs for GlcN6P, with 
reported values ranging from 1.1 to 100 min-1.33, 36-37  
Time-point cleavage gels are presented in Figure 2.12 and Figure 2.13. 
Experimentally determined pseudo-first-order rate constants are presented in Table 2.2. 
Of the nine GlcN6P analogues synthesized, five displayed substantial cleavage rates; 
namely the isosteric phosphonate 6, its N-methyl 27, and N,N-dimethyl 29 congeners, as 
well as malonyl ether analogue 14 and the phosphoramide 23 (Fig. 2.12). In contrast, the 
two nonisosteric phosphonate analogues, 8 and 12, showed very modest activation of 
glmS riboswitch self-cleavage, suggesting that the position of the phosphonate or 
phosphate in the RNA-active site is crucial for binding and catalysis. Deletion or 
insertion of one methylene (-CH2-) unit alters the distance between the phosphonate- 
presumed to coordinate to an active site Mg2+ ion- and the catalytically important amine 
functionality, thereby greatly decreasing actuator activity. As mentioned above, Ye  et al. 
also reported on studies of two truncated -hydroxyl phosphonate analogues of GlcN6P 
in 2010. These two compounds structurally resemble analogue 8, and -hydroxylation 
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failed to increase their potencies. Additionally, the mono-anionic carboxylate analogue 
19 is nearly inactive in the cleavage assay. This supports the proposal that di-carboxylate 
functionalities are superior to mono-carboxylates for Mg-binding. Perhaps related to this 
observation, it was also previously shown that glucosamine 6-sulfate is not an actuator 
for this ribozyme. To our surprise, the malonate analogue 18 exhibited a weak glmS 
actuation, similar to that of compound 19. Compared with malonyl ether analogue 14, the 
deletion of the 6-oxygen significantly reduces activity in the self-cleavage assay (Fig. 
2.13). Subsequently, the five active analogues and 18 were further characterized to 
determine their apparent second-order rate constants (kcat/Km). 
In these kinetic studies, the apparent pseudo-first order rate constants (kobs) were 
calculated  by fitting the percentage cleavage versus time to equation (1): 
௙೎೗೐ೌೡି௙బ
௙೟೚೟ೌ೗
ൌ ݇௢௕௦ݐ  (1) 
Note that kobs values were measured at different concentrations for each analogues. 
Under the presumed “kcat/Km conditions”, the kobs should have a linear relationship with 
the concentration. Commonly observed as the linear part of a Michaelis-Menten plot, the 
empirical “kcat/Km region” represents a range where the substrate concentration is < 20% 
Km. However, in this case, Km is not determined for these analogues. Nonetheless, within 
the assay concentration range (up to 100 mM), the plot of kobs vs concentration remained 
fairly linear for most analogues. Therefore, the second order rate constants were derived 
from the following equation (2): 
݇௢௕௦ ൌ
௞ౙ౗౪
௄ౣ
ሾሿ  (2) 
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Figure 2.12: Cleavage gels of the five most active analogues 
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 Pleasingly, the phosphonate analogue 6 and the malonyl ether 14 proved to be 
excellent actuators for the glmS riboswitch. Compared with GlcN, 6 and 14 displayed a 
22-fold and 27-fold greater catalytic efficiency, respectively. The previously promising 
phosphoramide 23, however, trailed in the second order kinetic analysis, with a kcat/Km of 
0.01 mM-1min-1. It has been reported that the P-N bond of phosphoramide is susceptible 
Figure 1.13: Cleavage gels of the less active analogues 
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to hydrolysis.63 Nonetheless, a stability test of 22 showed no apparent degradation in D2O 
at rt for days.  Although it is possible that the presence of RNA or Mg2+ phosphoramide 
cleavage may underlie some of the perceived decrease in riboswitch actuation,64 the 
phosphoramide functionality may simply be a poor surrogate in this case study. As for 
the N-methylated phosphonates 27 and 29, neither is as effective as analogue 6 in glmS 
activation, suggesting limited steric tolerance in this RNA active site. However, it should  
 
 
be noted that the dimethyl phosphonate 29 is 2-3 times more active than the less sterically 
hindered 27. In our hands, titration studies, yield pKa values of 8.2 and 7.8 for these two 
analogues, respectively (Table 2.2). As seen in Table 2.2 and Fig. 2.17, each titration 
curve has two inflection points, indicating two pKa values, corresponding to the second 
pKa of the diacid functionalities and the amine group. We presume that the first one is 
` kobs (min-1)a kcat/Km  
(mM-1min-1)b 
RCEc pKa1       
(-OH) 
pKa2      
(-NH) 
GlcN 0.174 ±0.025 0.0178 1.00 - - 
6 0.924 ±0.10 0.394 22.1 7.3 7.9 
14 1.006 ± 0.21 0.488 27.4 3.9 8.1 
23 0.101±0.013 0.0101 0.567   
27 0.027 ± 0.011 0.0035 0.197 7.6 8.2 
29 0.0423 ± 0.010 0.0100 0.562 7.5 7.8 
GlcN6P 1.1-100 (refs 33,36,37) - - 6.237 8.237 
Table 2.2: Kinetic characterization and pKas of GlcN6P analogues for glmS self-cleavage  
a 10 mM actuator, pH 7.3, 25 ˚C; rates are indicated ± standard deviation   
b 1.0-0.01 mM actuator, pH 7.3, 25 ˚C  
c Relative Catalytic Efficiency (RCE) = kcat/Km relative to GlcN. 
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induced by phosphate surrogates and the second one is by the amino group.  This 
suggests that it is optimal if the pKa of the 2-amino group is close to the pH of the 
cleavage assay (~7.3), so that this amino group can serve as both a general acid and a 
general base catalyst for RNA cleavage, as postulated above.  
C. Molecular Modeling and pKa Determination by Titration 
 Although compound 6 represents one of best analogues to date, it is still ~1/7 as 
active as GlcN6P. For future ligand design, we set out to assess the interactions between 
the phosphonate and the glmS riboswitch. Currently, there are 18 x-ray crystal structures 
of the glmS riboswitch from two different organisms: Thermoanaerobacter tengcongensis 
and Bacillus anthracis.65-69 Six structures are in the pre-cleavage stage with GlcN6P 
bound (2Z74; 2Z75; 3B4B; 3B4C; 3G8T ; 2NZ4). All of these riboswitches are mutated 
in the active site. Hence they can form a stable complex with bound actuator and are 
unable to undergo self-cleavage. 
 One riboswitch structure from B.anthracis with pdb code 2NZ466 was utilized in 
the molecular docking experiments. This RNA construct displays 98% identity with the B. 
cereus riboswitch employed in the self-cleavage assays here. As seen in Fig. 2.14, the 
active site adenosine (A-1) was modified by methylation of the 2’-hydroxyl group. 
Therefore, this RNA structure is inert toward GlcN6P-actuated self-cleavage. The 
coordinates of GlcN6P were removed from the complex structure, and the dianionic form 
of phosphonate analogue 6 was docked (Autodock 4). Compareing with the GlcN6P co-
crystal structure, compound 5 fits well in the active site in our best docked structure. 
Namely, the phosphonate binds strongly with one Mg2+ atom and the 2-amino group is 
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appropriately positioned in the catalytic pocket. In the native 3D structure, we did not 
observe any significant interactions between the bridging oxygen and the RNA, nor did 
we notice any deleterious effect from substituting methylene for this oxygen.  
 
 
 
 
 
 
 
 
 As discussed above, although phosphonates are generally isosteric to phosphates, 
they are not considered to be isoacidic analogues. The second pKa of a phosphonate 
monoester is usually around 7.5, which is one unit higher than that of a phosphate. This 
effect could result in a different distribution of phosphonate ionic species, compared with 
that of phosphates. Therefore, to better assess the ionization state of these analogues, the 
most interesting analogues were titrated to give an estimated pKa for the second proton 
dissociation. Indeed, the second pKa of phosphonate analogue 6 was determined to be 
~7.4 from titration curves. Therefore, at the assay pH (~7.3), only ~50% of the 
phosphonate is in di-anionic form. On the other hand, the second pKa of GlcN6P is 
Figure 2.14: Projected structure of phosphonate analogue 6 in the 
active site of glmS riboswitch 2NZ4 (Bacillus anthracis)  
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reported to be ~6.2, which means >90% of the phosphate will be fully deprotonated at the 
same pH. From the assay results of the carboxylate and sulfate analogues, we believe that 
only dianions can bind to the RNA efficiently through magnesium ion chelation. 
Therefore, the diminished activity of 5, relative to the native GlcN6, may be in part due 
to its elevated pKa.  
 Interestingly, malonyl ether analogue 14 is ~300-fold more active than the 
malonate analogue 18. Titration of these bis-carboxylates revealed that the second pKa of 
14 is ~3.9 and that of 18 is ~5.3. Theoretically, the difference between their ionization 
states is not significant at pH 6.2. The dianionic form is likely to be dominant for both 
phosphate-surrogate functionalities under the assay conditions. Thus, each compound is 
docked into the x-ray crystal structures as a dianion and the results are very interestingly 
(Fig.2.15). The malonyl ether analogue is properly placed in the active site. However, 
contrasting with to the natural metabolite GlcN6P or the phosphonate analogue 6, the di-
anionic bis-carboxylate appears well-suited to chelate both magnesium ions in the 
catalytic site. The malonate analogue 18 showed a similar bis-chelation pattern in the 
docking experiment. However, the docking result suggests that the 2-amino group is 
unable to reach the pocket where the cleavage occurs. Instead, the amino group sticks to 
the nearby P2.1 region, strongly interacting with the A42-U43 linkage. As a result, 
analogue 18 may well  bind to the riboswitch, but lacks the ability to actuate the self-
cleavage. On the other hand, due to its extended length, malonyl ether 14 binds to the 
anchoring Mg2+s, while still able to deploy the amino group into the active site. Of course, 
these models can, in principle, be tested by obtaining  x-ray structures of the analogue-
bound riboswitches.  
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III. Future directions 
 The glmS riboswitch represents an exciting subject for bioorganic chemistry. The 
fluorinated analogues are intriguing compounds for future SAR studies. The best actuator 
could then, in principal, be made into a prodrug form to improve its cell permeability (Fig 
Figure 2.15: Overlay of docked structures of malonate and malonyl ether 
analogues in the active site. Green represents malonate analogue; Magenta 
represents malonyl ether analogue. Both bis-carboxylates bind tightly with two Mg2+ 
ions. However, malonyl ether analogue poses the amino group to protonate the 
leaving oxygen, while for the  malonate analog, the amino group docks near the 
A42-U43 phosphodiester, instead of the scissile A-1-G1 phosphodiester, consistent 
with its weak actuator activity. 
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2.16). Disoproxil (bis-isoproxycarbonyloxymethyl ester) is an esterase-sensitive 
functional group and has been used in the prodrug form of tenofovir (Viread®).70 
Additionally, acyl imidazolides represent a novel group that were proposed in 
prodrugging non-steroidal anti-inflammatory drugs (NSAIDs), though the hydrolytic 
stability of such analogues need to be addressed for cellular studies.71  These and/or other 
prodrug forms could be prepared for the best analogues and tested for anti-bacterial  
activities.   
   
 
 
 
 
 
IV. Experimental Section 
A. Organic Synthesis 
General Methods 
Reactions were conducted under argon atmosphere using oven-dried glassware. 
Methylene chloride was distilled from CaH2. THF was distilled from sodium 
benzophenone ketyl. MeOH was distilled from magnesium-iodide. Other reagents were 
obtained from commercial sources and used without further purification. TLC was 
Figure 2.16: Two potential prodrug approaches  
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carried out on Silica Gel 60 F254 (Merck, layer thickness 0.2 mm). Flash chromatography 
was performed using Merck silica gel 60 (230-400 mesh). 1H NMR spectra were 
recorded on a Bruker-DRX-Avance- 500 MHz, 400 MHz and 300 MHz instrument with 
chemical shifts reported relative to residual CHCl3 (7.25 ppm). Proton-decoupled 13C 
NMR spectra were acquired on a Bruker-DRX-Avance 400 MHz and 600 MHz 
instrument with chemical shifts reported relative to CDCl3 (77.0 ppm). 31P NMR spectra 
were obtained on the 400 MHz instrument with chemical shifts reported relative to 85% 
phosphoric acid (0 ppm). Mass spectra were acquired at the Nebraska Center for Mass 
Spectrometry (University of Nebraska-Lincoln). 
6-O-(tert-Butyldiphenylsilyl)-D-glucal (45).  To a solution of D-
glucal (5 g, 34.2 mmol), imidazole (2.56 g, 37.6 mmol) in DMF 
(300 mL), was added tert-butyl(chloro)diphenylsilane (9.78 mL, 
37.6 mmol) dropwise through syringe. The reaction mixture was stirred at room 
temperature for 24h, and then quenched by addition of saturated NaHCO3. The mixture 
was extracted with DCM (3 x 50 mL). The organic phase was combined, dried over 
Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash 
column chromatography (20% EtOAc -hexanes) to yield 45 (12.9 g, 98%) as a colorless 
oil:  1H NMR (400 MHz, CDCl3) δ 7.71 – 7.73 (m, 4 H), 7.40 – 7.49 (m, 6 H), 6.34 (dd, J 
= 1.6, 6 Hz, 1 H), 4.74 (dd, J = 2.4, 6 Hz, 1 H), 4.30 (br s, 1 H), 4.03 (dd, J = 4, 11.6 Hz, 
1 H), 3.99 (dd, J = 4, 11.2 Hz, 1 H), 3.92 (ddd, J = 2.4, 6.8, 9.6 Hz, 1 H), 3.84 (td, J = 4, 
9.6 Hz, 1 H), 3.09 (d, J = 2.8 Hz, 1 H), 2.55 (d, J = 4 Hz, 1 H), 1.10 (s, 9 H); 13C NMR 
(100 MHz, CDCl3) δ 144.4, 135.7, 135.6, 132.9, 132.7, 129.99, 129.95, 127.89, 127.83, 
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102.4, 71.7, 69.7, 63.8, 26.8, 19.3; HRMS (FAB m/z) calcd for C22H28O4SiLi (M+Li+) 
391.1917, obsd 391.1906. 
3,4-Di-O-benzyl-6-O-(tert-Butyldiphenylsilyl)-D-glucal (1).  To 
a solution of 45 (6.3 g, 16.1 mmol) in DMF (100 mL) was added 
NaH (708 mg, 17.7 mmol) portionwise at 0 °C. After stirring for 
30 min, BnBr (2.1 mL, 17.7 mmol) was added through syringe. The reaction mixture was 
slowly raised to room temperature and stirred overnight. Saturated NH4Cl solution was 
added to quench the reaction. The mixture was extracted with DCM (3 x 50 mL). The 
organic phases were combined and sequentially washed with NH4Cl, water, brine. The 
organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The residue 
was purified by flash column chromatography (10% Et2O -hexanes) to yield 1 (7.6 g, 
80%) as a colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.75 (m, 4 H), 7.27 – 7.50 
(m, 14 H), 7.22 – 7.28 (m, 2 H), 6.29 (d, J = 6.4 Hz, 1 H), 4.73 (d, J = 11.6 Hz, 1 H), 4.65 
(s, 2 H), 4.56 (d, J = 11.2 Hz, 1H), 4.50 (dd, J = 4.4, 6.4 Hz, 1 H), 4.42 (t, J = 4.4 Hz, 1 
H), 4.20 (dt, J = 2.8, 6 Hz, 1 H), 3.97 (dd, J = 6, 10.4 Hz, 1 H), 3.81 (dd, J = 5.2, 6.4 Hz, 
1 H), 3.79 (dd, J = 2.8, 10.8 Hz, 1 H), 1.11 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 143.3, 
138.1, 138.0, 136.0, 135.9, 134.1, 133.5, 129.8, 128.44, 128.38, 127.9, 127.79, 127.74, 
127.71, 127.66, 102.5, 76.3, 73.5, 73.2, 68.6, 67.8, 27.0, 19.2; HRMS (ESI m/z) calcd for 
C36H40O4SiNa (M+Na+) 587.2594, obsd 587.2585. 
 
3,4-Di-O-benzyl-6-O-(tert-butyldiphenylsilyl)-2-deoxy-2-iodo-
α-D-mannopyranosyl-2-(trimethylsilyl)ethanesulfonamide 
(46). To a suspension of glucal 1 (3.68 g, 6.54 mmol), 2-
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(trimethylsilyl)ethanesulfonamide (4.74 g, 26.2 mmol) and powdered 4 Å molecular 
sieves (4 g) in CH2Cl2 (30 mL) at 0 °C was added I(sym-collidine)2ClO4 (12.3 g, 26.2 
mmol) in CH2Cl2 (10 mL). Following stirring for 30 min, the mixture was filtered and 
diluted with CH2Cl2 (100 mL). The organic layers were sequentially washed with 
Na2S2O3 (30 mL), saturated CuSO4 (5 x 20 mL), Na2S2O3 (20 mL), and saturated NaCl 
(30 mL), dried over MgSO4, and concentrated in vacuo. The residue was purified by flash 
column chromatography (10% EtOAc -hexanes) to yield 46 (3.6 g, 64%) as a white foam: 
1H NMR (400 MHz, CDCl3) δ 7.67 – 7.71 (m, 4 H), 7.24 – 7.46 (m, 16 H), 5.62 (d, J = 
8.4 Hz, 1 H), 5.50 (dd, J = 4.8, 8.8 Hz, 1 H), 4.80 (d, J = 11.2 Hz, 1 H), 4.69 (d, J = 11.6 
Hz, 1 H), 4.63 (d, 11.2 Hz, 1 H), 4.59 (t, J = 4.4 Hz, 1 H), 4.57 (d, J = 11.6 Hz, 1 H), 4.13 
(t, J = 6.4 Hz, 1 H), 4.02 (dd, J = 4, 10.8 Hz, 1 H), 3.86 (dd, J = 4.4, 11.2 Hz, 1 H), 3.82 
(td, J = 4, 6 Hz, 1 H), 3.36 (dd, J = 3.6, 6.8 Hz, 1 H), 2.83 – 2.97 (m, 2 H), 1.10 (s, 9 H), 
0.84 – 1.01 (m, 2 H), -0.12 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 137.8, 137.1, 135.8, 
135.6, 133.3, 132.8, 129.79, 129.75, 128.52, 128.50, 128.2, 128.02, 127.97, 127.8, 127.7, 
82.2, 77.7, 77.2, 75.2, 74.2, 73.8, 71.9, 61.8, 51.1, 30.9, 26.9, 19.3, 10.1, -2.1; HRMS 
(ESI m/z) calcd for C41H54O6NSSi2INa(M+Na+) 894.2153, obsd 894.2149. 
 
Benzyl 3,4-bis-O-benzyl-6-O-(tert-butyldiphenylsilyl)-2-
dexoy-2-trimethylsilylethylsulfonyl-amino-β-D-
glucopyranoside (2). To a solution of iodosulfonamide 46 (2.1 g, 
2.35 mmol) and benzyl alcohol (365 L, 3.5 mmol) in THF (20 mL) at -78 °C was added 
LiHMDS (5.2 mL, 1M in THF, 5.2 mmol) dropwise. After stirring for 10 min, a solution 
of AgOTf (900mg, 3.5 mmol) in THF (5 mL) was added to the reaction mixture. The 
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reaction flask was covered with foil and allowed to warm to room temperature. The 
mixture was then stirred overnight followed by addition of solid NH4Cl (several 
equivalents). The mixture was stirred for 10 minutes and filtered through a pad of Celite. 
The filtrate was concentrated and further purified by flash column chromatography (20% 
EtOAc -hexanes) to afford 2 (1.6 g, 80%) as a white solid: 1H NMR (400 MHz, CDCl3) δ 
7.68 – 7.75 (m, 4 H), 7.17 – 7.44 (m, 21 H), 4.92 (d, J = 12 Hz, 1 H), 4.91 (d, J = 10.8 Hz, 
1 H), 4.86 (d, J = 9.6 Hz, 2 H), 4.70 (d, J = 10.8 Hz, 1 H), 4.61 (d, J = 11.6 Hz, 1 H), 4.33 
(d, J = 7.6 Hz, 1 H), 4.18 (d, J = 7.6 Hz, 1 H), 3.94 (d, J = 2.8 Hz, 2 H), 3.87 (t, J = 8.8 
Hz, 1 H), 3.46 – 3.60 (m, 2 H), 3.35 (td, J = 3.2, 9.2 Hz, 1 H), 2.90 – 3.09 (m, 2 H), 1.08 
(s, 9 H), 0.96 – 1.05 (m, 2 H), -0.11 (s, 9 H); 13C NMR (100 MHz, CDCl3) δ 137.9, 137.7, 
136.7, 135.9, 135.6, 133.5, 132.9, 129.72, 129.71, 128.61, 128.58, 128.50, 128.12, 128.06, 
127.99, 127.8, 127.8, 127.6, 99.8, 82.0, 77.9, 76.1, 74.86, 74.78, 69.9, 62.6, 58.8, 50.8, 
26.8, 19.3, 10.2, -2.17; HRMS (FAB m/z) calcd for C48H62O7NSSi2 (M+H+) 852.3786, 
obsd. 852.3770. 
 
N-benzyl-2-(trimethylsilyl)-N-((2R,3R,4R,5S,6R)-2,4,5-
tris(benzyloxy)-6-(((tert-
butyldiphenylsilyl)oxy)methyl)tetrahydro-2H-pyran-3-
yl)ethanesulfonamide (47). To a solution of 2 (1.2 g, 1.41 mmol) and BnBr (168 L, 
1.41 mmol) in DMF (20 mL) was added NaH (62 mg, 60% suspension in mineral oil) at 
0 °C. The reaction was allowed to rise to room temperature slowly. After stirring 
overnight, the reaction was diluted by CH2Cl2 and quench with saturated NH4Cl. The 
organic layers were sequentially washed with water and brine, then dried over MgSO4, 
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filtered and evaporated. The crude product was purified by flash column chromatography 
(10% EtOAc -hexanes) to afford 47 (1.13 g, 86%) as a colorless oil: 1H NMR (400 MHz, 
DMSO-d6, 90 °C) δ 7.65-7.71 (m, 4 H), 7.22-7.48 (m, 24 H), 7.13-7.19 (m, 2 H), 4.84 (d, 
J = 8.4 Hz, 1 H), 4.83 (d, J = 11.6 Hz, 1 H), 4.77 (s, 2 H), 4.71 (d, J = 11.2 Hz. 1H), 4.61 
(d, J = 11.2 Hz, 1 H), 4.53 (d, J = 15.6 Hz, 1 H), 4.50 (d, J = 11.6 Hz, 1 H), 4.46 (d, J = 
11.6 Hz, 1 H), 3.91-4.08 (m, 3 H), 3.75 (t, J = 8.8 Hz, 1 H), 3.67 (t, J = 9.6 Hz, 1 H), 3.54 
(ddd, J = 2.0, 4.8, 9.6 Hz, 1 H), 2.65-2.83 (m, 2 H), 1.06 (s, 9 H), 0.821-0.945 (m, 2 H), -
0.169 (s, 9 H); 13C NMR (100 MHz, C6D6, 75 °C) δ 139.2, 138.7, 137.9, 137.6, 135.9, 
135.7, 134.9, 134.1, 133.7, 129.6, 129.3, 128.4, 128.3, 128.2, 127.8, 127.6, 127.5, 127.3, 
127.2, 100.0, 80.3, 76.5, 74.5, 70.2, 63.6, 52.8, 51.3, 26.9, 26.5, 19.3, 10.1, -2.49; HRMS 
(FAB m/z) calcd for C55H68NO7SSi2 (M+H+) 942.4177, obsd. 942.4298. 
 
N-benzyl-2-(trimethylsilyl)-N-((2R,3R,4R,5S,6R)-2,4,5-
tris(benzyloxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-
yl)ethanesulfonamide (3). To a solution of 47 (629 mg, 0.67 
mmol) in THF (7 mL) was added TBAF (0.67 mL, 1 M solution in THF) dropwise at 
0 °C. The mixture was stirred at 0 °C for 16 h. Saturated NH4Cl was added to quench the 
reaction. The aqueous layer was extracted with Et2O (3 x 10 mL). The organic layer was 
dried over MgSO4, filtered, evaporated. The residue was purified by flash column 
chromatography (20% EtOAc -hexanes) to afford 3 (358 mg, 76%) as a colorless oil: 1H 
NMR (400 MHz, DMSO-d6, 90 °C) δ 7.42-7.48 (m, 2 H), 7.22-7.41 (m, 18 H), 4.86 (d, J 
= 11.6 Hz, 1 H), 4.71-4.82 (m, 3 H), 4.67 (s, 2 H), 4.47 (d, J = 6.8 Hz, 1 H), 4.45 (d, J = 
12 Hz, 1 H), 4.41 (t, J = 5.2 Hz, 1 H), 3.99 (t, J = 9.2 Hz, 1 H), 3.73-3.80 (m, 1 H), 3.71 
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(d, J = 8.8 Hz, 1 H), 3.65 (t, J = 5.2 Hz, 1 H), 3.60 (t, J = 8.4 Hz, 1 H), 3.39 (ddd, J = 2.4, 
4.8, 9.6 Hz, 1 H), 2.67-2.83 (m, 2 H), 0.857-0.900 (m, 2 H), -0.165 (m, 9 H); 13C NMR 
(100 MHz, DMSO-d6, 90 °C) δ 139.1, 138.9, 137.91, 137.88, 129.7, 128.65, 128.59, 
128.5, 128.4, 128.3, 128.1, 128.0, 127.9, 127.85, 127.78, 127.6, 99.4, 80.2, 76.3, 73.9, 
73.5, 70.2, 61.1, 50.2, 10.2, -1.74; HRMS (FAB m/z) calcd for C39H49NO7SSi2Na 
(M+Na+) 726.2897, obsd. 726.2902. 
 
Dibenzyl (2-((2R,3R,4R,5R,6R)-5-(N-benzyl-2--
trimethylsilyl)ethylsulfonamido)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-
yl)ethyl)phosphonate (5). To a solution of 3 (112 mg, 0.16 
mmol) and 2,6-di-tert-butyl-4-methylpyridine (98 mg, 0.48 mmol) in CH2Cl2 (2 mL), 
was slowly added trifluoromethanesulfonic anhydride (54 L, 0.32 mmol) at -40 °C and 
stirring continued for 0.5 h at that temperature. The reaction mixture was then 
concentrated in vacuo and directly applied to column chromatography (8% EtOAc -
hexanes) to afford the triflate 4 (120 mg, 90%) as a pale yellow oil: HRMS (ESI m/z) 
calcd for C40H48O9NF3S2SiNa (M+Na+) 858.2390, obsd. 858.2386.  
Then the triflate 4 (120 mg, 0.144 mmol) was dissolved in THF (2 mL) with dibenzyl 
methylphosphonate (151 mg, 0.576 mmol) and cooled to -78 °C. To the solution was 
added slowly n-BuLi (0.36 mL, 1.6 M solution in hexanes). After stirring for 10 min at -
78 °C, the reaction was quenched with saturated aqueous NH4Cl. Then Et2O (20 mL) was 
added to dilute the solution. The organic layers were sequentially washed with NH4Cl, 
water and brine, and then dried over MgSO4. Filtration and evaporation gave crude 
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product, which was purified by flash column chromatography (20-40% EtOAc-hexanes) 
to afford 5 (85 mg, 62%) as a colorless oil: 1H NMR (400 MHz, DMSO-d6, 90 °C) δ 
7.41-7.46 (m, 2 H), 7.17-7.40 (m, 28 H), 5.04 (d, J = 12.4 Hz, 1 H), 5.01 (d, J = 12.8 Hz, 
1 H), 4.98 (d, J = 12.8 Hz, 1 H), 4.96 (d, J = 12 Hz, 1 H), 4.72-4.83 (m, 4 H), 4.69 (d, J = 
11.2 Hz, 1 H), 4.57 (d, J = 4.57 Hz, 1 H), 4.50 (d, J = 15.6 Hz, 1 H), 4.44 (d, J = 12 Hz, 1 
H), 4.43 (d, J = 15.2 Hz, 1 H), 3.95 (t, J = 8.8 Hz, 1 H), 3.68 (t, J = 8.8 Hz, 1 H), 3.41 (dt, 
J = 2.8, 9.2 Hz, 1 H), 3.33 (t, J =  12.8 Hz, 1 H), 2.63-2.84 (m, 2 H), 2.02-2.16 (m, 1 H), 
1.81-2.02 (m, 2 H), 1.66-1.82 (m, 1 H), 0.839-0.948 (m, 2 H), -0.169 (s, 9 H); 13C NMR 
(100 MHz, DMSO-d6, 90 °C) δ 139.0, 138.6, 137.9, 137.8, 137.3 (d, Jcp = 6 Hz), 129.7, 
128.8, 128.6, 128.6, 128.49, 128.46, 128.1, 128.0, 127.9, 127.8, 127.7, 99.6, 83.3, 74.1, 
74.0 (d, Jcp = 15 Hz), 73.4, 70.6, 67.0 (d, Jcp = 7.5 Hz), 66.97 (d, Jcp = 7.5 Hz), 50.3, 
25.1 (d, Jcp = 5 Hz), 21.6 (d, Jcp = 139.5 Hz), 10.2, -1.75; 31P NMR (162 MHz, DMSO-
d6, 90 °C) δ 32.60; HRMS (ESI m/z) calcd for C54H64NO9PSSi2Na (M+Na+) 984.3706, 
obsd. 984.3746. 
 
Dibenzyl (2-((2R,3R,4R,5R,6R)-5-(benzylamino)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-
yl)ethyl)phosphonate (48). To a solution of 5 (162 mg, 0.168 
mmol) in DMF (3 mL) was added CsF (179 mg, 1.18 mmol) in 
one portion. The mixture was heated to 90 °C and stirred for 16 h. Saturated aqueous 
NH4Cl was added to quench the reaction. The mixture was extracted with ethyl acetate. 
The organic layers were dried over MgSO4, filtered and concentrated in vacuum. The 
crude product was purified by flash column chromatography (30-50% EtOAc-hexanes) to 
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give 48 (90 mg, 68%) as a white solid: 1H NMR (400 MHz, CDCl3) δ 7.22-7.39 (m, 28 
H), 7.16-7.19 (m, 2 H), 5.08 (d, J = 12 Hz, 1 H), 5.06 (d, J = 12 Hz, 1 H), 5.00 (d, J = 
11.6 Hz, 1 H), 4.98 (d, J = 12 Hz, 1 H), 4.90 (d, J = 11.6 Hz, 1 H), 4.86 (d, J = 12 Hz, 1 
H), 4.81 (d, J = 10.8 Hz, 1 H), 4.69 (d, J = 11.2 Hz, 1 H), 4.59 (t, J = 10.8 Hz, 2 H), 4.33 
(d, J = 8 Hz, 1 H), 4.01 (d, J = 13.2, Hz ,1 H), 3.82 (d, J = 13.2 Hz, 1 H), 3.44 (t, J = 8.4 
Hz, 1 H), 3.22-3.34 (m, 2 H), 2.72 (dd, J = 8, 10 Hz, 1 H), 2.15-2.29 (m, 1 H), 1.98-2.14 
(m, 1 H), 1.71-1.92 (m, 2 H); 13C NMR (100 MHz, CDCl3) δ 140.6, 138.0, 137.7, 137.4, 
136.44 (d, Jcp = 6 Hz), 136.43 (d, Jcp = 6 Hz), 128.6, 128.5, 128.45, 128.40, 128.35, 
128.27, 128.0, 127.9, 127.8, 126.8, 103.8, 83.5, 82.5, 75.1, 74.4 (d, Jcp = 16 Hz), 71.2, 
67.14 (d, Jcp = 6 Hz), 67.11 (d, Jcp = 6 Hz), 62.8, 53.7, 24.8 (d, Jcp = 4 Hz), 22.1 (d, Jcp 
= 142 Hz); 31P NMR (162 MHz, CDCl3) δ 33.27; HRMS (ESI m/z) calcd for 
C49H52NO7PNa (M+Na+) 820.3379, obsd 820.3378. 
 
 Glucosamine 6-phosphonate (6). A solution of 48 (46 mg, 0.058 
mmol) in MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C (18 mg) and trace amount of TFA (1 drop), under 
balloon pressure of hydrogen, for 24 h at room temperature. 
Filtrate the mixture through a pad of Celite and wash the filter cake with 2 mL MeOH. 
Suspend the filter cake in 2 mL H2O and stir for 5 min, and then filtrate again through a 
pad of Celite. Concentrate the aqueous solution and dry over high vacuum to yield 6 (12 
mg, 87%) as a colorless foam: 1H NMR (400 MHz, D2O) δ 5.30 (d, J = 3.6 Hz, 0.5 H), 
4.77 (d, J = 8.4 Hz, 0.5 H), 3.70-3.80 (m, 1 H), 3.50 (dd, J = 1.6, 8.8 Hz, 0.5 H), 3.35 (dt, 
J = 2.4, 10 Hz, 0.5 H), 3.23 (t, J = 9.2 Hz, 1 H), 3.17 (dd, J = 4, 10.8 Hz, 0.5 H), 2.85 (dd, 
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J = 2, 8.4 Hz, 0.5 H), 1.96-2.00 (m, 1 H), 1.52-1.72 (m, 2 H), 1.37-1.46 (m, 1 H); 13C 
NMR (100 MHz, D2O) δ 99.2, 89.2, 75.9 (d, Jcp = 16 Hz), 73.04, 73.05, 72.4, 71.4 (d, 
Jcp = 17 Hz), 69.8, 57.0, 54.5, 25.1 (d, Jcp = 4 Hz), 24.9 (d, Jcp = 3 Hz), 23.5 (d, Jcp = 
133 Hz), 23.6 (d, Jcp = 135 Hz); 31P NMR (162 MHz, D2O) δ 24.91, 24.77; HRMS (ESI 
m/z) calcd for C7H16NO7PNa (M+Na+) 280.0562, obsd 280.0567. 
 
N-methyl-2-(trimethylsilyl)-N-((2R,3R,4R,5S,6R)-2,4,5-
tris(benzyloxy)-6-(((tert-
butyldiphenylsilyl)oxy)methyl)tetrahydro-2H-pyran-3-
yl)ethanesulfonamide (49). To a solution of 2 (200 mg, 0.212 mmol) in DMF (2 mL) 
was added NaH (10 mg, 60% suspension in mineral oil, 0.233 mmol) at 0 °C. The 
mixture was stirred for 0.5 h at 0 °C. Then MeI (15 L, 0.233 mmol) was added to the 
solution. The reaction was allowed to rise to room temperature slowly. After stirring 
overnight, the reaction was diluted by CH2Cl2 and quench with saturated NH4Cl. The 
organic layers were sequentially washed with water and brine, then dried over MgSO4, 
filtered and evaporated. The crude product was purified by flash column chromatography 
(30% EtOAc-hexanes) to afford 49 (168 mg, 92%) as a colorless oil: 1H NMR (400 MHz, 
DMSO-d6, 90 °C) δ 7.13-7.81 (m, 25 H), 4.85 (d, J = 11.6 Hz, 2 H), 4.78 (d, J = 8.8 Hz, 
1 H), 4.78 (d, J = 10.8 Hz, 1 H), 4.74 (d, J = 11.2 Hz, 1 H), 4.68 (d, J = 12 Hz, 1 H), 4.62 
(d, J = 11.6 Hz, 1 H), 4.01 (dd, J = 2, 11.6 Hz, 1 H), 3.90-3.97 (m, 2 H), 3.72 (dd, J = 8.4, 
10 Hz, 1 H), 3.67 (dd, J = 8.4, 9.6 Hz, 1 H), 3.58 (ddd, J =  1.2, 4.4, 9.6 Hz, 1 H), 3.05 (s, 
3 H), 2.89-2.96 (m, 2 H), 1.07 (s, 9 H), 0.85-0.99 (m, 2 H), -0.09 (s, 9 H); 13C NMR (100 
MHz, DMSO-d6, 90 °C) δ 139.0, 138.8, 137.7, 135.7, 135.5, 135.0, 133.9, 133.7, 130.1, 
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128.8, 128.6, 128.5, 128.3, 128.21, 128.15, 128.07, 1277.9, 127.8, 127.7, 98.1, 79.3, 79.0, 
75.9, 74.3, 73.9, 70.2, 63.7, 62.4, 30.3, 19.4, 10.2, -1.7; HRMS (ESI m/z) calcd for 
C49H63NO7Si2SNa (M+Na+) 888.3762, obsd 888.3748. 
 
N-methyl-2-(trimethylsilyl)-N-((2R,3R,4R,5S,6R)-2,4,5-
tris(benzyloxy)-6-(hydroxymethyl) 
tetrahydro-2H-pyran-3-yl)ethanesulfonamide (24). TBAF 
(0.19 mL, 1 M solution in THF) was added to a solution of 49 (168 mg, 0.194 mmol) in 
THF (2 mL) at 0 °C. The mixture was raised to room temperature and stirred for 12 h. 
Then saturated NH4Cl was added and the mixture was extracted with Et2O. The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuum. 
The crude product was purified by flash column chromatography (40% EtOAc-hexanes) 
to yield 24 (113 mg, 93%) as a white solid: 1H NMR (400 MHz, DMSO-d6, 90 °C) δ 
7.22-7.42 (m, 15 H), 4.86 (d, J = 9.6 Hz, 1 H), 4.83 (d, J = 8.4 Hz, 1 H), 4.66-4.76 (m, 5 
H), 4.39 (t, J = 5.2 Hz, 1 H), 3.88 (dd, J = 8.4, 10.4 Hz, 1 H), 3.78 (ddd, J = 1.2, 4.0, 12.0 
Hz, 1 H), 3.67 (dd, J = 8.4, 10.4 Hz, 1 H), 3.64 (t, J = 6.4 Hz, 1 H), 3.59 (t, J = 8.4 Hz, 1 
H), 3.42 (ddd, J = 2, 4.8, 9.2 Hz, 1 H), 2.86-2.92 (m, 2 H), 2.97 (br s, 1 H), 2.82 (s, 3 H), 
0.841-0.956 (m, 2 H), -0.095 (s, 9 H); 13C NMR (100 MHz, DMSO-d6, 90 °C) δ 139.1, 
137.8, 128.7, 128.6, 128.5, 128.4, 128.2, 128.1, 127.9, 127.8, 127.7, 98.3, 79.5, 79.1, 76.4, 
74.1, 73.7, 70.5, 62.3, 61.2, 47.5, 31.1, 30.3, 10.2, -1.65; HRMS (ESI m/z) calcd for 
C33H45NO7SSiNa (M+Na+) 650.2584, obsd. 650.2587. 
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 Dibenzyl (2-((2R,3R,4R,5R,6R)-3,4,6-tris(benzyloxy)-5-(N-methyl-2-
(trimethylsilyl)ethyl 
sulfonamido)tetrahydro-2H-pyran-2-yl)ethyl)phosphonate 
(25). To a solution of 24 (188 mg, 0.3 mmol) and 2,6-di-tert-
butyl-4-methylpyridine (184 mg, 0.9 mmol) in CH2Cl2 (3 mL), 
was slowly added trifluoromethanesulfonic anhydride (101 L, 
0.6 mmol) at -40 °C and stirring continued for 0.5 h at that temperature. The reaction 
mixture was then concentrated in vacuo and directly applied to column chromatography 
(10-20% EtOAc -hexanes) to afford the corresponding triflate (186 mg, 82%) as a pale 
yellow oil: HRMS (ESI m/z) calcd for C34H44O9NF3S2SiNa (M+Na+) 759.2179, obsd. 
782.2056.  
 
Then the triflate (186 mg, 0.246 mmol) was dissolved in THF (3 mL) with dibenzyl 
methylphosphonate (258 mg, 0.984 mmol) and cooled to -78 °C. To the solution was 
added slowly n-BuLi (0.62 mL, 1.6 M solution in hexanes, 0.984 mmol). After stirring 
for 15 min at -78 °C, the reaction was quenched with saturated aqueous NH4Cl. Then 
Et2O (50 mL) was added to dilute the solution. The organic layers were sequentially 
washed with NH4Cl, water and brine, and then dried over MgSO4, filtered and 
concentrated in vacuum to give crude product, which was purified by flash column 
chromatography (30-40% EtOAc-hexanes) to afford 25 as a colorless oil: 1H NMR (400 
MHz, DMSO-d6, 90 °C) δ 7.15-7.65 (m, 25 H), 5.06 (dd, J = 1.6, 8.4 Hz, 1 H), 5.03 (dd, 
J = 2, 8.4 Hz, 1 H), 5.00 (dd, J = 2.4, 8 Hz, 1 H), 4.97 (dd, J = 2.4, 8 Hz, 1 H), 4.84 (d, J 
= 11.2 Hz, 1 H), 4.78 (d, J = 7.2 Hz, 1 H), 4.75 (d, J = 6.8 Hz, 1 H), 4.71 (d, J = 10.8 Hz, 
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1 H), 4.65 (d, J = 8.4 Hz, 1 H), 4.62 (d, J = 9.6 Hz, 1 H), 4.60 (d, J = 9.2 Hz, 1 H), 3.82 
(dd, J = 8.4, 10.4 Hz, 1 H), 3.68 (dd, J = 8.4, 10 Hz, 1 H), 3.43 (dt, J = 2.8, 9.2 Hz, 1 H), 
3.35 (dd, J = 8.4, 9.2 Hz, 1 H), 2.85-2.94 (m, 2 H), 2.81 (s, 3 H), 1.66-2.21 (m, 4 H), 
0.83- 1.02 (m, 2 H), -0.09 (s, 9 H); 13C NMR (100 MHz, DMSO-d6, 90 °C) δ 138.9, 
138.7, 137.8, 137.3 (d, Jcp = 6 Hz), 128.8, 128.7, 128.6, 128.5, 128.4, 128.2, 128.05, 
128.02, 127.93, 127.86, 127.7, 98.6, 82.7, 79.0, 74.3, 74.0 (d, Jcp = 15 Hz), 73.7, 70.8, 
67.0 (d, Jcp = 6 Hz), 66.96 (d, Jcp = 6 Hz), 47.6, 30.4, 25.1 (Jcp = 4 Hz), 21.6 (Jcp = 139 
Hz), 10.2, -1.7; 31P NMR (162 MHz, CDCl3) δ 32.62; HRMS (ESI m/z) calcd for 
C43H48NO7PNa (M+Na+) 908.3393, obsd 908.3367. 
 
Dibenzyl (2-((2R,3R,4R,5R,6R)-3,4,6-tris(benzyloxy)-5-
(methylamino)tetrahydro-2H-pyran-2-yl)ethyl)phosphonate 
(26). To a solution of 25 (107 mg, 0.12 mmol) in DMF (2 mL) 
was added CsF (127 mg, 0.84 mmol) in one portion. The 
mixture was heated to 90 °C and stirred for 12 h. Saturated aqueous NH4Cl was added to 
quench the reaction. The mixture was extracted with ethyl acetate. The combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuum. The crude product 
was purified by flash column chromatography (50% EtOAc-hexanes) to give 26 (62 mg, 
72%) as a pale yellow solid: 1H NMR (400 MHz, CDCl3) δ 7.23-7.42 (m, 25 H), 5.08 (d, 
J = 11.6 Hz, 1 H), 5.05 (d, J = 11.6 Hz, 1 H), 5.00 (d, J = 12 Hz, 1 H), 4.98 (d, J = 11.6 
Hz, 1 H), 4.94 (d, J = 11.6 Hz, 1 H), 4.84 (d, J = 7.2 Hz, 1 H), 4.81 (d, J = 6.4 Hz, 1 H), 
4.70 (d, J = 11.6 Hz, 1 H), 4.62 (d, J = 10.8 Hz, 1 H), 4.56 (d, J = 11.6 Hz, 1 H), 4.26 (d, 
J = 8.0 Hz, 1 H), 3.41 (dd, J = 8.4, 10 Hz, 1 H), 3.31 (t, J = 9.2 Hz, 1 H), 3.25 (dt, J = 2.8, 
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9.2 Hz, 1 H), 2.51 (dd, J = 8, 10 Hz, 1 H), 2.42 (s, 3 H), 2.15-2.27 (m, 1 H), 1.94-2.11 (m, 
1 H), 1.70-1.99 (m, 2 H), 1.65 (s, 1 H); 13C NMR (100 MHz, CDCl3) δ 138.2, 137.7, 
137.4, 136.43 (d, Jcp = 6 Hz), 136.42 (d, Jcp = 6 Hz), 128.6, 128.5, 128.42, 128.40, 
128.00, 127.98, 127.94, 127.84, 127.81, 103.3, 83.3, 82.5, 77.3, 75.1, 74.9, 74.3 (d, Jcp = 
16 Hz), 71.1, 67.14 (d, Jcp = 7 Hz), 67.11 (d, Jcp = 7 Hz), 65.1, 24.8 (d, Jcp = 4 Hz), 
22.1 (d, Jcp = 141 Hz); 31P NMR (162 MHz, CDCl3) δ 33.11; HRMS (ESI m/z) calcd for 
C43H48NO7PNa (M+Na+) 744.3066, obsd 744.3081. 
 
N-Methyl glucosamine 6-phosphonate (27). A solution of 26 (36 
mg, 0.05 mmol) in MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C (15 mg) and trace amount of TFA (1 drop), under 
balloon pressure of hydrogen, for 24 h at room temperature. 
Filtrate the mixture through a pad of Celite and wash the filter cake with 2 mL MeOH. 
Suspend the filter cake in 2 mL H2O and stir for 5 min, and then filtrate again through a 
pad of Celite. Concentrate the aqueous solution and dry over high vacuum to yield 27 (11 
mg, 82%) as a colorless foam: 1H NMR (400 MHz, D2O) δ 5.45 (d, J = 3.2 Hz, 0.7 H), 
4.94 (d, J = 8.4 Hz, 0.3 H), 3.62-3.84 (m, 1.7 H), 3.36 (t, J = 7.6 Hz, 0.3 H), 3.20-3.27 (m, 
1 H), 3.15 (dd, J = 3.2, 10.4 Hz, 0.7 H), 2.72-2.94 (m, 0.3 H), 2.76 (s, 0.9 H), 2.72 (s, 2.1 
H), 1.90-2.09 (m, 1 H), 1.48-1.77 (m, 3 H); 13C NMR (100 MHz, D2O) δ 91.8, 87.4, 75.5 
(d, Jcp = 16 Hz), 73.4, 73.1, 70.8 (d, Jcp = 17 Hz), 70.3, 69.5, 63.0, 61.3, 30.95, 30.86, 
24.7 (d, Jcp = 3 Hz), 24.5 (d, Jcp = 3 Hz), 22.90 (d, Jcp = 134 Hz), 22.89 (d, Jcp = 134 
Hz); 31P NMR (162 MHz, D2O) δ 25.25, 25.06; HRMS (ESI m/z) calcd for C8H19NO7P 
(M+H+) 272.0899, obsd 272.0891. 
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Dibenzyl (2-((2R,3R,4R,5R,6R)-3,4,6-tris(benzyloxy)-5-
(dimethylamino)tetrahydro-2H-pyran-2-
yl)ethyl)phosphonate (28). To a solution of 26 (75 mg, 0.1 
mmol) in THF (1 mL) was added n-BuLi (71 L, 1.6 M solution 
in hexanes, 0.11 mmol) dropwise at -78 °C. The mixture was stirred at that temperature 
for 30 min, followed by addition of MeI (7 L, 0.11 mmol). The solution was then raised 
to 0 °C and stirred for 3 h when TLC indicated the completion of the reaction. The 
reaction was quenched with saturated NH4Cl and extracted with Et2O. The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuum. The crude 
product was purified by flash column chromatography (30% EtOAc-hexanes) to give 28 
(68 mg, 93%) as a pale yellow solid: 1H NMR (400 MHz, CDCl3) δ 7.24-7.42 (m, 25 H), 
5.09 (dd, J = 3.2, 9.2 Hz, 1 H), 5.06 (dd, J = 2.8, 8.8 Hz, 1 H), 5.01 (dd, J = 1.2, 8 Hz, 1 
H), 4.98 (dd, J = 1.2, 8.4 Hz, 1 H), 4.97 (d, J = 11.2 Hz, 1 H), 4.87 (d, J = 10.8 Hz, 1 H), 
4.84 (d, J = 11.6 Hz, 1 H), 4.75 (d, J = 10.4 Hz, 1 H), 4.59 (d, J = 10.8 Hz, 1 H), 4.54 (d, 
J = 11.6 Hz, 1 H), 4.43 (d, J = 8.8 Hz, 1 H), 3.54 (dd, J = 8, 10 Hz, 1 H), 3.16-3.25 (m, 2 
H), 2.67 (dd, J = 8.4, 10 Hz, 1 H), 2.46 (s, 6 H), 2.15-2.28 (m, 1 H), 1.98-2.11 (m, 1 H), 
1.82-1.92 (m, 1 H), 1.66-1.81 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 138.9, 138.2, 
137.3, 136.45 (d, Jcp = 6 Hz), 136.43 (d, Jcp = 6 Hz), 128.6, 128.42, 128.40, 128.35, 
128.32, 128.2, 128.1, 128.01, 127.97, 127.94, 127.8, 127.7, 127.5, 100.1, 82.3, 80.7, 77.3, 
75.1, 75.0, 73.9 (d, Jcp = 15 Hz), 70.5, 69.4, 67.1 (d, Jcp = 6 Hz), 41.7, 25.1 (d, Jcp = 4 
Hz), 22.0 (d, Jcp = 141 Hz); 31P NMR (162 MHz, CDCl3) δ 33.32; HRMS (ESI m/z) 
calcd for C44H50NO7PNa (M+Na+) 758.3223, obsd 758.3226. 
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N, N-Dimethyl glucosamine 6-phosphonate (29). A solution of 
28 (62 mg, 0.084 mmol) in MeOH (3 mL) was stirred in the 
presence of 40% Pd(OH)2/C (25 mg) and trace amount of TFA (1 
drop), under balloon pressure of hydrogen, for 24 h at room 
temperature. Filtrate the mixture through a pad of Celite and evaporate the solvent to 
yield 29 (21 mg, 89%) as a colorless foam: 1H NMR (400 MHz, D2O) δ 5.50 (d, J = 2.8 
Hz, 0.4 H), 5.02 (d, J = 8.4 Hz), 3.97 (t, J = 9.2 Hz, 0.4 H), 3.73-3.82 (m, 1 H), 3.22-2.39 
(m, 2 H), 3.04 (dd, J = 1.6, 8.8 Hz, 0.6 H), 2.95 (s, 2.4 H), 2.93 (s, 3.6 H), 1.97-2.04 (m, 1 
H), 1.42-1.79 (m, 3 H); 13C NMR (100 MHz, D2O) δ 91.2, 88.3, 75.6 (d, Jcp = 16 Hz), 
73.9, 73.8, 70.9 (d, Jcp = 17 Hz), 69.4, 68.8, 67.5, 65.8, 42.2 (br), 41.2 (br), 40.6 (br), 
24.9 (d, Jcp = 3 Hz), 24.7 (d, Jcp = 3 Hz), 23.2 (d, Jcp = 134 Hz), 22.7 (d, Jcp = 133 Hz); 
31P NMR (162 MHz, D2O) δ 25.60, 25.40; HRMS (ESI m/z) calcd for C9H21NO7P 
(M+H+) 286.1056, obsd 286.1061. 
 
Dibenzyl 2-(((2R,3S,4R,5R,6R)-5-(N-benzyl-2-
(trimethylsilyl)ethylsulfonamido)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-
yl)methoxy)malonate (13).  To a stirred solution of 3 (100 mg, 
0.14 mmol) and rhodium acetate dimer (6 mg, 0.014 mmol) in benzene (1 mL), under 
reflux, was added, dropwise, a solution of dibenzyl diazomalonate (44 mg, 0.14 mmol) in 
benzene (1 mL). After complete addition, the reaction mixture was refluxed for 16 h. 
Volatiles were removed under reduced pressure and the crude residue purified by flash 
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chromatography (20% EtOAc-hexane) to give  13 (102 mg, 73%) as a white solid: 1H 
NMR (400 MHz, DMSO-d6, 90 °C) δ 7.20-7.55 (m, 30 H), 5.23 (d, J = 12.8 Hz, 1 H), 
5.21 (d, J = 12.4 Hz, 1 H), 5.17 (d, J = 12.4 Hz, 1 H), 5.16 (d, J = 12.4 Hz, 1 H), 4.96 (s, 
1 H), 4.76-4.87 (m, 4 H), 4.64 (s, 2 H), 4.42-4.56 (m, 3 H), 4.00 (t, 8.8 Hz, 1 H), 3.93 (d, 
J = 3.2 Hz, 2 H), 3.72 (t, J = 8.4 Hz, 1 H), 3.68 (t, J = 9.6 Hz, 1 H), 3.59 (td, J = 3.2, 10 
Hz, 1 H), 2.64-2.83 (m, 2 H), 0.84-0.94 (m, 2 H), -0.17 (m, 9 H); 13C NMR (100 MHz, 
DMSO-d6, 90 °C) δ 166.6, 166.5, 139.0, 138.7, 137.9, 137.7, 135.82, 135.76, 129.7, 
128.8, 128.65, 128.61, 128.58, 128.50, 128.23, 128.20, 128.05, 128.00, 127.96, 127.89, 
127.81, 127.7, 99.4, 80.0, 79.8, 74.8, 74.0, 73.6, 70.5, 70.4, 67.3, 67.2, 50.3, 10.2, -1.75; 
HRMS (ESI m/z) calcd for C56H63NO11SSiNa (M+Na+) 1008.3789, obsd 1008.3747.  
 
Dibenzyl 2-(((2R,3S,4R,5R,6R)-5-(benzylamino)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-yl)methoxy)malonate 
(50). A suspension of 13 (162 mg, 0.16 mmol) and CsF (125 mg, 
0.82 mmol) in DMF (2 mL) was heated at 90 °C for 16 h. The 
reaction was then cooled down and quenched with aqueous 
NH4Cl. The mixture was extracted with EtOAc. The combined organic phase was dried, 
filtered and concentrated in vacuum. The crude product was purified by flash column 
chromatography (20-40% EtOAc-hexanes) to give 50 (93 mg, 71%) as a white solid: 1H 
NMR (400 MHz, CDCl3) δ 7.13 – 7.15 (m, 2 H), 7.21 – 7.32 (m, 28 H), 5.20 (d, J = 12 
Hz, 1 H), 5.17 (s, 2 H), 5.11 (d, J = 12 Hz, 1 H), 4.87 (d, J = 11.6 Hz, 1 H), 4.86 (s, 1 H), 
4.82 (d, J = 11.6 Hz, 1 H), 4.77 (d, J = 10.8 Hz, 1 H), 4.69 (d, J = 10.8 Hz, 1 H), 4.65 (d, 
J = 11.6 Hz, 1 H), 4.55 (d, J = 12 Hz, 1 H), 4.35 (d, J = 7.6 Hz, 1 H), 3.99 (t, J = 2.8 Hz, 
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1 H), 3.97 (t, J = 2 Hz, 1 H), 3.91 (dd, J = 1.6, 12.4 Hz, 1 H), 3.79 (d, J = 12.8 Hz, 1 H), 
3.74 (d, J = 9.2 Hz, 1 H), 3.47 (ddd, J = 1.6, 4.4, 9.2 Hz, 1 H), 3.45 (t, J = 9.2 Hz, 1 H), 
2.70 (dd, J = 7.6, 10 Hz, 1 H); 13C NMR (100 MHz, CDCl3) δ 166.5, 166.4, 140.5, 138.1, 
138.0, 137.4, 135.0, 134.9, 128.59, 128.57, 128.48, 128.40, 128.36, 128.30, 128.1, 127.95, 
127.90, 127.84, 127.76, 126.8, 103.9, 88.3, 80.1, 78.2, 75.4, 74.8, 74.7, 71.1, 70.3, 67.56, 
67.49, 62.3, 53.48, 53.45; HRMS (FAB m/z) calcd for C51H52O9N (M+H+) 822.3642, 
obsd 822.3640. 
 
Glucosamine 6-malonyl ether (14). A suspension of 50 (56 mg, 
0.068 mmol) in MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C (23 mg) and trace amount of TFA (1 drop), under 
balloon pressure of hydrogen, for 24 h at room temperature. 
Filtrate the mixture through a pad of Celite and wash the filter cake with 2 mL MeOH. 
Suspend the filter cake in 2 mL H2O and stir for 5 min, and then filtrate again through a 
pad of Celite. Concentrate the aqueous solution and dry over high vacuum to yield 14 (13 
mg, 72%) as a colorless foam: 1H NMR (500 MHz, D2O) δ 5.42 (d, J = 2.8 Hz, 0.6 H), 
4.92 (d, J = 6.8 Hz, 0.4 H), 4.65 (s, 0.4 H), 4.64 (s, 0.6 H), 4.04 (td, J = 2.4, 8 Hz, 0.6 H), 
3.95 (dd, J = 1.2, 9.2 Hz, 0.4 H), 3.86-3.91 (m, 2 H), 3.82 (dd, J = 4.8, 9.2 Hz, 0.4 H), 
3.62-3.69 (m, 0.6 H), 3.60 (t, J = 7.6 Hz, 0.6 H), 3.55 (t, J = 7.6 Hz, 0.4 H), 3.29 (dd, J = 
2.8, 8.4 Hz, 0.6 H), 3.01 (dd, J = 6.8, 8.4 Hz, 0.4 H); 13C NMR (100 MHz, D2O) δ 171.4, 
171.3, 92.8, 89.1, 75.1, 71.8, 70.7, 69.6, 69.4, 69.3, 56.6, 54.2; HRMS (ESI m/z) calcd for 
C9H15NO9Na (M+Na+) 304.0645, obsd 304.0658.  
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Dibenzyl 2-(((2R,3R,4R,5R,6R)-5-(N-benzyl-2-
(trimethylsilyl)ethylsulfonamido)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-yl)methyl)malonate 
(15). To a solution of the triflate 4 (122 mg, 0.156 mmol) and 
dibenzyl malonate (177 mg, 0.624 mmol) in THF (2 mL) was added LiHMDS (0.624 mL, 
1 M solution in THF, 0.624 mmol) at -78 °C. The solution was then slowly warmed to 
room temperature and stirred overnight. Aqueous NH4Cl was added to quench the 
reaction. The mixture was extracted with Et2O (2 x 20 mL). The combined organic layers 
were dried over MgSO4, filtered and concentrated in vacuum. The residue was purified 
by flash column chromatography (20% EtOAc-hexanes) to afford 15 (124 mg, 82%) as a 
colorless oil: 1H NMR (400 MHz, DMSO-d6, 90 °C) δ 7.21-7.48 (m, 30 H), 5.16 (s, 2 H), 
5.16 (d, J = 12.4 Hz, 1 H), 5.08 (d, J = 12.4 Hz, 1 H), 4.68-4.79 (m, 5 H), 4.63 (d, J = 
11.2, 1 H), 4.50 (d, J = 15.6 Hz, 1 H), 4.43 (d, J = 15.6 Hz, 1 H), 4.33 (d, J = 11.6 Hz, 1 
H), 3.97 (br, 1 H), 3.79 (dd, J = 5.2, 9.2 Hz, 1 H), 3.70 (br, 1 H), 3.39-3.47 (m, 2 H), 
2.61-2.79 (m, 2 H), 2.47 (dd, J = 2.4, 9.2 Hz, 1 H), 2.05-2.13 (m, 2 H), -0.19 (s, 9 H), 13C 
NMR (100 MHz, DMSO-d6, 90 °C) δ 168.9, 168.8, 139.0, 138.5, 137.8, 136.10, 136.08, 
129.7, 128.82, 128.78, 128.64, 128.62, 128.60, 128.5, 128.4, 128.3, 128.08, 128.05, 
127.95, 127.93, 127.8, 127.7, 99.6, 83.5, 74.1, 73.5, 72.5, 70.4, 67.1, 67.0, 50.3, 48.8, 
31.2, 10.2, -1.77; HRMS (ESI m/z) calcd for C56H63O10NSSiNa (M+Na+) 992.3840, obsd 
992.3856. 
 
Dibenzyl 2-(((2R,3R,4R,5R,6R)-5-(benzylamino)-3,4,6-tris(benzyloxy)tetrahydro-
2H-pyran-2-yl)methyl)malonate (16) To a solution of 15 (224 mg, 0.23 mmol) in DMF 
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(3 mL) was added CsF (175 mg, 1.15 mmol) in one portion. The 
suspension was heated to 90 °C and stirred at that temperature for 
16 h. Then the reaction was quenched with aqueous ammonium 
chloride and extracted with ethyl acetate. The combined organic 
phase was dried over MgSO4, filtered and concentrated in vacuum. The crude product 
was purified by flash column chromatography (20-30% EtOAc-hexanes) to give 16 (80 
mg, 44%) as a white solid:  1H NMR (400 MHz, CDCl3) δ 6.95 – 7.33 (m, 30 H), 5.16 (s, 
2 H), 5.16 (d, J = 12.4 Hz, 1 H), 5.11 (d, J = 12.4 Hz, 1 H), 4.87 (d, J = 11.2 Hz, 1 H), 
4.83 (d, J = 10.8 Hz, 1 H), 4.81 (d, J = 12 Hz, 1 H), 4.68 (d, J = 10.8 Hz, 1 H), 4.67 (d, J 
= 11.2 Hz, 1 H), 4.49 (d, J = 12 Hz, 1 H), 4.23 (d, J = 8 Hz, 1 H), 3.98 (d, J = 12.8 Hz, 1 
H), 3.79 (d, J = 12.8 Hz, 1 H), 3.77 (dd, J = 5.2, 10 Hz, 1 H), 3.40 (t, J = 8.4 Hz, 1 H), 
3.34 (t, J = 8.8 Hz, 1 H), 3.28 (dt, J = 2.4, 10 Hz, 1 H), 2.70 (dd, J = 8, 9.2 Hz, 1 H), 2.61 
(ddd, J = 2.4, 10, 14 Hz, 1 H), 2.05 – 2.14 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 169.0, 
168.8, 140.6, 138.0, 137.7, 137.5, 135.3, 128.63, 128.57, 128.54, 128.45, 128.40, 128.37, 
128.29, 128.2, 128.01, 127.99, 127.94, 127.91, 127.7, 126.9, 103.8, 83.3, 82.7, 75.1, 72.4, 
71.0, 67.2, 62.6, 53.4, 48.6, 31.1; HRMS (FAB m/z) calcd for C51H52O8N (M+H+) 
806.3693, obsd 806.3713.  
 
Glucosamine 6-malonate (18). A suspension of 16 (39 mg, 
0.048 mmol) in MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C (15 mg) and trace amount of TFA (1 drop), under 
balloon pressure of hydrogen, for 24 h at room temperature. 
Filtrate the mixture through a pad of Celite and wash the filter cake with 2 mL MeOH. 
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Suspend the filter cake in 2 mL H2O and stir for 5 min, and then filtrate again through a 
pad of Celite. Concentrate the aqueous solution and dry over high vacuum to yield 18 (10 
mg, 78%) as a colorless foam: 1H NMR (400 MHz, D2O) δ 5.27 (d, J = 3.6 Hz, 0.45 H), 
4.76 (d, J = 8.4 Hz, 0.55 H), 3.66-3.76 (m, 1 H), 3.57 (dd, J = 8.4, 10.4 Hz, 0.45 H), 3.15-
3.30 (m, 2.1 H), 2.89 (dd, J = 8.4, 10.4 Hz, 0.45 H), 2.20-2.37 (m, 1 H), 1.68-1.84 (m, 1 
H); 13C NMR (100 MHz, D2O) δ 178.4, 178.2, 92.8, 88.9, 74.3, 73.75, 73.73, 71.9, 69.6, 
69.5, 56.9, 54.4, 31.8, 31.7, 31.6, 31.5; HRMS (ESI m/z) calcd for C9H16NO8 (M M+H+) 
266.0876, obsd 266.0978.  
 
Benzyl 3-((2R,3R,4R,5R,6R)-5-(N-benzyl-2-
(trimethylsilyl)ethylsulfonamido)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-yl)propanoate (17). 
Further elution (40-50% EtOAc-hexanes) to give 17 (67 mg, 
35%) as a white solid: 1H NMR (400 MHz, DMSO-d6, 90 °C) δ 7.22-7.46 (m, 25 H), 
5.12 (d, J = 12.4 Hz, 1 H), 5.08 (d, J = 12.8 Hz, 1 H), 4.70- 4.77 (m, 5 H), 4.62 (d, J = 
11.6 Hz, 1 H), 4.51 (d, J = 15.2 Hz, 1 H), 4.44 (d, J = 7.6 Hz, 1 H), 4.41 (d, J = 3.6 Hz, 1 
H), 3.96 (t, J = 8.8 Hz, 1 H), 3.69 (t, J = 8.8 Hz, 1 H), 3.35-3.43 (m, 2 H), 2.63-2.85 (m, 2 
H), 2.48 (dd, J = 2.8, 10 Hz, 2 H), 2.11-2.20 (m, 1 H), 1.73-1.82 (m, 1 H), 0.82-0.96 (m, 
2 H), -0.17 (s, 9 H), 13C NMR (100 MHz, DMSO-d6, 90 °C) δ 172.8, 139.1, 138.7, 
137.89, 137.84, 136.9, 129.7, 128.8, 128.64, 128.60, 128.5, 128.3, 128.2, 128.07, 128.04, 
127.94, 127.91, 127.8, 127.6, 99.6, 83.6, 74.1, 73.7, 73.5, 70.5, 65.9, 50.3, 30.2, 27.3, 
10.2, -1.75; HRMS (ESI m/z) calcd for C48H57O8NSSiNa (M+Na+) 858.3472, obsd 
858.3477. 
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Benzyl 3-((2R,3R,4R,5R,6R)-5-(benzylamino)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-yl)propanoate (51). To 
a solution of 17 (41 mg, 0.05 mmol) in DMF (1 mL) was added 
CsF (53 mg, 0.35 mmol) in one portion. The suspension was 
heated to 90 °C and stirred overnight. Then the reaction was quenched with aqueous 
ammonium chloride and extracted with ethyl acetate. The combined organic phase was 
dried over MgSO4, filtered and concentrated in vacuum. The crude product was purified 
by flash column chromatography (50% EtOAc-hexanes) to give 51 (26 mg, 78%), as a 
white solid: 1H NMR (400 MHz, CDCl3) δ 7.13-7.42 (m, 25 H), 5.17 (d, J = 12.4 Hz, 1 
H), 5.14 (d, J = 12.4 Hz, 1 H), 4.92 (d, J = 10 Hz, 1 H), 4.90 (d, J = 7.2 Hz, 1 H), 4.87 (d, 
J = 7.2 Hz, 1 H), 4.72 (d, J = 4 Hz, 1 H), 4.69 (d, J = 3.6 Hz, 1 H), 4.61 (d, J = 15.6 Hz, 1 
H), 4.36 (d, J = 8 Hz, 1 H), 4.03 (d, J = 13.2 Hz, 1 H), 3.84 (d, J = 12.8 Hz, 1 H), 3.48 (t, 
J = 8.8 Hz, 1 H), 3.37 (t, J = 9.2 Hz, 1 H), 3.32 (td, J =  2.4, 9.2 Hz, 1 H), 2.75 (dd, J =  8, 
9.6 Hz, 1 H), 2.46-2.63 (m, 2 H), 2.27-2.37 (m, 1 H), 1.80-1.89 (m, 1 H), 1.66 (br, 1 H),  
13C NMR (100 MHz, CDCl3) δ 173.1, 140.5, 138.0, 137.8, 137.4, 136.0, 128.64, 128.61, 
128.56, 128.5, 128.4, 128.33, 128.27, 128.0, 127.8, 126.9, 103.8, 83.5, 82.8, 75.1, 73.9, 
71.1, 66.3, 62.7, 53.5, 30.4, 27.1; HRMS (ESI m/z) calcd for C43H46O6N (M+H+) 
672.3325, obsd 672.3319. 
 
Glucosamine 6-carboxylate (19). A solution of 51 (26 mg, 0.038 
mmol) in MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C (10 mg) and trace amount of TFA (1 drop), under 
88 
 
balloon pressure of hydrogen, for 24 h at room temperature. Filtrate the mixture through a 
pad of Celite and evaporate the solvent to yield 19 (5 mg, 63%) as a colorless foam: 1H 
NMR (400 MHz, D2O) δ 5.22 (d, J = 4 Hz, 0.45 H), 4.66 (d, J = 8.4 Hz, 0.55 H), 3.61-
3.75 (m, 1 H), 3.41 (dd, J = 9.2, 10 Hz, 0.45 H), 3.24 (dt, J = 2, 9.6 Hz, 0.55 H), 3.14 (t, J 
= 9.2 Hz, 1 H), 3.08 (dd, J = 3.6, 10.4 Hz, 0.55 H), 2.75 (dd, J = 8.8, 10.2 Hz, 0.45 H), 
2.07-2.28 (m, 2 H), 1.92-2.06 (m, 1 H), 1.47-1.61 (m, 1 H); HRMS (ESI m/z) calcd for 
C9H16NO8 (M M+Na+) 266.0876, obsd 266.0978.; HRMS (EI m/z) calcd for 
C8H15NO6Na (M+Na+) 244.0797, obsd 266.0802.  
 
Dibenzyl (((2S,3S,4R,5R,6R)-5-(N-benzyl-2-
(trimethylsilyl)ethylsulfonamido)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-
yl)methyl)phosphonate (7). To a solution of the triflate 4 (219 
mg, 0.28 mmol) and dibenzyl phosphite (187 L, 0.84 mmol) in THF (3 mL) was added 
LiHMDS (0.84 mL, 1 M solution in THF, 0.84 mmol) at -78 °C. The solution was then 
slowly warmed to room temperature and stirred overnight. Aqueous NH4Cl was added to 
quench the reaction. The mixture was extracted with Et2O (2 x 20 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuum. The residue 
was purified by flash column chromatography (20-30% EtOAc-hexanes) to afford 7 (212 
mg, 80%) as a colorless oil: 1H NMR (400 MHz, DMSO-d6, 90 °C) δ 7.18-7.58 (m, 30 
H), 4.95-5.08 (m, 4 H), 4.71-4.83 (m, 5 H), 4.64 (d, J = 11.7 Hz, 1 H), 4.52 (d, J = 15.5 
Hz, 1 H), 4.42 (d, J = 15.5 Hz, 1 H), 4.29 (d, J = 11.7 Hz, 1 H), 3.99 (t, J = 9.6 Hz, 1 H), 
3.68-3.82 (m, 2 H), 3.51 (t, J = 8.8 Hz, 1 H), 2.60-2.82 (m, 2 H), 2.12-2.38 (m, 2 H), 
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0.80-0.96 (m, 2 H), -0.19 (s, 9 H); 13C NMR (100 MHz, DMSO-d6, 90 °C) δ 138.9, 138.6, 
137.8, 137.5, 137.2, 137.11 (d, Jcp = 7 Hz), 137.10 (d, Jcp = 7 Hz), 129.7, 128.8, 128.7, 
128.6, 128.5, 128.4, 128.10, 128.06, 127.97, 127.91, 127.8, 127.7, 99.2, 83.6 (d, J = 14 
Hz), 74.2, 73.5, 70.58, 70.52, 70.2, 67.02 (d, Jcp = 6 Hz), 66.97 (d, Jcp = 5 Hz), 50.3, 
28.7 (d, J = 140 Hz), 10.2, -1.77; 31P NMR (162 MHz, DMSO-d6, 90 °C) δ 28.88; 
HRMS (ESI m/z) calcd for C53H62O9NSiPSNa (M+Na+) 970.3550, obsd 970.3526 
 
Dibenzyl (((2S,3S,4R,5R,6R)-5-(benzylamino)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-
yl)methyl)phosphonate (52). To a solution of 7 (78 mg, 0.082 
mmol) in DMF (1 mL) was added CsF (87 mg, 0.57 mmol) in 
one portion. The reaction was heated to 90 °C and stirred at that temperature for 16 h. 
Then aqueous ammonium chloride was added and the mixture was extracted with ethyl 
acetate. The organic phase was combined, dried over MgSO4, filtered and concentrated in 
vacuum. The crude product was purified by flash column chromatography (40-50% 
EtOAc/hexanes) to give 52 (49 mg, 77%) as a white solid:  1H NMR (400 MHz, CDCl3) δ 
7.14–7.35 (m, 30 H), 4.99 – 5.08 (m, 4 H), 4.87 (d, J = 11.6 Hz, 1 H), 4.78 (d, J = 11.6 
Hz, 1 H), 4.70 (d, J = 11.6 Hz, 1 H), 4.62 (d, J = 11.2 Hz, 1 H), 4.49 (d, J = 11.6 Hz, 1 H), 
4.38 (d, J = 8 Hz, 1 H), 3.99 (d, J = 12.8 Hz, 1 H), 3.80 (d, J = 12.8 Hz, 1 H), 3.67-3.77 
(m, 1 H), 3.46 (t, J = 8.8 Hz, 1 H), 3.41 (dd, J = 8.8, 16.4 Hz, 1 H), 2.77 (dd, J = 8, 9.6 
Hz, 1 H), 2.36 (ddd, J = 2, 15.2, 19.6 Hz, 1 H), 2.01 (app dt, J = 10, 15.6 Hz, 1 H), 1.68 
(br, 1 H); 13C NMR (100 MHz, CDCl3) δ 140.6, 137.9, 137.7, 137.3, 136.39 (d, Jcp = 6 
Hz), 136.33 (d, Jcp = 6 Hz), 128.61, 128.58, 128.4, 128.3, 128.03, 127.99, 127.92, 127.7, 
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126.8, 103.5, 83.54 (d, Jcp = 2 Hz), 82.5 (d, Jcp = 14 Hz), 75.1, 74.9, 70.8, 70.5 (d, Jcp = 
7 Hz), 67.24 (d, Jcp = 6 Hz), 67.08 (d, Jcp = 6 Hz), 62.7, 53.4, 28.7 (d, Jcp = 142 Hz); 
31P NMR (162 MHz, CDCl3) δ 29.60; HRMS (ESI m/z) calcd for C48H50O7NPNa 
(M+Na+) 806.3223, obsd 806.3243. 
 
Glucosamine 5-phosphonate (8). A solution of 52 (42 mg, 0.054 
mmol) in MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C (12 mg) and trace amount of TFA (1 drop), under 
balloon pressure of hydrogen, for 24 h at room temperature. Filtrate the mixture through a 
pad of Celite and wash the filter cake with 2 mL MeOH. Suspend the filter cake in 2 mL 
H2O and stir for 5 min, and then filtrate again through a pad of Celite. Concentrate the 
aqueous solution and dry over high vacuum to yield 8 (12 mg, 88%) as a colorless foam: 
1H NMR (400 MHz, D2O) δ 5.34 (d, J = 3.2 Hz, 0.5 H), 4.86 (d, J = 8 Hz, 0.5 H), 4.06 
(ddt, J = 3.6, 9.6, 9.6 Hz, 0.5 H), 3.82 (dd, J = 9.2, 10.4 Hz, 0.5 H), 3.56-3.65 (m, 1 H), 
3.26 (t, J = 8.8 Hz, 0.5 H), 3.24 (t, J = 9.2 Hz, 1 H), 3.23 (dd, J = 3.2, 9.6 Hz, 0.5 H), 2.94 
(dd, J = 8.8, 10.8 Hz, 0.5 H), 2.02-2.16 (m, 1 H), 1.69-1.81 (m, 1 H); 13C NMR (100 
MHz, D2O) δ 92.8, 89.0, 74.6 (d, Jcp = 12 Hz), 74.5 (d, Jcp = 11 Hz), 72.7 (d, Jcp = 4 
Hz), 71.9, 69.5, 67.9 (d, Jcp = 5 Hz), 56.7, 54.3, 31.2 (d, Jcp = 133 Hz), 30.8 (d, Jcp = 
133 Hz); 31P NMR (162 MHz, D2O) δ 20.7, 20.0; HRMS (EI m/z) calcd for 
C6H14O7NPNa (M+Na+) 266.0406, obsd 266.0414. 
 
Diethyl 2-(((2R,3R,4R,5R,6R)-5-(N-benzyl-2-(trimethylsilyl)ethylsulfonamido)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-yl)methyl)malonate (9): To a solution of the 
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triflate 4 (205 mg, 0.25 mmol) and diethyl malonate (152 L, 1 
mmol) in THF (2 mL) was added LiHMDS (1 mL, 1 M solution 
in THF, 1 mmol) at -78 °C. The solution was then slowly 
warmed to room temperature and stirred overnight. Aqueous 
NH4Cl was added to quench the reaction. The mixture was extracted with Et2O (2 x 20 
mL). The combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuum. The residue was purified by flash column chromatography (20% EtOAc-
hexanes) to afford 9 (194 mg, 92%) as a colorless oil: 1H NMR (400 MHz, DMSO-d6, 
90 °C) δ 7.22-7.65 (m, 20 H), 4.73-4.82 (m, 5 H), 4.66 (d, J = 11.6 Hz, 1 H), 4.53 (d, J = 
15.6 Hz, 1 H), 4.47 (d, J = 16.4 Hz, 1 H), 4.43 (d, J = 12 Hz, 1 H), 4.06-4.24 (m, 4 H), 
4.02 (br, 1 H), 3.74 (t, J = 8 Hz, 1 H), 3.64 (dd, J = 5.2, 8.8 Hz, 1 H), 3.44 (dd, J = 2, 5.2 
Hz, 2 H), 2.67-2.84 (m, 2 H), 2.46 (ddd, J = 1.6, 9.2, 14 Hz, 1 H), 2.01-2.09 (m, 1 H), 
1.21 (td, J = 7.2, 10.4 Hz, 6 H), 0.86-0.96 (m, 2 H), -0.16 (s, 9 H); 13C NMR (100 MHz, 
DMSO-d6, 90 °C) δ 169.2, 169.0, 139.0, 138.6, 137.85, 137.81, 129.7, 128.7, 128.6, 
128.5, 128.0, 127.9, 127.8, 127.7, 99.6, 83.6, 74.2, 73.5, 72.6, 70.4, 61.33, 61.31, 50.3, 
48.8, 31.2, 14.3, 14.2, 10.2, -1.79; HRMS (ESI m/z) calcd for C46H59O10NSSiNa (M+Na+) 
868.3527, obsd 868.3514. 
 
Ethyl 3-((2R,3R,4R,5R,6R)-5-(N-benzyl-2-
(trimethylsilyl)ethylsulfonamido)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-yl)propanoate (53).  
To a solution of  9 (135 mg, 0.16 mmol) in DMSO (2 mL) was 
added LiCl (51 mg, 1.2 mmol) in one potion. The suspension was refluxed at 200 °C for 
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8 h. Then the reaction was cooled down to room temperature and quenched with aqueous 
NH4Cl. The mixture was extracted with Et2O (3 x 10 mL). The combined organic layers 
were dried over MgSO4, filtered and concentrated in vacuum. The residue was purified 
by flash column chromatography (10% EtOAc-hexanes) to afford 53 (118 mg, 96%) as a 
colorless oil: 1H NMR (400 MHz, DMSO-d6, 90 °C) δ 7.23-7.52 (m, 20 H), 4.72-4.80 (m, 
5 H), 4.63 (d, J = 11.6 Hz, 1 H), 4.52 (d, J = 15.6 Hz, 1 H), 4.45 (10.8 Hz, 1 H), 4.44 (d, 
16 Hz, 1 H), 4.04-4.12 (m, 2 H), 3.97 (t, J = 8.8 Hz, 1 H), 3.70 (t, J = 8.8 Hz, 1 H), 3.34-
3.42 (m, 2 H), 2.65-2.82 (m, 2 H), 2.42 (t, 8.4 Hz, 1 H), 2.09-2.18 (m, 1 H), 1.70-1.79 (m, 
1 H), 1.19 (t, J = 7.2 Hz, 1 H), 0.85-0.92 (m, 2 H), -0.17 (9 H); 13C NMR (100 MHz, 
DMSO-d6, 90 °C) δ 172.9, 139.1, 138.7, 137.89, 137.87, 129.7, 128.7, 128.6, 128.5, 
128.1, 128.04, 128.00, 127.95, 127.94, 127.8, 127.7, 99.5, 83.6, 74.1, 73.7, 73.4, 70.4, 
60.1, 50.3, 30.3, 27.3, 14.5, 10.2, -1.75; HRMS (ESI m/z) calcd for C43H55O8NSSiNa 
(M+Na+) 796.3315, obsd 796.3320. 
 
N-benzyl-2-(trimethylsilyl)-N-((2R,3R,4R,5R,6R)-2,4,5-
tris(benzyloxy)-6-(3-hydroxypropyl)tetrahydro-2H-pyran-3-
yl)ethanesulfonamide (10).  To a stirred suspension of LiAlH4 
(17 mg, 0.44 mmol) in dry THF (2 mL) was added dropwise a 
solution of 53 (173 mg, 0.22 mmol) in dry THF at 0 °C under nitrogen. The reaction 
mixture was warmed to room temperature and stirred for 2 h. After successively adding 
water, 15% NaOH and water at 0 °C, the mixture was diluted with EtOAc. The aqueous 
layer was extracted by EtOAc. The organic layers were combined, dried over MgSO4, 
filtered and concentrated. Purification by flash column chromatography (30% EtOAc-
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hexanes) gave 10 (153 mg, 95%) as a colorless oil: 1H NMR (400 MHz, DMSO-d6, 
90 °C) δ 7.23-7.52 (m, 20 H), 4.82 (d, J = 11.6 Hz, 1 H), 4.77 (d, J = 12.8 Hz, 1 H), 4.76 
(s, 2 H), 4.72 (d, J = 11.6 Hz, 1 H), 4.65 (d, J = 11.6 Hz, 1 H), 4.53 (d, J = 15.2 Hz, 1 H), 
4.49 (d, J = 8.8 Hz, 1 H), 4.45 (d, J = 12.8 Hz, 1 H), 3.97 (t, J = 8.8 Hz, 1 H), 3.71 (t, J = 
8.8 Hz, 1 H), 3.48 (t, J = 6.4 Hz, 2 H), 3.39 (dt, J = 2.8, 9.2 Hz, 1 H), 3.35 (t, J = 9.2 Hz, 
1 H), 2.67-2.83 (m, 2 H), 1.87-1.96 (m, 1 H), 1.67-1.75 (m, 1 H), 1.49-1.63 (m, 2 H), 
0.83-0.95 (m, 2 H), -0.16 (s, 9 H); 13C NMR (100 MHz, DMSO-d6, 90 °C) δ 139.1, 138.8, 
137.9, 129.7, 128.67, 128.59, 128.58, 128.46, 128.1, 128.03, 127.99, 127.93, 127.86, 
127.80, 127.6, 99.4, 84.0, 74.7, 74.1, 73.5, 70.4, 61.4, 50.3, 28.9, 28.4, 10.2, 10.1, -1.75; 
HRMS (ESI m/z) calcd for C41H53O7NSSiNa (M+Na+) 754.3210, obsd 754.3212. 
 
Dibenzyl (3-((2R,3R,4R,5R,6R)-5-(N-benzyl-2-
(trimethylsilyl)ethylsulfonamido)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-
yl)propyl)phosphonate (11). To a solution of 10 (75 mg, 0.1 
mmol) in THF (1 mL) was added triphenylphosphine (53 mg, 0.2 mmol), imidazole (15 
mg, 0.223 mmol), and idodine (51 mg, 0.2 mmol). The mixture was stirred at room 
temperature overnight and then diluted with Et2O. The organic layer was sequentially 
washed with saturated Na2S2O3, water and brine, followed by drying and concentration in 
vacuum. The residue was purified by flash column chromatography (10% EtOAc-
hexanes) to afford the iodide (72 mg, 85%) as a colorless oil: 1H NMR (300 MHz, 
DMSO-d6, 90 °C) δ 7.21-7.62 (m, 20 H), 4.68-4.91 (m, 5 H), 4.6 2 (d, J = 9 Hz, 1 H), 
4.41-4.55 (m, 3 H), 3.95 (t, J = 9 Hz, 1 H), 3.69 (t, J = 9 Hz), 3.37 (t, J = 9 Hz, 2 H), 3.29 
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(t, J = 6 Hz, 1 Hz), 3.06 (br, 1 H), 2.63-2.84 (m, 2 H), 1.80-2.04 (m, 3 H), 1.47-1.65 (m, 1 
H), 0.86 (t, J = 6 Hz, 2 Hz), -0.18 (s, 9 Hz); 13C NMR (300 MHz, DMSO-d6, 90 °C) δ 
139.1, 138.7, 137.87, 137.86, 129.8, 128.7, 128.6, 128.5, 128.10, 128.06, 128.00, 127.9, 
127.8, 127.6, 99.5, 83.6, 74.2, 73.7, 73.4, 70.5, 50.3, 32.5, 29.6, 10.2, 8.6, -1.7; HRMS 
(ESI m/z) calcd for C41H52O6NSSiINa (M+Na+) 864.2227, obsd 864.2224. 
 
To a solution of the iodide (72 mg, 0.08 mmol) and dibenzyl phosphite (56 L, 0.25 
mmol) was added LiHMDS (0.25 mL, 1 M in THF, 0.25 mmol) dropwise at -78 °C, the 
solution was allowed to warm to room temperature and stirred for 1 h before quenched 
with aqueous NH4Cl. The aqueous layer was separated and extracted with Et2O. 
Combined organic layers were dried, filtered and concentrated. The phosphonate product 
11 was purified by flash column chromatography (30%-% EtOAc-hexanes) as a colorless 
oil (56 mg, 68%): 1H NMR (400 MHz, DMSO-d6, 90 °C) δ 7.21-7.48 (m, 30 H), 5.04 (d, 
J = 8.8 Hz, 1 H), 5.01 (d, J = 8.4 Hz, 1 H), 4.98 (dd, J = 2, 8 Hz, 1 H), 4.95 (dd, J = 2, 8 
Hz, 1 H), 4.79 (d, J = 8.4 Hz. 1 H), 4.76 (d, J = 12 Hz, 1 H), 4.73 (br, 2 H) 4.67 (d, J = 
11.6 Hz, 1 H), 4.58 (d, J = 11.2 Hz, 1 H), 4.51 (d, J = 15.2 Hz, 1 H), 4.43 (dd, J = 1.6, 12 
Hz, 2 H), 3.94 (t, J = 9.2 Hz, 1 H), 3.68 (t, J = 9.2 Hz, 1 H), 3.35 (dt, J = 2.8, 9.6 Hz, 1 H), 
3.30 (t, J = 9.2 Hz, 1 H), 2.63-2.83 (m, 2 H), 1.28-1.92 (m, 6 H), 0.85-0.91 (m, 2 H), -
0.17 (s, 9 H); 13C NMR (100 MHz, DMSO-d6, 90 °C) δ 139.1, 138.7, 137.9, 137.8, 137.3 
(d, Jcp = 6 Hz), 129.7, 128.8, 128.66, 128.59, 128.57, 128.46, 128.42, 128.1, 128.03, 
127.98, 127.95, 127.88, 127.78, 127.6, 99.4, 83.7, 74.1 (d, Jcp = 5 Hz), 73.4, 70.4, 66.87 
(d, Jcp = 6 Hz), 66.88 (Jcp = 6 Hz), 50.3, 32.2 (d, Jcp = 15 Hz), 25.5 (Jcp = 137 Hz), 
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18.6 (d, Jcp = 5 Hz), 10.2, -1.76; 31P NMR (162 MHz, DMSO-d6, 90 °C) δ 32.65; HRMS 
(ESI m/z) calcd for C55H66O9NPSSiNa (M+Na+) 998.3846, obsd 998.3835. 
 
Dibenzyl (3-((2R,3R,4R,5R,6R)-5-(benzylamino)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-
yl)propyl)phosphonate (54). To solution of 11 (98 mg, 0.1 
mmol) in DMF (1 mL) was added CsF (107 mg, 0.7 mmol) in 
one portion. The reaction was heated at 90 °C for 16 h, followed by addition of aqueous 
ammonium chloride. The mixture was extracted by ethyl acetate and the combined 
organic layers were dried, filtered and concentrated in vacuum. The crude product was 
purified by flash column chromatography (50% EtOAc/hexanes) to give 54 (59 mg, 72%) 
as a white solid: 1H NMR (400 MHz, CDCl3) δ 7.147.34 (m, 30 H), 5.06 (dd, J = 1.6, 8.8 
Hz, 1 H), 5.03 (dd, J = 1.2, 8.8 Hz, 1 H), 4.97 (dd, J = 4, 8 Hz, 1 H), 4.94 (dd, J = 4, 7.6 
Hz, 1 H), 4.67 (d, J = 11.2, 1 H), 4.56 (app t, J = 9.6 Hz, 2 H), 4.33 (d, J = 8 Hz, 1 H), 
4.00 (d, J = 12.8 Hz, 1 H), 3.81 (d, J = 12.8 Hz, 1 H), 3.44 (t, J = 9.2 Hz, 1 H), 3.28 (t, J 
= 9.2 Hz, 1 H), 3.21 (t, J = 8.8 Hz, 1 H), 2.70 (dd, J = 8, 10 Hz, 1 H), 1.64–1.88 (m, 5 H), 
1.48–1.57 (m, 1 H); 13C NMR (100 MHz, CDCl3) δ 138.0, 137.8, 137.3, 136.4 (d, Jcp = 6 
Hz), 128.63, 128.61, 128.5, 128.45, 128.39, 128.34, 128.05, 127.99, 127.94, 127.91, 
127.88, 127.82, 126.9, 103.5, 83.6, 82.8, 75.1 (d, Jcp = 1 Hz), 74.4, 71.0, 67.1 (d, Jcp = 6 
Hz), 62.7, 53.5, 32.3 (d, Jcp = 17 Hz), 26.1 (d, Jcp = 140 Hz), 18.8 (d, Jcp = 5 Hz); 31P 
NMR (162 MHz, CDCl3) δ 33.17; HRMS (ESI m/z) calcd for C50H54O7NPNa (M+Na+) 
834.3536, obsd 834.3524. 
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Glucosamine 7-phosphonate (12). A solution of 54 (33 mg, 0.04 
mmol) in MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C (12 mg) and trace amount of TFA (1 drop), under 
balloon pressure of hydrogen, for 24 h at room temperature. 
Filtrate the mixture through a pad of Celite and wash the filter cake with 2 mL MeOH. 
Suspend the filter cake in 2 mL H2O and stir for 5 min, and then filtrate again through a 
pad of Celite. Concentrate the aqueous solution and dry over high vacuum to yield 12 (9 
mg, 85%) as a colorless foam: 1H NMR (400 MHz, D2O) δ 5.34 (d, J = 3.6 Hz, 0.4 H), 
4.83 (d, J = 8.4 Hz, 0.6 H), 3.79 (dt, J = 3.2, 9.2 Hz, 0.6 H), 3.76 (t, J = 10.4 Hz, 0.4 H), 
3.54 (dd, J = 9.2, 10.4 Hz, 0.4 H), 3.38 (t, J = 9.2 Hz, 0.6 H), 3.18-3.33 (m, 1.6 H), 2.90 
(dd, J = 8.4, 10.4 Hz, 0.4 H), 1.80-1.94 (m, 1 H), 1.42-1.77 (m, 5 H); 13C NMR (100 
MHz, D2O) δ 93.0, 89.0, 75.2, 73.30, 73.29, 72.3, 70.3, 69.8, 56.9, 54.4, 31.7 (d, Jcp = 17 
Hz), 31.2 (d, Jcp = 17 Hz), 27.4 (d, Jcp = 133 Hz), 27.5 (d, Jcp = 133 Hz), 18.9 (br); 31P 
NMR (162 MHz, D2O) δ 25.7 (br); HRMS (ESI m/z) calcd for C8H19O7NP (M+H+) 
272.0899, obsd 272.0904. 
N-((2R,3R,4R,5R,6R)-6-(azidomethyl)-2,4,5-
tris(benzyloxy)tetrahydro-2H-pyran-3-yl)-N-benzyl-2-
(trimethylsilyl)ethanesulfonamide (20). To a solution of the 
triflate 4 (247 mg, 0.32 mmol) in THF was added TMSN3 (131 L, 1 mmol) dropwise at 
room temperature. The solution was stirred for 12h then quenched with aqueous NH4Cl. 
The mixture was extracted with ether. Then combined organic layers were dried, filtered 
and concentrated in vacuum. The crude product was purified by flash column 
chromatography (10% EtOAc/hexanes) to give 20 (208 mg, 89%) as a colorless oil: 1H 
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NMR (400 MHz, DMSO-d6, 90 °C) δ 7.23-7.52 (m, 20 H), 4.91 (d, J = 8.4 Hz, 1 H), 
4.85 (d, J = 11.6 Hz, 1 H), 4.79 (d, J = 11.2 Hz, 1 H), 4.76 (s, 1 H), 4.72 (d, J = 11.6 Hz, 
1 H), 4.60 (d, J = 11.2 Hz, 1 H), 4.53 (d, J = 15.6 Hz, 1 H), 4.49 (d, J = 11.6 Hz, 1 H), 
4.47 (d, J = 15.6 Hz, 1 H), 4.05 (t, J = 9.2 Hz, 1 H), 3.75 (t, J = 9.2 Hz, 1 H), 3.65-3.70 
(m, 1 H), 3.56 (d, J = 8.4 Hz, 1 H), 3.45-3.54 (m, 2 H), 2.64-2.81 (m, 2 H), 0.82-0.94 (m, 
2 H), -0.17 (m, 9 H); 13C NMR (100 MHz, DMSO-d6, 90 °C) δ 138.9, 138.5, 137.8, 
137.6, 129.8, 128.70, 128.65, 128.63, 128.5, 128.2, 128.1, 128.0, 127.8, 127.7, 99.4, 80.9, 
74.5, 74.2, 73.6, 70.5, 63.9, 51.8, 50.4, 10.2, -1.76; HRMS (ESI m/z) calcd for 
C50H54O7NPNa (M+Na+) 751.2962, obsd 751.2948. 
 
(2R,3R,4R,5R,6R)-6-(azidomethyl)-N-benzyl-2,4,5-
tris(benzyloxy)tetrahydro-2H-pyran-3-amine (55). A mixture 
of 20 (322 mg, 0.44 mmol) and CsF (471 mg, 3.1 mmol) in 
DMF (5 mL) was stirred for 16 h at 90 °C. The reaction was quenched by adding aqueous 
NH4Cl. The mixture was extracted by DCM. The combined organic layers were dried, 
filtered and concentrated in vacuum. The residue was purified by flash column 
chromatography (30% EtOAc/hexanes) to give 55 (198 mg, 80%) as a white solid: 1H 
NMR (400 MHz, CDCl3) δ; 13C NMR (100 MHz, CDCl3) δ 7.13-7.41 (m, 20 H), 4.96 (d, 
J = 11.6 Hz, 1 H), 4.91 (d, J = 11.6 Hz, 1 H), 4.87 (d, J = 11.2 Hz, 1 H), 4.71 (d, J = 11.2 
Hz, 1 H), 4.65 (d, J = 11.6 Hz, 1 H), 4.60 (d, J = 11.2 Hz, 1 H), 4.45 (d, J = 8 Hz, 1 H), 
4.02 (d, J = 12.8 Hz, 1 H), 3.83 (d, J = 12.8 Hz, 1 H), 3.46-3.57 (m, 3 H), 3.34-3.43 (m, 2 
H), 2.78 (t, J = 8.8 Hz, 1 H), 1.69 (br, 1 H); 13C NMR (100 MHz, CDCl3) δ 140.5, 137.8, 
137.5, 137.2, 128.66, 128.69, 128.5, 128.4, 128.3, 128.2, 128.04, 128.00, 127.9, 126.9, 
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103.6, 83.5, 79.6, 75.1, 75.04, 75.03, 71.1, 62.6, 53.5, 51.4; HRMS (ESI m/z) calcd for 
C34H36O4N4Na (M+Na+) 587.2634, obsd 587.2639. 
 
(2R,3R,4R,5R,6R)-6-(aminomethyl)-N-benzyl-2,4,5-
tris(benzyloxy)tetrahydro-2H-pyran-3-amine (21). To a 
solution of 55 (127 mg, 0.22 mmol) and triphenylphosphine 
(174 mg, 0.66 mmol) in THF (2 mL) was added H2O (20 L, 1.1 mmol). The mixture 
was stirred at room temperature for 12 h when TLC indicated the completion of reaction. 
The solution was concentrated under vacuum and the residue was purified by flash 
column chromatography (30/70/10: EtOAc/hexanes/Et3N) to give 21 (110 mg, 93%) as a 
white solid: 1H NMR (400 MHz, CDCl3) δ 7.14-7.42 (m, 20 H), 4.94 (d, J = 13.2 Hz, 1 
H), 4.93 (d, J = 11.6 Hz, 1 H), 4.87 (d, J = 11.2 Hz, 1 H), 4.73 (d, J = 12 Hz, 1 H), 4.68 (s, 
1 H), 4.67 (d, J = 10.8 Hz, 1 H), 4.47 (d, J = 8 Hz, 1 H), 4.04 (d, J = 12.8 Hz, 1 H), 3.86 
(d, J = 12.8 Hz, 1 H), 3.48-3.56 (m, 1 H), 3.33 (t, J = 6.8 Hz, 1 H), 3.11 (d, J = 12 Hz, 1 
H), 2.78-2.89 (m, 1 H), 2.76 (dd, J = 8, 9.2 Hz, 1 H), 1.50 (br, 2 H); 13C NMR (100 MHz, 
CDCl3) δ 140.6, 138.1, 137.8, 137.5, 128.62, 128.58, 128.46, 128.37, 128.30, 128.1, 
128.0, 127.9, 126.8, 104.1, 83.7, 80.0, 75.1, 74.9, 71.4, 62.8, 53.6; HRMS (ESI m/z) 
calcd for C34H38O4N2Na (M+Na+) 561.2729, obsd 561.2721. 
 
Dibenzyl (((2R,3R,4R,5R,6R)-5-(benzylamino)-3,4,6-
tris(benzyloxy)tetrahydro-2H-pyran-2-
yl)methyl)phosphoramidate (22). To a solution of 21  (65 mg, 
0.12 mmol) in DCM (1 mL) was added slowly 
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dibenzylphosphoryl chloride (0.72 mL, 0.5 mol in toluene (freshly prepared from NCS 
and dibenzyl phosphite), 0.36 mmol). Then Et3N (167 L, 1.2 mmol) was added through 
syringe. The reaction was stirred for 6 h at room temperature and then quenched by 
aqueous NH4Cl. The mixture was extracted with DCM and the organic layers were dried, 
filtered and concentrated in vacuum. The residue was purified by flash column 
chromatography (40/60/5: EtOAc/hexanes/Et3N) to give 22 (66 mg, 69%) as a white 
solid: 1H NMR (400 MHz, CDCl3) δ 7.11-7.38 (m, 30 H), 5.01-5.06 (m, 4 H), 4.87 (d, J = 
11.6 Hz, 1 H), 4.83 (d, J = 11.6 Hz, 1 H), 4.74 (d, J = 10.8 Hz, 1 H), 4.65 (d, J = 11.2 Hz, 
1 H), 4.4.59 (d, J = 10. 4 Hz, 1 H), 4.59 (d, J = 12.4 Hz, 1 H), 4.34 (d, J = 8 Hz, 1 H), 
3.98 (d, J = 12.8 Hz, 1 H), 3.79 (d, J = 12.8 Hz, 1 H), 3.36-3.45 (m, 2 H), 3.21-3.32 (m, 2 
H), 2.97-3.35 (m, 2 H), 2.62- 2.68 (m, 1 H), 1.66 (br, 1 H); 13C NMR (100 MHz, CDCl3) 
δ 140.5, 137.9, 137.7, 137.3, 136.3 (d, Jcp = 8 Hz), 128.63, 128.60, 128.56, 128.54, 
128.50, 128.39, 128.34, 128.29, 128.1, 128.01, 127.97, 127.92, 127.87, 127.85, 126.9, 
104.1, 83.3, 79.4, 75.0, 74.8, 74.51 (d, Jcp = 7 Hz), 71.5, 68.14 (d, Jcp = 5 Hz), 68.10 (d, 
Jcp = 5 Hz), 62.5, 53.5, 42.2; 31P NMR (162 MHz, CDCl3) δ 9.53; HRMS (ESI m/z) 
calcd for C48H51O7N2PNa (M+Na) + 821.3332, obsd 821.3348. 
 
Glucosamine 6-phosphoramide (23). A solution of 22 (44 mg, 
0.055 mmol) in MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C (17 mg) and trace amount of TFA (1 drop), under 
balloon pressure of hydrogen, for 24 h at room temperature. 
Filtrate the mixture through a pad of Celite and wash the filter cake with 2 mL MeOH. 
Suspend the filter cake in 2 mL H2O and stir for 5 min, and then filtrate again through a 
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pad of Celite. Concentrate the aqueous solution and dry over high vacuum to yield 23 (11 
mg, 80%) as a colorless foam: 1H NMR (400 MHz, D2O) δ 5.37 (d, J = 3.2 Hz, 0.7 H), 
4.87 (d, J = 8.4 Hz, 0.3 H), 3.98 (dt, J = 2, 9.2 Hz, 0.7 H), 3.80 (t, J = 9.6 Hz, 0.7 H), 
3.50-3.71 (m, 1.3 H), 3.26-3.45 (m, 2.3 H), 3.24 (dd, J = 3.2, 10.4 Hz, 0.7 H), 2.95 (t, J = 
8.8 Hz, 0.3 H); 31P NMR (162 MHz, D2O) δ 1.44 (br); HRMS (ESI m/z) calcd for 
C6H15O7N2PNa (M+Na) + 281.0514, obsd 281.0517. 
 
B. Self-Cleavage Assay 
Preparation of RNA. Templates for transcription were prepared by primer 
extension and PCR amplification using synthetic DNA corresponding to ribozyme 
sequence. Ribozymes were prepared by in vitro transcription using T7 RNA polymerase 
and 32P-labeled by incorporation of [32P]-UTP. Transcription products were separated by 
denaturing 10% polyacrylamide gel electrophoresis (PAGE) and ribozymes were eluted 
in solution containing 50 mM HEPES (pH 7.3 at 22˚C) and 200 mM NaCl, precipitated 
with ethanol, and redissolved in water.  
Self-Cleavage Assay. Ribozyme reactions were performed as previously 
described.37 Briefly, reactions contained ligand analog as indicated and were performed 
under standard conditions consisting of incubation at 22˚C in solution containing 50 mM 
HEPES pH 7.3. A saturating concentration of MgCl2 was used in order to avoid a slow 
folding step and to allow for formation of native glmS RNA structure.69 The [32P]-UTP-
labeled glmS ribozyme (<250 nM) was prefolded in 50 mM HEPES pH 7.5, 0.1 mM 
EDTA, and 50 mM MgCl2 at 22 ˚C. Reactions were started by adding coenzyme at 
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varying concentration (10 mM – 10 µM final concentration) in 50 mM HEPES pH 7.3 
buffer. Reactions were terminated by the addition of a gel loading dye containing 10 M 
urea, 50 mM EDTA, 0.1% bromophenol blue, 0.1% xylene cyanol. Products were 
separated by denaturing 10% PAGE and analyzed using a PhosphorImager and 
IMAGEQUANT software (Molecular Dynamics). kobs values for self-cleavage were 
derived by plotting the natural logarithm of the fraction of uncleaved ribozyme versus 
time and establishing the negative slope of the resulting line. Stated values represent the 
average of at least three replicate assays. First-order cleavage rates were obtained at 
different concentrations of coenzyme in the linear range of a Michaelis−Menten plot 
(coenzyme concentration ~20% of apparent Km value) and were fit by linear regression to 
obtain apparent second-order rate constants kcat/Km.36  
 
C. pKa Titration Experiments 
 Each analogue was prepared in 1 mM (6, 27, 29) or 3 mM (18, 22) solution and 
titrated with 100 mM NaOH solution. pH was recorded after each addition of 0.1 
equivalent of NaOH solution (blue curve). The reciprocal of the change of pH (1/	pH) 
was plotted to aid identification of the inflection points (Fig. 2.17, red curve). 
 
D. Molecular Docking 
The crystal structure of glucosamine-6-phosphate bound to the (2’-OMe)A-1 
glmS riboswitch was obtained from the Brookhaven Protein Data Bank 
(http://www.rcsb.org/pdb) (PDB ID:2NZ4). This glmS riboswitch is obtained from 
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Bacillus anthracis which is the same source of the riboswitch in our cleavage assay. 
Ligands were prepared with Spartan 08 with phosphate-mimicking groups fully 
deprotonated. Virtual docking experiments were performed using Autodock 4. Each trial 
was run in a grid map with X x Y x Z dimensions = 40 x 40 x 20 Å  centered at C-5 of 
GlcN6P from the reference structure. The Lamarckian Genetic Algorithm was used as the 
search method. Each trials consisted of 100 runs, with a maximum of 2,500,000 energy 
A B 
C D 
E1 E2 
 
Figure 2.17: Titration curves for GlcN6P analogues. (A) 6; (B) 27; (C) 29. (D) 14; (E1) 18 
with 100 mM NaOH; (E2) 18 with 100 mM HCl. 
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evaluations. Images were generated in VMD with conformations in the lowest energy 
cluster.  
The Mg-O distances were slightly adjusted to represent typical binding distances 
in crystal structures. In this crystal structure (2NZ4), the phosphate is ~4 Å away from 
each magnesium ion. However a typical binding distance between oxygen and 
magnesium is ~ 2.5 – 3.0 Å, as observed in 2H0Z (2.44 Å, 3.30 Å); 2Z74 (2.56 Å, 2.63 
Å); 2Z75 (2.55 Å, 2.88 Å).Therefore, the structure is subsequently adjusted using Spartan 
2008. 
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Chapter 3  
Hydrolytically-Stable Bivalent Ligands for CI-MPR  
I. Introduction 
A. Background of M6P/IGF2R 
Lectins are carbohydrate-binding proteins.1-5 Different from carbohydrate-specific 
enzymes and antibodies, they do not possess any enzymatic activities and are not 
generated from the immune system.6 The first lectin was discovered in plants; Stillmark 
reported the isolation of ricin from castor beans in 1888.3 Since then, numerous lectins 
have been found in all six kingdoms of life.4 Through protein-carbohydrate interactions, 
they regulate many cellular processes such as microbial adhesion, cell-cell recognition 
and protein sorting. As the interpreters of the sugar code, lectins have drawn growing 
interest from the biochemical and biophysical research community in the post-genomic 
era. For example, in 2003, Fisher reported that during the window of receptivity, human 
fetal trophoblasts express L-selectin while uterine epithelial cells up-regulates sialyl-
LewisX (sLeX) based ligands.7 This selectin-sLeX recognition was proposed to be critical 
for pregnancy establishment. Recently, from ultrasensitive mass spectrometric analyses, 
human sperm-egg binding was also suggested to be mediated through sLeX ligands.8 
However, while human oocytes (zona pellucida) were shown to be coated with sLeX 
sequences, human spermatozoa are known to lack the expression of selectins.9 Therefore, 
the sLeX-binding lectin that crucially controls human fertilization remains mysterious; 
this represents one of many important lectins that need to be identified.  
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In the early 1980s, two distinct lectins were recognized as mannose 6-phosphate 
(M6P) binding proteins. Designated as “P-type” lectins, cation-dependent M6P receptor 
(CD-MPR) and cation-independent M6P receptor (CI-MPR) bind phosphorylated high-
mannose N-glycans (Fig. 3.1).10 By then, these M6P-bearing carbohydrates had been 
known to mediate the intracellular trafficking of newly synthesized lysosomal enzymes.11 
Also called as “acid hydrolases” (owing to the acidic environment of lysosome), these 
hydrolytic enzymes play an essential role in catabolism of  various cellular 
macromolecules. The deficiency of these enzymes in lysosomes results in the 
macromolecule accumulation, causing a variety of lysosomal storage diseases, such as I-
cell disease (mucolipidosis type II).12-14  
 
 
 
 
 
 
 
 
Lysosomal enzymes are assembled by the ribosomes that are bound to rough 
endoplasmic reticulum (RER). To be successfully delivered to the lysosome, the nascent  
Figure 3.1: Structure of the full-size, high-mannose N-glycan (red 
hydroxyl groups= possible phosphorylation sites) 
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Figure 3.2: MPR pathway for intracellular lysosomal enzyme trafficking 
Figure 3.3: The two-step phosphorylation of N-glycans in mammalian 
cells 
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proteins need to be labeled with a M6P marker for recognition by MPRs.15 Selected 
asparagine residues are co-translationally glycosylated with the high-mannose glycan 
(GlcNAc2Man9Glc3),16-17 followed by sequential removal of terminal glucoses.18 The 
oligosaccharide is then trimmed down for glycoprotein folding and maturation (Fig. 
3.2).15, 18 Phosphorylation of the exposed mannose is a two-step enzymatic process, 
utilizing UDP-N-acetylglucosamine (UDP-GlcNAc) as the phosphate source (Fig. 3.3). 
First, N-acetylglucosamine-1-phosphotransferase transfers GlcNAc-1-P to the 6-hydroxyl 
group of mannose, forming a phosphodiester bond.19 Then N-acetylglucosamine-1-
phosphodiester -N-acetylglucosaminidase, commonly known as “uncovering enzyme” 
20-21, removes the GlcNAc, unmasking the terminal M6P residue. Subsequently, these 
phosphorylated glycoproteins will  strongly bind to MPRs in the trans-Golgi network 
(TGN) at a pH of ~6.3. Then the cargo-bound MPRs travel to the late endosome, where 
pH drops below 6.3. Consequently, MPRs release the acid hydrolases which are 
ultimately transported to the lysosome for their functions (Fig. 3.3).22-24 In the meantime, 
MPRs do not enter the lysosomes. Instead, they are recycled back to the cell surface or 
TGN for the next delivery.25-26 MPR pathway is conserved in vertebrates,27 and has been 
discovered in several invertebrates. 28-29  
P-lectins are characterized by the presence of one or more mannose 6-phosphate 
receptor homology (MRH) domains.30 MRH domains share a similar fold and size. They 
use four key residues (Gln, Arg, Glu and Tyr) to bind the mannose. Three disulfide bonds 
are also conserved through MRH domains.31-32 Other MRH-containing proteins have 
been discovered in ER and Golgi compartments, such as human glucosidase II -
subunit33-34, GlcNAc-phosphotransferase -subunit35-36, ortholog of fungi Yos9p (OS-9)37-
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38 and XTP3-B (Erlectin)39-40. They bind non-phosphorylated high mannose N-glycans to 
assess the glycoprotein folding or traffic them through different compartments.30  
Thus far, three-dimensional structures have been reported for 11 MRH domains.30, 
41 CD-MPR is a 46 kDa type-I transmembrane protein, composed of four functional 
domains.10 Its single MRH domain is embedded in its 159-residue extracytoplasmic 
region. Several crystal structures of ligand-free42, M6P-bound43 or pentamannosyl 
phosphate (PMP)-bound44 CD-MPR have been solved. The crystal structures show that 
the receptor exists as a dimer. Three disulfide bonds are critical for generating the ligand 
binding conformation. Furthermore, four key residues (Q66, R111, E133, and Y143) are 
shown to have extensive contacts with the 2-, 3-, and 4-hydroxyl groups of the 
phosphorylated mannose (Fig. 3.4).44-45 This is consistent with the observation that 
glucose 6-phosphate (2-epimer of M6P) has ~10,000 fold less affinity to CD-MPR, 
compared with M6P. Another active site residue,  Asp103, coordinates the divalent 
cations to enhance its binding affinity.  
In contrast to CD-MPR, CI-MPR is a ~300 kDa transmembrane glycoprotein, 
with 15 homologous domains in its extracytoplasmic region. Each domain has ~147 
amino acids that share a 15-40% identity with CD-MPR.46 Two high-affinity binding 
sites for M6P are located in domain 1-3 and domain 9.28, 47-48 The three-dimensional 
structures for 8 out of the 15 MRH domains (domains 1, 2, 3, 5, 11, 12, 13, 14) have been 
solved.49-53 A structure-based sequence alignment shows that domain 1-3 uses the same 
key residues to bind M6P as does the CD-MPR, however, it lacks the aspartate residue 
for cation chelation (Fig. 3.5).52 Recently, a low-affinity M6P binding site was identified 
in domain 5, which exhibited a preference to the GlcNAc-P-Man phosphodiester.54  
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Figure 3.4: A. Crystal structure of bovine CD-MPR with M6P bound (2RL8); 
B. Active site residues (MRH-conserved residues marked in purple) 
A
B
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Figure 3.5 : A. Crystal structure of Domain 1-3 of bovine CI-MPR with M6P bound 
(1SYO); B. Active site residues (MRH-reserved residues marked in purple) 
A 
B 
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In addition to its role in intracellular protein sorting and trafficking, CI-MPR also 
plays an important role in the endocytic pathway. A small percentage (~ 10%) of the CI-
MPR is distributed in the cell surface.55-57 The cell-surface receptors can bind M6P-
containing ligands and deliver them to the endosome via the “secretion-recapture” 
pathway.58 For example, some acid hydrolases are secreted into the medium even though 
they carry a M6P marker. This is particularly significant for some activated macrophages 
under inflammatory conditions. Surface CI-MPR can bind and internalize these enzymes, 
to ultimately transport them to lysosome.59  
Moreover, harnessing its versatile MRH domains, CI-MPR can bind a variety of 
non-M6P-containing ligands for their endocytosis and degradation in lysosome.60 Perhaps, 
most importantly, CI-MPR was found to bind insulin-like growth factor II (IGF-II) via 
domain 11 in the extracellular region (Fig. 3.6).61-63 The IGF system is involved in 
various signaling pathways that are critical for cell proliferation and malignant 
transformation.64 The IGF axis comprises two growth factors (IGF-I and IGF-II), three 
types of receptor (IGF1R, CI-MPR/IGF2R and IR-A) and a family of IGF binding 
proteins (IGFBPs).65 IGF-II promotes cell growth, survival and differentiation, mainly 
through interactions with IGF1R.66 It can also stimulate cell mitosis via binding to insulin 
receptor isoform A (IR-A), which is predominantly expressed in the fetus and cancer 
cells.67 Another high-affinity receptor for IGF-II is CI-MPR, which mostly targets IGF-II 
for degradation, thereby controlling the bioavailability of IGF-II in bloodstream.68-70 As a 
result, CI-MPR is also referred to as M6P/IGF2R or simply IGF2R. CI-MPR exploits its 
hydrophobic sites in domain 11 to interact with IGF-II, distinct from the binding pattern 
for M6P. In humans, site-directed studies have shown that F48, R49, S50, A54 and L55 
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are the key binding residues.70 It is also known that the residues in repeat domain 13 
contribute significantly to the high-affinity binding (~ 0.1 nM) (Fig. 3.6).71-72  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Schematic structure of the CI-MPR dimer with a 
postulated bivalent interaction with M6P-containing ligands 
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Although M6P binds unrelated domains, the presence of a M6P-containing acid 
hydrolase seems to stimulate the receptor-mediated endocytosis of IGF-II. In 1998, York 
et al. have shown that in the presence of excess (10 nM) human -glucuronidase (hGUS), 
the internalization rate of a iodine-125-labeled IGF-II was accelerated by 3-4 fold.73 On 
the other hand, this cooperative effect was not observed for M6P, even at a saturation 
concentration (10 mM). This leads to the postulation that the multivalent hGUS promotes 
the oligomerization, most likely dimerization, of the receptor.74-75 The consequent 
conformational change will be transduced to the endoplasmic region, resulting in an 
accelerated endocytosis of the ligand-receptor complex. Therefore, in a similar fashion  a 
synthetic ligand that cross-bridges two monomeric receptors, could potentially stimulate 
the endocytosis of circulating IGF-II. The limited bioavailability of IGF-II would 
ultimately inhibit growth and survival of cancer cells that are dependent on IGF-II 
signaling.76 Thus, the  igf2r gene has been acclaimed as a potential anti-cancer gene, 
particularly for suppressing breast tumor.77-78  Thus, we set out to develop such bivalent 
ligands for the receptor.  
B. Previous Work  on Multivalent Ligands for M6P/IGF2R 
Figure 3.7: Bock’s synthetic glycopeptides as bivalent ligands for IGF2R 
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Multivalency has been observed throughout many cellular processes, particularly 
frequent in lectin-carbohydrate recognition.79-80 Monovalent interactions between a 
carbohydrate and a protein are usually weak. Hence, to achieved a specific cellular 
response, multivalent oligosaccharide ligands are regularly employed to interact with 
lectins.81-83 By occupying multiple binding sites, these ligands usually possess 
exponentially high affinities to the receptors. Nonetheless, it is important to distinguish a 
high-affinity ligand from an “effector.” In addition to its apparent high affinity, an 
effector also has the desired functions such as clustering receptors.84-86 For instance, Bock 
et al. have synthesized a series of phosphorylated glycopeptides for CI-MPR.87-88 One of 
these bivalent ligands displayed three orders of magnitude higher binding affinity than 
M6P, leading to the assumption that this is the first small molecule that spans two M6P-
binding sites. However, in the 1998 study, this ligand failed to  increase the IGF-II 
endocytosis rate.73 Indeed, the protecting groups of these peptides seem to have a major 
influence on the binding affinities. Specifically, when the central lysine residue was not 
protected instead of being protected with an anthranoyl group, the binding affinity of the 
peptide decreased by ~220-fold (Fig. 3.7).88 This implies that the exhibited high affinity 
is a result from the strong interaction with non-M6P binding sites. The ligand did not 
really fulfill the true “bivalency”.  
In addition to the glycopeptide-based approach, some groups have constructed 
various oligosaccharide-tethered ligands. Hindsgaul et al.  synthesized the pentamannosyl 
core found in the N-glycans.89 And they demonstrated that the bis-phosphorylated ligand 
exhibited ~10-fold higher affinity than the mono-phosphorylated pentasaccharide. It is 
also noted that mono-phosphorylated pentamannose exhibited 12-fold higher affinity than 
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M6P, suggesting that the high mannose scaffold  may be important to the receptor 
binding (Fig. 3.8).  
 
 
 
 
 
 
More recently, Chen and co-workers made a triantennary GlcNAc2Man5P2 ligand. 
Subsequent modification allows this ligand to be covalently attached to human carbonic 
anhydrase II (HCAII) via a cysteine residue. After labeling with a fluorescent tag, the 
neoglycoprotein was subjected to IGF2R-mediated cellular uptake, and demonstrated 
much faster internalization rate compared with the apoprotein.90 Additionally, a series of 
mono- and bis-phosphorylated N-glycans were enzymatically prepared from digestion of 
bovine ribonuclease B (RNase B) and soybean agglutinin. Derivatized with a fluorescent 
label/tether, they were printed on glass slides and measured for binding to IGF2R.91 
Despite the success of this biomimetic approach, the preparation of these phosphorylated 
carbohydrates is usually tedious. The enzymatic synthesis sometimes cannot provide 
defined glycan structures.91 Thus, our group set out to explore novel synthetic strategies 
to rapidly assemble bivalent ligands that contain M6P mimics. And we seek ligands that 
have three orders of magnitude higher binding affinity than M6P exhibited by hGUS. 
Figure 3.8: Hindsgaul’s synthetic biantennary oligosaccharide 
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II. Results and Discussion 
A. Monovalent ligands and cross-metathesis approach 
Previously, both Montero and our group have synthesized phosphonate analogues 
of M6P.92 In addition, our group has synthesized a panel of other hydrolytically stable 
analogues, and tested them for binding affinities.93 Pleasingly, the replacement of the 
bridging oxygen with carbon did not have a deleterious effect on the receptor binding. 
Phosphonate analogue displayed an IC50 of ~25 M to the receptor, which is similar to 
that of M6P (Fig. 3.9). Moreover, the second best ligand, malonate analogue, showed 
only a 3-fold weaker binding to IGF2R. Subsequently, these two analogues were utilized 
tobuild bivalent ligands by cross metathesis chemistry. The allyl mannoside was easily 
prepared from methyl -D-mannopyranoside. By triflate displacement chemistry, 
manolate functionality was installed smoothly. The Ru(II)-mediated cross metathesis, 
followed by hydrogenation, efficiently tethered two surrogates together through a carbon 
chain (Fig. 3.10). For the synthesis of ligand 7, the alcohol 2 was subjected to cross 
Figure 3.9: Monovalent ligands synthesized and tested in Berkowitz-MacDonald 
collaboration 
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metathesis to yield the diol 6 in 84% yield (E/Z = 4/1). The bis-triflate was then cleanly 
prepared and displaced by two equivalents of dibenzyl lithiomethylphosphonate in 75% 
yield. The product was subsequently hydrogenated, to afford the first bivalent ligand that 
bears two phosphonate analogues (Fig. 3.11). However, both ligands 5 and 7 
demonstrated little effect of sought-after bivalency. A quick molecular modeling using 
Merck Molecular Force Field (MMFF) estimated the distance between two phosphorus 
atoms to be around 12 Å. This is likely too short to intermolecularly span two M6P 
Figure 3.10: Synthesis of bis-malonate analogue of M6P 
Figure 3.11: Synthesis of bis-phosphonate analogue of M6P 
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binding sites. In 2004, Olson et al. constructed a homology model of the whole receptor, 
based on the crystal structures of domain 1-3, using topographical information from 
amino acid sequence of each domain. They estimated that the distance between the M6P-
binding sites domain 3 and domain 9 on a single receptor is ~ 45 Å for a “bent” model.53 
And few studies have shed light on the length required for a ligand to bind two sites 
intermolecularly.  Therefore, we decided  to make a set of bivalent ligands with longer 
tethers.94  
 
Benzylation of -D-mannopyranoside, followed by treatment with acetic 
anhydride yielded the di-acetate compound 8. A Vorbrüggen-type glycosylation95 using 
TMSOTf afforded a set of alkene terminated mannosides. Then Grubbs-I catalyst was 
utilized in the alkene cross metathesis96 to generate the bis-mannosides. Following the 
removal of acetate groups, triflate displacement chemistry was efficiently applied to each 
of the diol substrates. The final alkene hydrogenation/global debenzylation step rendered 
four bis-phosphonate ligands (9 – 12) with incrementally increased lengths  (Fig. 3.12). 
These compounds represents the first set of “molecular rulers” that has been developed to 
Figure 3.12: Synthesis of a set of phosphatase-inert “molecular rulers” 
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probe the bivalent interactions with the receptor. The IC50 values and relative binding 
affinities (RBAs) are summarized in Table 3.1, as well as the estimated P-P distances. 
Statistically, all these compounds exhibited a similar binding affinity to M6P, suggesting 
they still bind in a monovalent manner. Although compound 12 has about twice the 
length of the original  ligand 7, its RBA showed little improvement. Furthermore, the 12-
carbon tether starts to have a detrimental effect on the solubility of these bis-phosphonate 
ligands in water. Thus, we need to build the bivalent ligands with longer and more 
hydrophilic tethers. More importantly, we seek diverse structural features in the new 
generation of ligands, to acquire more information about the bivalent contact between the 
receptor and the native ligands. 
 
 
 
 
 
 
 
 
 
Figure 3.13: One of the low-energy conformers of the 12-C tethered 
ligands found by a MMFF minimization 
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B. Ligand Diversification at the Linking Stage 
Synthetic ligands have been regularly employed to probe multivalent 
interactions.81, 83-84 This is because the natural ligands are commonly too complex to 
apprehend. For instance, hGUS is a homotetrameric glycoprotein. In each monomer, four 
Asn residues could potentially be glycosylated with a variety of high-mannose N-glycans, 
ranging from Man5GlcNAc2 to Man9GlcNAc2.97 Therefore, it is extremely difficult to 
interpret how hGUS achieves multivalency through interactions with IGF2R. In contrast, 
small-molecule ligands have defined structures, such as valency and distance. And they 
are relatively easy to modify for extensive SAR studies. Hence, these “tailored ligands” 
are important tools to probe multivalent interactions with macromolecules.98 Furthermore, 
synthetic ligands can block the binding of the natural ligands, thereby inducing desired 
cellular response.99 In this particular case, however, the goal is to have a synthetic ligand 
Ligand IC50(n) (μM)a RBAb Mr Lengthc 
M6P 11.5 ± 2.51 (4) 1.0 340 NA 
G6P >10 (4) NA 282 NA 
9 (6C) 4.76 
 2.50 (4) 2.63 
 0.74 666 18.5Å 
10 (8C) 5.03 
 1.34 (4) 2.39 
 0.83 694 19.5Å 
11 (10C) 4.44 
 1.40 (4) 2.65 
 0.52 722 21.8Å 
12 (12C) 3.65 
 0.54 (4) 3.13 
 0.52 750 24.7Å 
aIC50s for competitive displacement of radiolabeled PMP-BSA from the receptor (n = no. of trials); bRBA = relative binding affinity, normalized to free M6P; cLength = P-P distance, as estimated by 
molecular mechanics minimization (MMFF)  
Table 3.1.  Relative CI-MPR binding affinities 
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that activates the IGF2R-mediated endocytosis, leading to the inhibition of IGF-II 
dependent tumor growth. And with our phosphonate analogue as the binding motif, such 
a bivalent ligand would become a novel anti-cancer drug candidate instantly.  
Pioneering studies from Kiessling group have demonstrated the great influence of 
tethers or valency on the ligand-receptor binding.84, 98, 100-101 However, few groups have 
looked over the effect of linkages despite a growing list of conjugation chemistries. It 
appears many multivalent ligands are linked through 1,4-triazoles, utilizing the copper(I)-
catalyzed azide-alkyne cycloaddition (CuAAC).102 Indeed, this transformation has 
become so popular that this chemistry has become synonymous with the term “click 
chemistry”. Although CuAAC is highly efficient, the myopic focus on this chemistry is 
truly a missed opportunity.103 Namely, with the azide functionality, one can rapidly 
diversify the linkage with an array of conjugation chemistries.104 In this manner, one can 
introduce diversity to the important molecular features, such as size, shape and 
lipophilicity. Therefore, we decided to demonstrate this linker-diversification strategy, by 
building a new generation of bivalent ligands for IGF2R.  
Figure 3.14: Synthesis of an azide-terminated mannosyl phosphonate  
143 
 
The synthesis of the new set of ligands emanates from n-pentenyl 2,3,4-tri-O-
benzyl--D-mannopyranoside 13. Triflate displacement chemistry was successfully 
applied, with 66% yield over the two steps, that installed the phosphonate moiety. The 
terminal double bond was then subjected to ozonolysis, followed by treatment with 
dimethyl sulfide. Further reduction of the aldehyde yielded the intermediate 15. 
Tosylation of the terminal -OH, followed by NaN3 displacement afford the key azido 
precursor 16, set for a series of conjugation chemistries.  
In the meantime, we have selected pentabutylene glycol (PBG) as the tethering 
part. It represents the type of tethers with ideal length, flexibility and hydrophilicity for 
our system. PBG was synthesized in gram scale following Gin’s iterative process (Fig. 
Figure 3.15: Gin’s iterative procedure for synthesis of pentabutylene glycol  
Figure 3.16: Synthesis of three types of tethers 
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3.15).105 2,5-Dimethoxy tetrahydrofuran was treated with 1,4-butanediol and catalytic p-
toluenesulfonic acid (TsOH) to generate the diacetal in 75% yield. Reductive opening of 
the seven-membered ring resulted in tributylene glycol quantitatively. Swern oxidation 
efficiently converted the terminal alcohols to aldehydes, which were reacted with 1,4-
butanediol and TsOH to give the extended diacetal. Further treatment with borane-THF 
rendered PBG in 91% yield. PBG was further modified to install functional groups that 
are ready to couple with azides (Fig. 3.16). First the terminal hydroxyl groups were 
oxidized to carboxylic acids, of which DCC-promoted esterification yielded the 
phosphine-ester 21 expeditiously. PBG was also converted to the dialdehyde 19, followed 
by Corey-Fuchs reaction to afford diacetylene 22. Finally, Appel reaction transformed the 
diol to diiodide 20 in 93% yield. Methyl 2-(diphenylphosphino)-5-hydroxybenzoate was 
used to displace the iodide, providing a different phosphino-ester, compound  23.  
With both coupling components in hand, we set out to examine a set of five 
conjugation reactions, as a novel strategy to introduce diversity to the ligands. First, the 
phosphino-esters 21 and 23 were reacted with the azide precursor respectively, to provide 
two distinct amide linkages. This Staudinger-type conjugation was first developed by the 
Bertozzi group.106-107  Azides can be efficiently reduced by phosphines to afford aza-ylide 
intermediates. Hydrolysis of these ylides gives amines and phosphine oxide. By cleverly 
using an adjacent ester,  Bertozzi et al. were able to trap the aza-ylide to form a 
phosphonium amide. Upon hydrolysis108, the phosphonium amide broke down to 
phosphine oxide and an amide bond, which serves as the linkage to a variety of 
bioconjugates.109  
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Herein, for the “traceless” coupling between 21 and 16, the formed phosphine 
oxide was released from the reaction to yield the simple amide linked compound 24. On 
the other hand, for the ligation of 23 and 16, hydrolysis expelled MeOH as the byproduct, 
while phosphine oxide was conserved as a part of a novel linkage. The latter strategy was 
successfully utilized to engineer cell surfaces.106, 110 Thus it is intriguing to employ this 
underused linking functionality in our system. Both Staudinger-type ligation proceeded 
efficiently with over 82% yield (>90% for each coupling). Alternatively, compound 24 
could be accessed by Williams ligation which uses thio carboxylic acids to react with 
azides.111 However, we found the azide 16 to be a challenging substrate for this type of 
transformation. The reaction between 16  and the bis-thio carboxylic acid rendered the 
desired product in <20% yield, with a notable decomposition of the azide.  
Next, we set out to explore two types of azide-alkyne chemistries. CuAAC has 
been widely applied in bioorganic chemistry, ranging from ligand assembly to target  
Figure 3.20: Ru(II)- and Cu(I)-catalyzed azide-alkyne Huisgen cycloaddition 
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Figure 3.17: “Traceless” Staudinger ligation to make the simple amide linkage 
Figure 3.18:  Staudinger ligation to make the triphenylphosphine oxide-amide linkage 
Figure 3.19: Williams thioacid-azide ligation to make simple amide linkage 
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labeling.112 There are numerous bioconjugates and small-molecule conjugates that bear  
the 1,4-triazole linkage. Recently, Ru(II)-catalyzed azide-alkyne cycloaddition (RuAAC) 
has emerged as an exciting alternative.113-114 Although this reaction is not as efficient as 
CuAAC, it provides an interesting 1,5-triazole linking functionality. This regioisomeric 
linkage could, in principle, forge the molecule in a different trajectory. For example, 
Liskamp et al. have utilized the triazole group to replace the E-ring of vancomycin, 
aiming to synthesize the constrained mimics of the antimicrobial agent.115 The successful 
execution of the CuAAC and RuAAC reactions lead to two macrocyclic peptides with 
distinct structural features. However, the synthesis of these vancomycin analogues was 
not completed and no biochemical studies were presented. Herein, the Huisgen 
cycloaddition reactions were conducted with both the copper and ruthenium catalysts, to 
yield the 1,4-triazole linked compound 27 and the 1,5-triazole linked 26, respectively 
(Fig 3.20). After the global debenzylation., two bivalent phosphonate ligands were 
afforded. And a direct comparison of the binding affinities of the 1,4- and 1,5-triazole 
linked ligands  is prominent. 
Finally, we set out to explore an even less exploited ligation chemistry, namely 
the 1,3-dipolar cycloaddition reactions of azides and sulfonyl cyanide. Subsequent 
nucleophilic aromatic substitution (SNAr) of the sulfonyl tetrazoles could ligate various 
nucleophiles to the tetrazole components. This transformation was first discovered under 
thermal conditions by Demko and Sharpless.116 Tosyl cyanide (TsCN)117, owing to its 
relative stability and commercial accessibility, is the only sulfonyl cyanide that has been 
explored in this reaction.  A wide range of aliphatic azides gave quantitative yields; 
however, aromatic azides are generally poor substrates for the cycloaddition. In 2007, 
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Vilarrasa et al. examined an array of metal catalysts and found Cu2(OTf)2 is particularly 
effective in promoting the reactions.118 Hence, we initially attempted to fulfill the 
cycloaddition of azide 16 and tosyl cyanide using this catalyst. As seen in Table 3.2, the 
tetrazole 28 was synthesized in poor to moderate yields under catalysis, with 
Cu2(OTf)2•C7H8 complex giving the best result (48% yield). Perhaps more 
disappointingly, the Cu(I)-catalyzed cycloaddition reactions afforded mediocre 
selectivities. The 1,4- and 1,5-tetrazole linkages were generated in a ratio of ~ 3:7. And 
these two regioisomers proved to be difficult to separate. Other metals also failed to give 
satisfactory results. Notably, Fokin’s Ru(II) catalyst113 failed to produce any detectable 
product after 48 h (Table 3.2, entry 5). Hence, we set to examine this reaction under 
thermal conditions. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
entry catalyst solvent temp (C) time, h 
yield 
(%) sel.
a 
1 Cu2(OTf)2•C6H6 CH2Cl2 23 22 31 75/25 
2 Cu2(OTf)2•C7H8 CH2Cl2 23 22 48 70/30 
3 Cu(OTf)2 CH2Cl2 23 22 13 71/29 
4 ZnCl2 CH2Cl2 23 22 15 93/7 
5 Cp*(COD)RuCl CH2Cl2 23 48 0 NA 
6 none none 95 20 72 >99/1 
7 none none 95b  1 70 >99/1 
Table 3.2: Optimization of the azide-sulfonyl cyanide 1,3-dipolar cycloaddition 
a. Selectivity of the cycloaddition reaction with ratios of 1,5-tetrazole over 1,4-tetrazole. b. This reaction 
temperature was achieved by microwave irradiation. 
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To our satisfaction, the functionally dense azide 16 reacted efficiently with TsCN 
at 95 °C without any solvent. The desired sulfonyl 1,5-tetrazole was synthesized in 72% 
yield as the only detected isomer (Table 3.2, entry 6). Next, we utilized microwave to 
promote this thermal reaction to a greater efficiency. Vilarrasa et al. have used 
microwave irradiation to facilitate the 1,3-dipolar cycloaddition reactions between azides 
and acetyl cyanides.118 However, prior to this work, no one has reported the use of 
microwave to accelerate the cycloaddition of an azide and tosyl cyanide. A synthesizer 
demo was kindly provided by CEM at that time. The reaction was then heated at 95 °C 
under microwave irradiation. TLC analysis indicated the completion of the reaction 
within 1 h. Further purification afforded only the 1,5-tetrazole compound 28 in 70% yield 
(Table 3.2, entry 7). This represents a significant improvement of the reaction efficiency, 
compared with the one using the conventional heating source. The sulfonyl tetrazole 28 
was then reacted with the nucleophilic PBG alkoxide, providing the 1,5-tetrazole-linked 
compound 29 in 79% yield (89% for each displacement, Fig. 3.21). 
 
 
 
 
 
 
 
Figure 3.21: Demko-Sharpless azide-nitrile cycloaddition/SNAr sequence 
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C. Binding Affinity Assay 
All the protected bis-phosphonate compounds (24, 25, 26, 27, 29) were subjected 
to the final global deprotection step, to afford the active ligands (BL1 – BL5) for the 
binding affinity assay. The assay was conducted in Prof. MacDonald’s lab at the 
University of Nebraska Medical Center (UNMC). Thanks to Prof. MacDonald and 
graduate student Megan Zavorka’s patient guidance, I had the opportunity to have a 
hands-on experience of this displacement assay.  
IGF2R was previously prepared and immobilized on the cyanogen bromide-
activated Sepharose resin. I125-PMP-BSA, a radiolabelled high-affinity ligand, was 
utilized to competitively bind to the receptor. Thus, aliquots of receptor resins were 
incubated with I125-PMP-BSA, in the presence of increasing concentrations of synthetic 
ligands. The mixture was agitated at 4 °C for 16 h, followed by repetitive washing with 
buffer. The I125-PMP-BSA-bound resins were then quantified in a Perkin-Elmer 
WIZARD Automatic Gamma Counter. The data were converted to percent binding 
values by comparing with the test ligand-free controls. Then these values were plotted 
against the concentrations of test ligands in semi-log graphs. Nonlinear regression 
analysis (Prism GraphPad) was applied to estimate the best-fit curve and IC50 for each 
ligand. Relative binding affinities (RBAs) were also calculated for each compound by 
comparing to the IC50 of M6P. Each value in Table 3.3 represents the mean of at least 
three replicate experiments.  
In addition to the binding affinities, a few molecular features of these linking 
functionalities are also listed in the table, particularly the ones related to the Lipinski’s 
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rule of five119; namely, (i) number of hydrogen bond donors, (ii) number of hydrogen 
bond acceptors, (iii) molecular weight, (iv) calculated logP (of the molecules with methyl 
groups on each side)and (v) angle types of the two linkage bonds. 
 
ligand BL1 BL2  BL3   BL4   BL5 
linkage 
     
functional 
group amide 
amide & 
triphenyl 
phosphine oxide 
1,4-triazole 1,5-triazole 
1,5-
tetrazole 
RBAa 2.1 0.67 1.3 3.9 2.4 
H-bond 
donor  1 1 0 0 0 
H-bond 
acceptor 1 2 2 2 3 
M.W. 43 319 67 67 68 
clogP -1.078 1.319 -0.261 -0.261 -0.238 
angle linear obtuse obtuse acute acute 
 
As seen in Table 3.3, the linkage shapes seem to have the most prominent effect 
on the receptor binding. 1,5-Triazole-linked BL4 exhibited a 3-fold higher RBA than the 
1,4-triazole linked BL3. Moreover, 1,5-tetrazole linked ligand BL5 displayed the second 
strongest binding in this series. These two linkages represent the “bent” trajectory that 
might support the desired conformation for receptor binding. On the other hand, the  
amide linkage is linear and the amide linked BL1 displayed a mediocre RBA (2.1). For 
the ligand BL2, the steric hindrance seems paramount for the receptor. While this linking 
functionality served well in the purpose of cell-surface engineering, the 
Table 3.3: Molecular features of the linkages and RBAs of the bivalent ligands 
a. Relative binding affinity was calculated by dividing the IC50 value for each compound by that of M6P 
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triphenylphosphine oxide-amide linkage trailed other ligands here, exhibiting the lowest 
binding affinity (RBA = 0.67). It should be noted that even the best ligand BL4 did not 
provide the sought-after 3 orders of magnitude higher RBA than M6P. Instead, BL4 only 
showed a statistically 2-fold higher binding affinity than M6P. This implies that these 
bidentate ligands fail to concurrently bind two binding sites. There are many possible  
reasons for this result and a few of them are discussed in detail later.  
D. PEG Based Bivalent Ligands 
 
entry base solvent additive yield (%) 
1 NaH DMF none 45 
2 Ag2O         DMF none 0 
3 PS-TBD DMF none 0 
4 PS-BEMP DMF none 0 
5 KHMDS THF none 31a 
6 NaHMDS toluene none 77a 
7 NaHMDS toluene crown ether 72a 
8 KHMDS toluene none 87a 
a. The reaction was carried out using the following procedure: To a solution of tetraethylene 
glycol (1 equiv.) in toluene (0.2 mmol) was added KHMDS (0.5 M in toluene, 2.1 equiv.) 
and additive (2.1 equiv.). After stirring at r.t. for 0.5 h, the mixture was cooled to -78°C and 
added to a solution of  30 (2.1 equiv) in toluene. The reaction was slowly warmed to r.t. and 
stirred for 8-10 h. After aqueous workup, column chromatographic purification (5% MeOH-
EtOAc) yielded compound 31 as a colorless oil. 
Table 3..4: Optimization of the displacement reaction of the sulfonyl tetrazole 
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Out of this study, the newly-improved azide-cyanide cycloaddition/SNAr ligation 
chemistry is one of the most interesting results. To further demonstrate the potential of 
this method in chemical biology, we employed it to synthesize a second generation of 
ligands with incrementally increasing lengths . Commercially available polyethylene 
glycols (PEGs) were utilized as proof of principle. Therefore, the tetrazole compound 28 
was prepared in large scale under microwave conditions. The substitution reactions 
proceeded efficiently for the sodium alkoxides with 6,8,10 and 12 PEG units.  
However, PEG-4 reacted poorly with 28 using NaH in DMF (45% yield). To 
improve the yield, we explored the SNAr under various conditions. The tetrazole 
compound 30 was utilized as a model substrate and can be accessed readily. Then we 
tried an array of bases with diverse structures (Table 3.4). Ag2O and two polystyrene-
immobilized bases (PS-TBD, PS-BEMP) met with little success in facilitating the 
substitution. On the other hand, NaHMDS proved to be an  efficient base in this reaction. 
The tetrazole compound 31 was produced in 77% yield in toluene (Table 3.4, entry 6). 
However, the yield decreases dramatically in more polar solvents such as THF or diethyl 
ether. This suggests that the poor solvation of the anion markedly increases its 
nucleophilicity, thereby accelerating this SNAr reaction. Additionally, using KHMDS, we 
were able to improve the yield to 87% (Table 2.4, entry 8), which means >93% yield for 
each coupling. Subsequently, the optimized conditions were applied to the reaction  
between PEG-4 and 28, which proceeded very efficiently as well. The tetrazoles linked, 
PEG-4 tethered bis-phosphonate 29 was made in 78% yield. Further deprotection of these 
compounds afforded a new set of ligands that could potentially measure the spatial 
distance between two M6P binding sites.  
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Nonetheless, the binding affinity assay demonstrated little to no difference among 
these PEG-tether ligands (Table 3.5). These results indicate that even the closest distance 
between two binding sites is beyond these ligands’ reach. One reason is that PEGs tend to 
take folded conformations in aqueous medium. This phenomenon was even quantified in 
the recent review by Gambhir et al.120 In water, the length of a PEG polymer (PEG-n) can 
be described in terms of the Flory radius (F), which can be calculated using equation (1).  
	 ൌ ݊
య
ఱ (1)
  This equation proved to be practical for larger PEGs (n = 103 - 104). Herein, we 
applied the equation to have a rough idea of the lengths of these shorter PEG tethers. The 
F of PEG-12 is calculated to be around 15 Å, which falls short of the predicted distance 
between two binding sites (~ 30 – 50 Å).49 Therefore, the marriage between PEG tethers 
and the cycloaddition/SNAr sequence may be more useful in probing shorter distances.  
Overall, ten bivalent ligands were synthesized in this study. Although they did not exhibit 
the sought-after binding affinities, we did gain some insights on the ligand-receptor 
interactions. For example, the receptor showed a notable preference for the cis-linked 
ligands, suggesting the rigid conformation of the native ligand is crucial for high affinity 
binding. Moreover, the triphenylphosphine oxide moiety was not well tolerated in the 
protein interactions. This indicates steric hindrance does play a role in binding this 
receptor, even for the monovalent interactions. The reason(s) why these ligands failed to 
cross-bridge IGF2R is not yet clear. In addition to their shorter lengths, there are a couple 
of other plausible factors. 1) These ligands are still too flexible compared with naturally-
occurring oligosaccharides. The conformational dynamics of the receptor requires the 
ligands to be orientated in a specific way to chelate. Although we introduced heterocycles 
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or amide bonds as the rigid linker, the ligand can still take numerous conformations 
thanks to the PBG or PEG tether. Thus, the entropy penalty could simply be too high for 
these ligands to concomitantly bind two receptors. 2) The -1,2-linked mannose 
disaccharide could be critical for high-affinity binding. As we analyze previous ligands 
for this receptor, it seems the oligosaccharide motif is preserved through high-binding-
affinity ligands. More importantly, as seen in the crystal structure of the bovine CD-MPR 
(PMP-bound), the residues (D43, Y45) inside the M6P binding pocket have significant 
interactions with the penultimate mannoside (Fig. 3.22).44  Therefore, to achieve high 
binding affinities and induce receptor dimerization, it may be important to add the second 
mannose to our ligand design.  
 
  
entr
y Ligand    n SNAr (%)
a debenzylation yield (%) 
Flory 
radius (Å)b 
1 BL6 4 78 91 9.2 
2 BL7 6 79 89 10.2 
3 BL8 8 84 90 12.2 
4 BL9 10 78 92 13.9 
5 BL10 12 64 92 15.5 
 
 
a. For n = 4, the yield is from the reaction in toluene using KHMDS. All other yields are from 
reactions in DMF with NaH. b. Flory radius is calculated from the equation F = n3/5 ( = 3.5 
Å for PEG). 
Table 3.5: Synthesis of PEG-tethered ligands as spatial probes 
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In conclusion, we have demonstrated a way to generate diversity at the linking 
stage, even with the functionally dense sugar-phosphonate. One can quickly assemble a 
library of diverse ligands, by harnessing the versatility of an azido terminus. This is 
particularly useful in synthesizing peptidomimetic libraries, as all five linkages have 
amide or amide-mimicking character. Moreover, for the first time, the Sharpless-Demko 
cycloaddition/SNAr sequence has been  applied in probing the distance between two 
binding sites. Given the popularity of PEG spacers in multivalent ligand assembly, we 
believe that this strategy will find broad application in chemical biology.  
Figure 3.22: Crystal structure of bovine CD-MPR with phosphoryl pentamannoside 
bound. The image was rendered from IC39. Three of the pentamannose were found in the 
active site. The MRH domain-preserved residues interact with the terminal M6P (purple 
color). The penultimate mannose interacts with D43 and Y45. The antepenultimate mannose 
weakly interacts with Q68 (not shown here). 
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In the future, we can increase the rigidity of our ligands which may decrease the 
entropy penalty for the binding event. Oligopeptide and oligosaccharide tethers are 
confined structures that could be utilized in the ligand assembly. By screening a series of 
short peptides, we may find a ligand that takes the optimal conformation for binding. 
Furthermore, we should make the -1,2-linked mannose disaccharide that is armed with 
phosphonate functionality and use it as the monomeric precursor to build bivalent or 
multivalent ligands.  
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III. Experimental Section 
A. Organic Synthesis 
Reactions were conducted under argon atmosphere using oven-dried glassware. 
Methylene chloride was distilled from CaH2. THF was distilled from sodium 
benzophenone ketyl. MeOH was distilled from magnesium-iodide. Other reagents were 
obtained from commercial sources and used without further purification. Flash 
chromatography was performed using Merck silica gel 60 (230-400 mesh). 1H NMR 
spectra were recorded on a Bruker-DRX-Avance 500 MHz and 400 MHz instrument with 
chemical shifts reported relative to residual CHCl3 (7.25 ppm). Proton-decoupled 13C 
NMR spectra were acquired on a Bruker-DRX-Avance 400 MHz and 600 MHz 
instrument with chemical shifts reported relative to CDCl3 (77.0 ppm). 31P NMR spectra 
were obtained on the 400 MHz instrument with chemical shifts reported relative to 85% 
phosphoric acid (0 ppm). Mass spectra were acquired at the Nebraska Center for Mass 
Spectrometry (University of Nebraska-Lincoln). 
 
n-Pentenyl 2,3,4-tri-O-benzyl-6-O-
trifluoromethanesulfonyl--D-mannopyranoside (32). To a 
solution of n-pentenyl 2,3,4-tri-O-benzyl--D-mannopyranoside 
(820mg, 1.58 mmol) and 2,6-di-tert-butyl-4-methylpyridine (1.3g, 6.32 mmol) in CH2Cl2 
(16 mL), was slowly added trifluoromethanesulfonic anhydride (794 L, 4.74mmol) at -
40 °C and stirring continued for 0.5 h at that temperature. The reaction mixture was then 
concentrated in vacuo and directly applied to column chromatography (8% EtOAc -
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hexanes) to afford 32 (942 mg, 92%) as pale yellow oil: 1H NMR (400 MHz, CDCl3)  
7.36-7.51 (m, 15H), 5.82-5.94 (m, 1H), 5.13 (dd, J = 1.6, 3.2 Hz, 1H), 5.05-5.11 (m, 1H), 
4.91 (d, J = 1.6 Hz, 1H), 4.85 (d, J = 12.4 Hz, 1H), 4.78 (d, J = 12.4 Hz, 1H), 4.74 (d, J = 
10.4 Hz, 1H), 4.74 (s, 2H), 4.70 (d, J = 11.2 Hz, 1H), 4.65 (dd, J =1.2, 5.2 Hz, 1H), 4.01-
4.08 (m, 1H), 3.94-4.02 (m, 2H), 3.87 (dd, J = 2.4, 2.8 Hz, 1H), 3.74 (td, J = 6.8, 9.6, 1H), 
3.46 (td, J = 6.4, 9.6 Hz, 1H), 2.12-2.21 (m, 2H), 1,73 (quint, J = 6.8 Hz, 2H); 13C NMR 
(100 MHz, CDCl3)  138.21, 138.19, 137.90, 137.87, 130.6, 129.0, 128.8, 128.6, 128.54, 
128.50, 128.4, 128.3, 128.13, 128.07, 127.85, 127.84, 126.2, 126.1, 120.3 (t, JC-F = 318 
Hz, 1C), 115.1, 113.9, 97.9, 80.1, 75.7, 75.2, 74.6, 73.7, 72.8, 72.2, 70.0, 67.3, 30.3, 28.6; 
19F NMR (376 MHz, CDCl3)  -74.5 (s, 3F). 
 
n-Pentenyl 6-deoxy-6-(dibenzyl)phosphonomethyl-
2,3,4-tri-O-benzyl--D-mannopyranoside (14).  To a solution 
of triflate 32 (942 mg, 1.45mmol) and dibenzyl 
methylphosphonate (1.6 g, 5.8 mmol) in THF (15 mL) at -78 °C was added slowly n-
BuLi (3.62 mL of a 1.6 M solution in hexane, 5.8 mmol). After stirring for 20 min at -
78 °C, the reaction was quenched with saturated aqueous NH4Cl. Et2O (100 mL) was 
added to dilute the solution. The organic layer was sequentially washed with NH4Cl, 
water and brine, and then dried over MgSO4. Filtration and evaporation gave crude 
product, which was purified by flash column chromatography (30-40% EtOAc-hexanes) 
to afford 14 (810 mg, 72%) as a colorless oil: 1H NMR (400 MHz, CDCl3)  7.26-7.43 
(m, 25H), 5.75-5.85 (m, 1H), 5.09 (d, J = 8.8 Hz, 1H), 5.06 (d, J = 8 Hz, 1H), 4.97-5.04 
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(m, 4H), 4.95 (d, J = 10.8 Hz, 1H), 4.80 (d, J = 12.4 Hz, 1H), 4.76 (d, J = 1.6 Hz, 1H), 
4.74 (d, J = 12.8 Hz, 1H), 4.66 (s, 2H), 4.62 (d, J = 10.8 Hz, 1H), 3.89 (dd, J = 2.8 Hz, 
9.6 Hz, 1H), 3.79 (dd, J = 2 Hz, 2.8 Hz, 1H), 3.68 (t, J = 9.6 Hz, 1H), 3.50-3.59 (m, 2H), 
3.31 (td, J = 6.4 Hz, 9.6 Hz, 1H), 2.11-2.30 (m, 2H), 2.00-2.11 (m, 2H), 1.70-1.92 (m, 
2H), 1.62 (quint, J = 6.8 Hz, 2H); 13C NMR (100 MHz, CDCl3)  138.5, 138.4, 138.0, 
136.5 (d, J = 6 Hz), 128.6, 128.5, 128.4, 128.2, 127.98, 127.95, 127.76, 127.74, 127.67, 
115.1, 97.9, 80.3, 78.3, 75.4, 74.9, 72.9, 72.2, 71.4 (d, 18 Hz), 67.16, 67.09, 66.7, 30.3, 
28.5, 24.7 (d, J = 4 Hz), 22.3 (d, J = 141 Hz); 31P NMR (162 MHz, CDCl3)  33.79; 
HRMS (ESI m/z) calcd for C47H53O8PNa (M+Na+) 799.3376, obsd 799.3401. 
 
3-Formylpropyl 6-deoxy-6-
(dibenzyl)phosphonomethyl 2,3,4-tri-O-benzyl--D-
mannopyranoside (33). 14 (2.6 g, 3.35 mmol) was dissolved in 
30 mL CH2Cl2. The solution was then cooled to -78 °C. A stream of O3/O2 was bubbled 
into the reaction mixture until the solution turned pale blue. Excess ozone was discharged 
by bubbling with N2.  The reaction was stirred at room temperature for 48h following 
addition of dimethyl sulfide (~30 equiv.). The residue obtained upon concentration was 
purified by flash column chromatography (20% EtOAc-hexanes) to afford 33 (2.2 g, 85%) 
as a colorless oil: 1H NMR (400 MHz, CDCl3)  9.69 (t, J = 1.6 Hz, 1H), 7.24-7.39 (m, 
25H), 5.058 (dd, J = 1.2 Hz, 8.8 Hz, 1H), 5.03 (dd, J = 1.2 Hz, 8.4 Hz, 1H), 4.99 (dd, J = 
1.6 Hz, 8 Hz, 1H), 4.96 (dd, J = 1.2 Hz, 8.4 Hz, 1H), 4.92 (d, J = 10.8 Hz, 1H), 4.77 (d, J 
= 12.4 Hz, 1H), 4.70 (s, 1H), 4.69 (d, J = 12.4 Hz, 1H), 4.63 (s, 2H), 4.59 (d, J = 10.8 Hz, 
1H), 3.80 (dd, J = 2.8 Hz, 8.8 Hz, 1H), 3.72 (dd, J = 2 Hz, 3.2 Hz, 1H), 3.64 (t, J = 9.6 
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Hz, 1H), 3.56 (td, J = 6.4 Hz, 9.6 Hz, 1H), 3.46 (dt, J = 2.4 Hz, 8.8 Hz, 1H), 3.29 (td, J = 
6.4 Hz, 9.6 Hz, 1H), 2.44 (ddt, J = 1.6 Hz, 17.4 Hz, 7.2 Hz, 1H), 2.37 (ddt, J = 1.6 Hz, 
17.6 Hz, 7.2 Hz, 1H), 2.11-2.24 (m, 2H), 1.68-1.88 (m, 4H); 13C NMR (100 MHz, CDCl3) 
 201.7, 138.4, 138.3, 136.5 (d, J = 6 Hz), 128.6, 128.4, 128.3, 128.2, 127.94, 127.91, 
127.89, 127.75, 127.73, 127.6, 97.9, 80.1, 78.2, 75.4, 74.8, 75.4, 74.8, 72.9, 72.2, 71.5 (d, 
J = 17 Hz), 67.1, 67.0, 66.3, 40.9, 24.7 (d, J = 4 Hz), 22.2 (d, J = 141 Hz), 22.1; 31P NMR 
(162 MHz, CDCl3)  33.58; HRMS (ESI m/z) calcd for C46H51O9PNa (M+Na+) 801.3168, 
obsd 801.3164. 
 
4-Hydroxybutyl 6-deoxy-6-
(dibenzyl)phosphonomethyl 2,3,4-tri-O-benzyl--D-
mannopyranoside (15). 33 (1.34 g, 1.72 mmol) was dissolved 
in 20 mL MeOH. NaBH4 (72 mg, 1.91 mmol) was added at room temperature in one 
portion. The mixture was stirred for another 30 min followed by addition of saturated 
aqueous NH4Cl. The solution was extracted with CH2Cl2 (3 × 25 mL). The organic layer 
was then dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
by flash column chromatography (40-60% EtOAc-hexanes) to afford 15 (1.28 g, 96%) as 
a colorless oil: 1H NMR (400 MHz, CDCl3)  7.23-7.38 (m, 25H), 4.93-5.06 (m, 4H), 
4.91 (d, J = 10.8 Hz, 1H), 4.77 (d, J = 12.4 Hz, 1H), 4.74 (d, J = 1.6 Hz, 1H), 4.70 (d, J = 
12.4 Hz, 1H), 4.63 (s, 2H), 4.58 (d, J = 10.8 Hz, 1H), 3.85 (dd, J = 2.8 Hz, 8.8 Hz, 1H), 
3.76 (dd, J = 2 Hz, 2.8 Hz, 1H), 3.64 (t, J = 9.2 Hz, 1H), 3.56-3.63 (m, 3H), 3.54 (dt, J = 
2.4 Hz, 9.2 Hz, 1H), 3.30 (td, J = 6 Hz, 9.6 Hz, 1H), 1.98-2.25 (m, 2H), 1.71-1.88 (m, 
2H), 1.51-1.67 (m, 4H); 13C NMR (100 MHz, CDCl3)  138.5, 138.3, 136.5 (d, J = 6 Hz), 
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128.6, 128.4, 128.3, 128.1, 127.94, 127.91, 127.89, 127.7, 127.6, 97.9, 80.3, 78.4, 75.3, 
74.9, 72.9, 72.2, 71.3 (d, 16 Hz), 67.3, 67.2, 67.1, 67.0, 62.3, 29.5, 25.8, 24.8 (d, J = 5 
Hz), 22.2 (d, J = 142 Hz); 31P NMR (162 MHz, CDCl3)  33.59; HRMS (ESI m/z) calcd 
for C46H53O9PNa (M+Na+) 803.3325, obsd 803.3312. 
 
4-Tosyloxybutyl 6-deoxy-6-
(dibenzyl)phosphonomethyl 2,3,4-tri-O-benzyl--D-
mannopyranoside (34). To a solution of 15 (414 mg, 0.54 
mmol) and anhydrous pyridine (172 L, 2.2 mmol) in distilled dichloromethane (5 mL) 
under argon, was added p-toluenesulfonyl chloride (418 mg, 2.2 mmol) in one portion. 
The solution was stirred at room temperature overnight. Then the reaction was diluted 
with CH2Cl2 (15 mL) and sequentially washed with NaHCO3, water and brine. The 
organic layer was dried over MgSO4, filtered and concentrated. The crude product was 
purified by flash column chromatography (10-30% EtOAc-hexanes) to afford 34 (474 mg, 
94%) as a colorless oil: 1H NMR (400 MHz, CDCl3)  7.78 (d, J = 8 Hz, 2H), 7.23-7.38 
(m, 27H), 5.04 (dd, J = 0.8 Hz, 8.8 Hz, 1H), 5.01 (dd, J = 1.2 Hz, 8.8 Hz, 1H), 4.97 (d, J 
= 8 Hz, 1H), 4.94 (d, J = 8 Hz, 1H), 4.89 (d, J = 10.4 Hz, 1H), 4.75 (d, J = 12.4 Hz, 1H), 
4.66 (d, J = 1.6 Hz, 1H), 4.67 (d, J = 12.4 Hz, 1H), 4.61 (s, 2H), 4.56 (d, J = 10.4 Hz, 1H), 
3.99 (t, J = 6.4 Hz,  2H), 3.78 (dd, J = 2.8 Hz, 9.2 Hz, 1H), 3.71 (t, J = 2 Hz, 1H), 3.61 (t, 
J = 9.2 Hz, 1H), 3.47 (td, J = 6 Hz, 9.6 Hz, 1H), 3.40 (dt, J = 2.4 Hz, 9.2 Hz, 1H), 3.21 
(td, J = 6 Hz, 9.6 Hz, 1H), 2.41 (s, 3H), 2.10-2.23 (m, 1H), 1.99-2.10 (m, 1H), 1.73-1.85 
(m, 2H), 1.58-1.72 (m, 2H), 1.46-1.58 (m, 2H); 13C NMR (100 MHz, CDCl3)  144.8, 
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138.4, 138.3, 136.5 (d, J = 6 Hz), 133.1, 129.9, 128.6, 128.4, 128.3, 128.2, 127.93, 
127.91, 127.89, 127.73, 127.69, 127.63, 97.8, 80.2, 78.2, 75.4, 74.8, 72.9, 72.2, 71.4 (d, 
18 Hz), 70.2, 67.11, 67.05, 66.4, 25.9, 25.4, 24.7 (d, J = 4 Hz), 22.4 (d, J = 141 Hz), 21.7; 
31P NMR (162 MHz, CDCl3)  33.59; HRMS (ESI m/z) calcd for C53H59O11PNa (M+Na+) 
957.3413, obsd 957.3403. 
 
4-Azidobutyl 6-deoxy-6-(dibenzyl)phosphonomethyl 
2,3,4-tri-O-benzyl--D-mannopyranoside (16). NaN3 (200 mg, 
3 mmol) was added to a solution of 34 (411 mg, 0.44 mmol) in 
DMF (5 mL) in one portion. After stirring for 12 h at room temperature, dichloromethane 
(40 mL) was added. The mixture was sequentially washed with saturated aqueous NH4Cl, 
water and brine. The organic layer was dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (20-30% EtOAc-
hexanes) to afford 16 (321 mg, 91%) as a colorless oil: 1H NMR (400 MHz, CDCl3)  
7.23-7.38 (m, 25H), 5.04 (dd, J = 0.8 Hz, 9.6 Hz, 1H), 5.01 (dd, J = 0.8 Hz, 8.4 Hz, 1H), 
4.98 (d, J = 8 Hz, 1H), 4.95 (d, J = 8 Hz, 1H), 4.90 (d, J = 10.8 Hz, 1H), 4.76 (d, J = 12.4 
Hz, 1H), 4.70 (s, 1H), 4.69 (d, J = 12 Hz, 1H), 4.62 (s, 2H), 4.57 (d, J = 10.8 Hz, 1H), 
3.82 (dd, J = 2.8 Hz, 9.2 Hz, 1H), 3.73 (t, J = 2 Hz, 1H), 3.63 (t, J = 9.2 Hz, 1H), 3.53 (td, 
J = 6 Hz, 9.6 Hz, 1H), 3.45 (dt, J = 2 Hz, 9.2 Hz, 1H), 3.28 (td, J = 6.4 Hz, 9.6 Hz, 1H), 
3.23 (br t, J = 6.4, 2H), 2.02-2.23 (m, 2H), 1.64-1.87 (m, 2H), 1.49-1.64 (m, 4H); 13C 
NMR (100 MHz, CDCl3)  138.4, 138.28, 138.25, 136.5 (d, J = 6 Hz), 128.6, 128.42, 
128.40, 128.3, 128.2, 127.93, 127.89, 127.73, 127.70, 127.6, 97.9, 80.2, 78.2, 75.4, 74.8, 
72.9, 72.2, 71.4 (d, J = 18 Hz), 67.10, 67.04, 66.7, 51.2, 26.6, 25.9, 24.7 (d, J = 4 Hz), 
164 
 
22.4, 22.2 (d, J = 142 Hz); 31P NMR (162 MHz, CDCl3) δ 33.59; HRMS (ESI m/z) calcd 
for C46H52N3O8PNa (M+Na+) 828.3390, obsd 828.3395. 
 
5,10,15,20-Tetraoxatetracosane-1,24-dioic 
acid (18). To a solution of pentabutylene glycol 1712 
(266 mg, 0.71 mmol) in acetone (3 mL) at room temperature, Jones Reagent was added 
dropwise until the solution color persisted orange. After stirring for 0.5 h, the reaction 
was quenched with isopropanol. Water (10 mL) was added and the solution was extracted 
with CH2Cl2 (5 × 10 mL). The combined organic layer was dried over MgSO4, filtered 
and concentrated in vacuo. The residue was purified by column chromatography (10% 
MeOH-EtOAc) to afford 18 (204 mg, 71%) as a colorless oil: 1H NMR (400 MHz, CDCl3) 
 8.85 (br, 2H), 3.43 (t, J = 5.6 Hz, 4H), 3.40 (br s, 12H), 2.41 (t, J = 7.2 Hz, 4H), 1.86 
(app quin, J = 6.4 Hz, 4H), 1.59 (br s, 12 H); 13C NMR (100 MHz, CDCl3) 70.7, 70.6, 
70.5, 69.5, 26.37, 26.34, 26.31, 24.8; HRMS (ESI m/z) calcd for C20H38O8Na (M+Na+) 
429.2464, obsd 429.2447. 
Bis(2-(diphenylphosphino)phenyl)- 5, 
10,15,20-tetraoxatetracosane-1,24- 
dioate (21). To a solution of 2-(diphenylphosphino)phenol (178 mg, 0.53 mmol), 
dicarboxylic acid 18 (107 mg, 0.26 mmol) and DMAP (8 mg, 0.065 mmol) in dry CH2Cl2 
(3 mL) was added a solution of DCC (156 mg, 0.76 mmol) in CH2Cl2 (1 mL) at room 
temperature. After stirring for 12 h, the mixture was filtered through Celite and 
concentrated in vacuo. The residue was purified by flash column chromatography (50% 
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EtOAc-hexanes) to afford 21 (210 mg, 87%) as a colorless oil: 1H NMR (400 MHz, 
CDCl3)  7.28-7.43 (m, 22H), 7.06-7.14 (m, 4H), 6.78-6.82 (m, 2H), 3.35-3.42 (m, 12H), 
3.34 (t, J = 6.4 Hz, 4H), 2.33 (t, J = 7.2 Hz, 4H), 1.75 (app quin, J = 6.8 Hz, 4H), 1.59-
1.63 (m, 12H); 13C NMR (100 MHz, CDCl3)  171.4, 152.8 (d, J = 17 Hz), 135.6 (d, J = 
11 Hz), 134.1, 133.9, 133.7 (d, J = 2 Hz), 130.3 (d, J = 14 Hz), 129.9, 129.0, 128.62, 
128.55, 126.1, 122.6 (d, J = 2 Hz), 70.64, 70.62, 70.60, 69.4, 30.8, 26.53, 26.50, 24.7; 31P 
NMR (162 MHz, CDCl3) δ -16.03; HRMS (ESI m/z) calcd for C56H64O8P2Na (M+Na+) 
949.3974, obsd 949.3989. 
5,10,15,20-Tetraoxatetracosane-1,24-dial (19). 
To a solution of oxalyl chloride (582 L, 6.67 mmol) in 
CH2Cl2 (20 mL) at -40 °C, DMSO (472 L, 6.67 mmol) was added dropwise. Then a 
solution of pentabutylene glycol (1 g, 2.67 mmol) in CH2Cl2 (10 mL) was added slowly 
within 10 min. After stirring for 1 h at -40 °C, triethylamine (9.3 mL, 67 mmol) was 
added, followed by stirring for another 30 min.  Upon completion, the reaction mixture 
was warmed to room temperature and poured into water (30 mL). The aqueous phase was 
extracted with CH2Cl2 (2 × 25 mL). The organic layer was dried, filtered and 
concentrated in vacuo. The residue was purified by flash column chromatography (40% 
EtOAc-hexanes) to afford 19 (818 mg, 82%) as a colorless oil: 1H NMR (400 MHz, 
CDCl3)  9.74 (t, J = 1.6 Hz, 2H), 3.40 (t, J = 6 Hz, 4H), 3.37-3.39 (m, 12H), 2.49 (dt, J 
= 1.6 Hz, 6.8 Hz, 4H), 1.83-1.90 (m, 4H), 1.53-1.59 (m, 12H); 13C NMR (100 MHz, 
CDCl3)  202.4, 70.7, 70.6, 70.5, 69.6, 41.0, 26.5, 26.4, 22.6; HRMS (ESI m/z) calcd for 
C20H38O6Na (M+Na+) 397.2566, obsd 397.2561. 
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1,1,26,26-Tetrabromo-6,11,16,21-tetra- 
oxahexacosa-1,25-diene (35). To a solution 
of triphenylphosphine (1.55 g, 5.93 mmol) and tetrabromomethane (983 mg, 2.96 mmol) 
in CH2Cl2 (5 mL) at 0 °C, was added a solution of dialdehyde 19 (277 mg, 0.74 mmol) in 
CH2Cl2 (4 mL). The mixture was stirred at 0 °C for 1h followed by evaporation of the 
solvent. The residue was purified by flash column chromatography (10-30% EtOAc-
hexanes) to afford the bis-dibromoalkene 35 (436 mg, 86%) as a colorless oil: 1H NMR 
(400 MHz, CDCl3)  6.39 (t, J = 8 Hz, 2H), 3.37-3.40 (m, 16H), 2.16 (app q, J = 7.2 Hz, 
4H), 1.66 (app quin, J = 6.8, 4H), 1.58-1.62 (m, 12H); 13C NMR (100 MHz, CDCl3)  
138.3, 88.9, 70.8, 70.63, 70.59, 69.7, 30.0, 27.9, 26.5; HRMS (ESI m/z) calcd for 
C22H38O4Br4Na (M+Na+) 704.9401, obsd 704.9417. 
 
6,11,16,21-Tetraoxahexacosa-1,25-diyne (22). 
35 (436 mg, 0.64 mmol) was dissolved in THF (7 mL) 
under argon. Then n-BuLi (2 mL of a 1.6 M solution in hexane, 3.2 mmol) was added at -
78 °C over 2 min. After stirring for 2 h, the reaction was quenched with saturated 
aqueous NH4Cl. The aqueous layer was extracted with Et2O (2 × 15 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The residue 
was purified by flash column chromatography (20% EtOAc-hexanes) to afford 22 (205 
mg, 84%) as a colorless oil: 1H NMR (400 MHz, CDCl3)  3.48 (t, J = 6.4 Hz, 4H), 3.37-
3.45 (m, 12H), 2.26 (dt, J = 2.4 Hz, 7.2 Hz, 4H), 1.92 (t, J = 2.4, 2H), 1.76 (app quin, J = 
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6.4 Hz, 4H), 1.57-1.67 (m, 12H); 13C NMR (100 MHz, CDCl3)  84.1, 70.7, 70.62, 70.59, 
69.0, 68.4, 28.6, 26.50, 26.47, 15.3; HRMS (ESI m/z) calcd for C22H38O4Na (M+Na+) 
389.2668, obsd 389.2685. 
 
Methyl 2-(diphenylphosphino)-5-hydroxybenzoate (36). To a 
solution of methyl 5-hydroxy-2-iodobenzoate (5.13g, 18.4 mmol) in 
anhydrous degassed CH3CN, anhydrous triethylamine (2.56 mL, 18.4 
mmol), palladium(II) acetate (166 mg, 0.74 mmol) and 1,4-bis(diphenylphosphino)butane 
(315 mg, 0.74 mmol) were added at room temperature. Diphenylphosphine (3.2 mL, 18.4 
mmol) was added to the mixture slowly via syringe upon which the solution turned deep 
red. The solution was heated at reflux for 4 h, after which the reaction was complete as 
indicated by TLC. The solution was concentrated under vacuum and the residue was 
purified by flash column chromarography (10% EtOAc-hexanes) to afford 36 as a white 
solid: 1H NMR (400 MHz, CDCl3)  7.56 (t, J = 2.8 Hz, 1H), 7.27-7.37 (m, 10H), 6.88 
(dd, J = 2.8 Hz, 8.4 Hz, 1H), 6.83 (dd, J = 3.6 Hz, 8.4 Hz, 1H), 5.37 (s, 1H), 3.76 (s, 3H); 
13C NMR (100 MHz, CDCl3)  167.1 (d, J = 2 Hz), 155.9, 138.2 (d, J = 11 Hz), 136.2, 
135.9 (d, J = 21 Hz), 133.7 (d, J = 20 Hz), 130.8 (d, J = 23 Hz), 128.50 (d, J = 14 Hz), 
128.49, 119.3, 117.7 (d, J = 3 Hz), 52.2;  31P NMR (162 MHz, CDCl3) δ -6.23; HRMS 
(ESI m/z) calcd for C20H17O3PNa (M+Na+) 359.0813, obsd 359.0817. 
 
1,24-Diiodo-5,10,15,20-tetraoxatetracosane (20). To a 
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solution of pentabutylene glycol (580 mg, 1.5 mmol) in dry THF (10 mL), imidazole 
(462 mg, 6.8 mmol), triphenyl phosphine (1.60 g, 6.1 mmol) and iodine (1.56 g, 6.1 
mmol) were added at room temperature. The mixture was stirred for 24 h. Then the 
reaction was diluted with Et2O (50 mL) and sequentially washed with saturated Na2S2O3 
(2 × 20 mL), water (20 mL) and brine (20 mL). The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (20% EtOAc-hexanes) to afford 20 (823 mg, 90%) as colorless oil: 1H 
NMR (400 MHz, CDCl3)  3.14-3.38 (m, 16H), 3.16 (t, J = 6.8 Hz, 4H), 1.86 (quin, J = 
6.8 Hz, 4H), 1.56-1.64 (m, 16H); 13C NMR (100 MHz, CDCl3)  70.7, 70.56, 70.51, 69.4, 
30.6, 30.4, 26.5, 7.0; HRMS (ESI m/z) calcd for C20H40O4I2Na (M+Na+) 621.0914, obsd 
621.0892. 
  
Dimethyl 5,5'-(5,10,15,20-tetraoxatetracosane-
1,24-diylbis(oxy))bis(2-(diphenylphosphino)-benzoate) 
(23). NaH (16 mg, 0.39 mmol) was added to a solution 
of methyl 2-(diphenylphosphino)-5-hydroxybenzoate (120 mg, 0.36 mmol) in DMF (0.4 
mL) at 0 °C. The mixture was allowed to warm to room temperature and stirred for 0.5 h, 
then a solution of diiodide 20 (96 mg, 0.16 mmol) in DMF (0.4 mL) was added to the 
reaction mixture. After stirring for 12 h, the reaction was diluted with DCM (10 mL) and 
quenched with saturated NH4Cl. The organic layer was sequentially washed with 
saturated NH4Cl (5 mL), water (3 × 5 mL) and brine (5 mL). The organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (30% EtOAc-Hexanes) to afford 23 (112 mg, 69%) as a 
169 
 
colorless oil: 1H NMR (400 MHz, CDCl3)  7.58 (t, J = 3.2 Hz, 2H), 7.25-7.39 (m, 20H), 
9.93 (dd, 2.8 Hz, 8.4 Hz, 2H), 6.85 (dd, 3.6 Hz, 8.4 Hz, 2H), 4.03 (t, 6.4 Hz, 4H), 3.77 (s, 
6H), 3.49 (t, J = 6.4 Hz, 4H), 3.42-3.47 (m, 12H), 1.85-1.92 (m, 4H), 1.74-1.79 (m, 4H), 
1.62-1.66 (m, 12H); 13C NMR (100 MHz, CDCl3)  167.1 (d, J = 2 Hz), 159.1, 138.4 (d, 
J = 12 Hz), 135.9, 135.8 (d, J = 21 Hz), 133.7 (d, J = 20 Hz), 130.6 (d, J = 22 Hz), 
128.45, 128.43 (d, J = 10 Hz), 118,5, 116.3 (d, J = 4 Hz), 70.7, 70.64. 70.61, 70.3, 67.9, 
52.1, 26.5, 26.3, 26.1; 31P NMR (162 MHz, CDCl3) δ -6.44; HRMS (ESI m/z) calcd for 
C60H73O10P2 (M+H+) 1015.4679, obsd 1015.4673.  
 
 (24). Azide 16 
(111mg, 0.14 mmol) and 
phosphine 21 (60 mg, 0.065 
mmol) were dissolved in DMF/H2O (1.4 mL, v/v = 6:1). The mixture was heated at 70 °C 
for 18h. The volatiles were removed under vacuum. The residue was purified by flash 
column chromatography (0-10% MeOH-EtOAc) to afford 24 (108 mg, 86%) as a 
colorless oil: 1H NMR (400 MHz, CDCl3)  7.25-7.39 (m, 50H), 5.95 (t, J = 5.2 Hz, 2H), 
4.90-5.07 (m, 8H), 4.89 (d, J = 10.8 Hz, 2H), 4.75 (d, J = 12.4 Hz, 2H), 4.70 (d, J = 2 Hz, 
2H), 4.69 (d, J = 12.4 Hz, 2H), 4.61 (s, 4H), 4.56 (d, J = 10.4 Hz, 2H), 3.82 (dd, J = 2.8 
Hz, 9.2 Hz, 2H), 3.75 (br s, 2H), 3.62 (t, J = 9.2 Hz, 2H), 3.46-3.55 (m, 4H), 3.34-3.46 
(m, 14H), 3.22-3.30 (m, 2H), 3.14-3.22 (m, 4H), 2.24 (t, J = 8.8 Hz, 4H), 2.11-2.23 (m, 
6H), 1.88 (app quin, J = 7.2 Hz, 4H), 1.69-1.84 (m, 4H), 1.54-1.67 (m, 12H), 1.41-1.54 
(m, 8H); 13C NMR (100 MHz, CDCl3)  172.8, 138.4, 138.31, 138.29, 136.4 (d, J = 6 
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Hz), 128.6, 128.38, 128.34, 128.2, 127.88, 127.86, 127.7, 127.63, 127.59, 97.9, 80.3, 78.3, 
75.4, 74.8, 72.9, 72.2, 71.2 (d, J = 16 Hz), 70.7, 70.6, 69.9, 67.14, 67.10, 67.08, 67.04, 
67.00, 39.1, 33.5, 26.7, 26.5, 25.8, 24.7 (d, J = 4 Hz), 22.6 (d, J = 141 Hz); 31P NMR 
(162 MHz, CDCl3) δ 33.58; HRMS (ESI m/z) calcd for C114H143N2O22P2 (M+H+) 
1929.9607, obsd 1929.9567.  
 
(25). A solution 
of the azide 16 (183 
mg, 0.23 mmol) and 23 
(115 mg, 0.11 mmol) 
in DMF/H2O (2.1 mL, v/v = 6:1) was stirred at room temperature overnight. The reaction 
was concentrated and directly purified by flash column chromatography (5-10% MeOH-
EtOAc) to afford 25 (183 mg, 71%) as a light yellow oil: 1H NMR (400 MHz, CDCl3)  
8.84 (br s, 2H), 7.64-7.68 (m, 8H), 7.53-7.56 (m, 6H), 7.43-7.49 (m, 8H), 7.24-7.42 (m, 
50H), 6.94-6.99 (m, 2H), 6.72-6.78 (m, 2H), 5.06 (d, J = 9.2 Hz, 2H), 5.03 (d, J = 8.8 Hz, 
2H), 5.00 (d, J = 8.4 Hz, 2H), 4.97 (d, J = 10.8 Hz, 2H), 4.92 (d, J = 10.8 Hz, 2H), 4.77 
(d, J = 12.4 Hz, 2H), 4.72 (s, 2H), 4.70 (d, J = 12.4 Hz, 2H), 4.64 (s, 4H), 4.59 (d, J = 
10.8 Hz, 2H), 4.07 (t, J = 6 Hz, 4H), 3.86 (dd, J = 2.8 Hz, 9.2 Hz, 2H), 3.77 (br s, 2H), 
3.64 (t, J = 9.2 Hz, 2H), 3.43-3.49 (m, 20H), 3.20 (td, J = 6 Hz, 9.6 Hz, 2H), 2.90-2.91 
(m, 4H), 2.06-2.17 (m, 2H), 2.17-2.28 (m, 2H), 1.82-1.93 (m, 6H), 1.68-1.81 (m, 6H), 
1.65 (br s, 12H), 1.38-1.44 (m, 8H); 13C NMR (100 MHz, CDCl3)   167.2 (d, J = 5 Hz), 
162.3 (d, J = 4 Hz), 143.3 (d, J = 9 Hz), 138.5, 138.4, 136.5 (d, J = 6 Hz), 135.5 (d, J = 7 
Hz), 132.2, 131.8, 131.7, 131.1, 128.8, 128.6, 128.5, 128.4, 128.3, 128.1, 127.90, 127.85, 
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127.65, 127.61, 127.53,120.6, 119.5, 117.3 (d, J = 10 Hz), 116.1 (d, J = 13 Hz), 97.7, 
80.3, 78.2, 75.3, 74.9, 72.8, 72.1, 71.3 (d, J = 18 Hz), 70.7, 70.64, 70.61, 70.2, 68.1, 
67.09, 67.0, 66.8, 39.9, 26.9, 26.5, 26.3, 25.9, 25.4, 24.7 (d, J = 4 Hz), 22.2 (d, J = 142 
Hz); 31P NMR (162 MHz, CDCl3)  34.75, 33.70; HRMS (ESI m/z) calcd for 
C150H172N2O26P4Na2 (M+2Na+) 1293.5466, obsd 1293.5475. 
 (27). To a 
mixture of 16 (130 mg, 
0.162 mmol) and 
bisalkyne 22 (30 mg, 0.078 mmol) in THF/H2O/t-BuOH (1 mL, v/v/v = 1:1:1) was added 
copper sulfate (0.2 M solution in H2O, 155 L, 0.031 mmol), followed by sodium 
ascorbate (freshly prepared 1 M solution in H2O, 62 L, 0.062 mmol). The reaction 
mixture was stirred vigorously overnight at room temperature. After completion, the 
volatiles were removed under vacuum and the residue was purified by flash column 
chromatography (0-10% MeOH-EtOAc) to afford 27 (135 mg, 88%) as a colorless oil: 1H 
NMR (400 MHz, CDCl3)  7.25-7.39 (m, 52H), 5.06 (dd, J = 1.2 Hz, 8.8 Hz, 2H), 5.03 
(dd, J = 1.2 Hz, 8.8 Hz, 2H), 4.99 (d, J = 7.6 Hz, 2H), 4.96 (d, J = 8.8 Hz, 2H), 4.92 (d, J 
= 10.4 Hz, 2H), 4.78 (d, J = 12.4 Hz, 2H), 4.71 (s, 2H), 4.70 (d, J = 12.4 Hz, 2H), 4.64 (s, 
4H), 4.59 (d, J = 10.4 Hz, 2H), 4.28 (t, J = 6.8 Hz, 4H), 3.82 (dd, J = 2.8 Hz, 8.8 Hz, 2H), 
3.74 (t, J = 1.6 Hz, 2H), 3.64 (t, J = 9.6 Hz, 2H), 3.56 (td, J = 6 Hz, 9.6 Hz, 2H), 3.48 (t, J 
= 6.4 Hz, 4H), 3.43-3.50 (m, 14H), 3.27 (td, J = 6 Hz, 9.6 Hz, 2H), 2.80 (t, J = 7.2 Hz, 
4H), 2.13-2.24 (m, 2H), 2.02-2.13 (m, 2H), 1.96 (app quin, J = 6.4 Hz, 4H), 1.69-1.88 (m, 
8H), 1.64-1.65 (m, 12H), 1.50-1.58 (m, 4H); 13C NMR (100 MHz, CDCl3)  147.8, 138.4, 
138.24, 138.22, 136.4 (d, J = 5 Hz), 128.6, 128.40, 128.38, 128.37, 128.33, 128.2, 127.90, 
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127.87, 127.72, 127.66, 127.62, 120.7, 97.9, 80.1, 78.2, 75.4, 74.8, 72.9, 72.2, 71.4 (d, J 
= 17 Hz), 70.69, 70.64, 70.61, 69.9, 67.12, 67.06, 66.5, 49.9, 29.5, 27.4, 26.5, 26.4, 24.7 
(d, J = 4 Hz), 22.4, 22.2 (d, J = 142 Hz); 31P NMR (162 MHz, CDCl3) δ 33.52; HRMS 
(ESI m/z) calcd for C114H142N6O20P2Na (M+Na+) 1999.9652, obsd 1999.9602. 
 
(26). A mixture of 
16 (194 mg, 0.24 mmol), 
bisalkyne 22 (40 mg, 
0.11 mmol) and Cp*RuCl(COD) (8 mg, 0.022 mmol) in THF (1 mL) was stirred at room 
temperature under argon for 24 h. The reaction was concentrated under vacuum and the 
residue was purified by flash column chromatography (0-10% MeOH-EtOAc) to afford 
26 (112 mg, 52%) as a greenish oil: 1H NMR (400 MHz, CDCl3)  7.47 (s, 2H) 7.27-7.39 
(m, 50H), 5.06 (d, J = 7.6 Hz, 2H), 5.03 (dd, J = 8.4 Hz, 2H), 5.00 (d, J = 8 Hz, 2H), 4.97 
(d, J = 8.8 Hz, 2H), 4.92 (d, J = 10.4 Hz, 2H), 4.78 (d, J = 12.4 Hz, 2H), 4.72 (s, 2H), 
4.71 (d, J = 12.4 Hz, 2H), 4.64 (s, 4H), 4.59 (d, J = 10.8 Hz, 2H), 4.22 (t, J = 6.8 Hz, 4H), 
3.83 (dd, J = 2.4 Hz, 9.2 Hz, 2H), 3.76 (br s, 2H), 3.65 (t, J = 9.2 Hz, 2H), 3.57 (td, J = 6 
Hz, 9.6 Hz, 2H), 3.43-3.50 (m, 18H), 3.29 (td, J = 6 Hz, 9.6 Hz, 2H), 2.71 (t, J = 7.2 Hz, 
4H), 2.14-2.22 (m, 2H), 2.07-2.14 (m, 2H), 1.87-1.95 (m, 8H), 1.70-1.85 (m, 4H), 1.64 
(br s, 12H), 1.50-1.58 (m, 4H); 13C NMR (100 MHz, CDCl3)  138.4, 138.3, 136.5 (d, J = 
6 Hz), 136.4, 132.1 128.6, 128.39, 128.38, 128.33, 128.16, 127.91, 127.89, 127.86, 127.7, 
127.65, 127.61, 97. 9, 80.2, 78.1, 75.4, 74.8, 72.9, 72.2, 71.4 (d, J = 18 Hz), 70.9, 70.7, 
70.6, 69.0, 67.11, 67.05, 66.5, 47.3, 28.4, 27.0, 26.54, 26.51, 24.7 (d, J = 4 Hz), 22.2 (d, J 
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= 142 Hz), 19.8; 31P NMR (162 MHz, CDCl3) δ 33.57; HRMS (ESI m/z) calcd for 
C114H142N6O20P2Na (M+Na+) 1999.9652, obsd 1999.9569. 
 
Dibenzyl (2-((2R,3S,4S,5S,6S)-3,4,5-
tris(benzyloxy)-6 (4-(5-tosyl-1H-tetrazol-1-
yl)butoxy)tetrahydro-2H-pyran-2-
yl)ethyl)phosphonate (28). (i) Procedure with metal catalysts: Metal catalyst (20 
mol%) was added to a solution of 16 (30 mg, 0.04 mmol) and p-toluenesulfonyl cyanide 
(7.4 mg, 0.04 mmol) in DCM. The mixture was kept at ~ 1 M concentration and stirred 
for 20 h or 48 h. Then the solvent was removed under vacuum. The crude product was 
purified by flash column chromatography (60% EtOAc-hexanes). The yield was given as 
a mixture of 1,4- and 1,5-regioisomers with the ratio determined by 1H NMR. (ii) 
Procedure using oil bath heating: A vial was charged with a stir bar, p-toluenesulfonyl 
cyanide (109 mg, 0.6 mmol) and S6 (442 mg, 0.55 mmol), and tightly capped. The 
reaction mixture was stirred neat at 95 °C for 20 h. The crude product was then purified 
as indicated above (60% EtOAc-hexanes) to afford 28 (391 mg, 72%) as the only product. 
(iii) Procedure under microwave irradiation: 16 (50 mg, 0.06 mmol), p-
toluenesulfonyl cyanide (12 mg, 0.06 mmol) and a stir bar were placed at the bottom of a 
CEM 10 mL vial. The vial was filled with N2, sealed and irradiated at 95 °C using a CEM 
Discover® SP synthesizer. After 1 h, the vial was cooled down and the crude product was 
purified as indicated above to yield 28 (43 mg, 70%) as a pale yellow oil: 1H NMR (400 
MHz, CDCl3)  7.99 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8 Hz, 2H), 7.22-7.41 (m, 25H), 5.06 
(dd, J = 2 Hz, 9.2 Hz, 1H), 5.04 (dd, J = 1.6 Hz, 8.8 Hz, 1H), 5.00 (dd, J = 1.2 Hz, 8.8 Hz, 
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1H), 4.97 (dd, J = 1.6 Hz, 7.6 Hz, 1H), 4.93 (d, J = 10.8 Hz, 1H), 4.79 (d, J = 12.4 Hz, 
1H), 4.68-4.76 (m, 4H), 4.66 (s, 2H), 4.60 (d, J = 10.8 Hz, 1H), 3.85 (dd, J = 2.8 Hz, 9.2 
Hz, 1H), 3.80 (t, J = 2 Hz, 1H), 3.59-3.66 (m, 1H), 3.60 (t, J = 8.4 Hz, 1H), 3.50 (dt, J = 
2.4 Hz, 8.8 Hz, 1H), 3.32 (td, J = 6.4 Hz, 9.6 Hz, 1H), 2.50 (s, 3H), 2.17-2.28 (m, 1H), 
1.97- 2.17 (m, 3H), 1.70-1.92 (m, 2H), 1.52-1.66 (m, 2H); 13C NMR (100 MHz, CDCl3) 
 155.0, 147.6, 138.4, 138.3, 136.5 (d, J = 6 Hz), 134.1, 130.4, 129.3, 128.9, 128.6, 
128.40, 128.39, 128.36, 128.32, 128.1, 127.91, 127.89, 127.72, 127.70, 127.6, 98.0, 80.0, 
78.2, 75.3, 74.9, 72.9, 72.1, 71.5 (d, J = 17 Hz), 67.1, 67.0, 66.3, 49.7, 27.2, 26.0, 24.7 (d, 
J = 4 Hz), 22.2 (d, J =141 Hz), 21.9; 31P NMR (162 MHz, CDCl3) δ 33.53; HRMS (ESI 
m/z) calcd for C54H59N4O10PSNa (M+Na+) 1009.3587, obsd 1009.3611. 
 
General procedure A for displacement of the sulfonyl tetrazole 28. To a 
stirred solution of pentabutylene glycol or polyethylene glycol (1 equiv.) in DMF (0.2 
mmol) was added NaH (2.1 equiv.) in one portion. The mixture was stirred at room 
temperature for 30 min, and then a solution of 28 (2.1 equiv.) in DMF (0.2 mmol) was 
added. The resulting solution was stirred at room temperature for 12 h. Then the reaction 
was quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with 
EtOAc. The combined organic phases were dried over MgSO4, filtered and concentrated 
under vacuum. The crude product was then purified by flash column chromatography to 
afford 1,5-tetrazole-linked ligands. 
(29): Following general 
procedure A, with pentabutylene 
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glycol (22 mg, 0.057 mmol) and 28 (113 mg, 0.11 mmol), with column chromatographic 
purification (10% MeOH-EtOAc), was obtained compound 29 (92 mg, 79%) as a 
colorless oil1H NMR (400 MHz, CDCl3)  7.24-7.41 (m, 50H), 5.06 (d, J = 8 Hz, 2H), 
5.03 (d, J = 8.4 Hz, 2H), 4.99 (d, J = 8 Hz, 2H), 4.96 (d, J = 8 Hz, 2H), 4.91 (d, J = 10.8 
Hz, 2H), 4.78 (d, J = 12.4 Hz, 2H), 4.71 (s, 2H), 4.70 (d, J = 11.6 Hz, 2H), 4.64 (s, 4H), 
4.53-4.61 (m, 6H), 4.04 (t, J = 7.2 Hz, 4H), 3.82 (dd, J = 3.2 Hz, 9.2 Hz, 2H), 3.74 (t, J = 
2.4 Hz, 2H), 3.65 (t, J = 9.6 Hz, 2H), 3.56 (td, J = 6 Hz, 9.6 Hz, 2H), 3.37-3.48 (m, 18H), 
3.28 (td, J = 6 Hz, 9.6 Hz, 2H), 2.14-2.26 (m, 2H), 2.02-2.14 (m, 2H), 1.94 (quint, J = 7.2 
Hz, 4H), 1.68-1.88 (m, 12H), 1.61-1.68 (m, 12H), 1.47-1.57 (m, 4H); 13C NMR (100 
MHz, CDCl3)  161.1, 138.4, 138.25, 138.22, 136.5 (d, J = 6 Hz), 128.6, 128.40, 128.38, 
128.37, 128.32, 128.2, 127.90, 127.87, 127.85, 127.71, 127.66, 127.61, 97.9, 80.1, 78.1, 
75.4, 74.8, 73.3, 72.9, 72.2, 71.4 (d, J = 17 Hz), 70.8, 70.66, 70.59, 69.9, 67.1, 67.0, 66.3, 
45.2, 26.5, 26.2, 25.90, 25.87, 27.6 (d, J = 4 Hz), 22.2 (d, J = 141 Hz); 31P NMR (162 
MHz, CDCl3)  33.48; HRMS (ESI m/z) calcd for C114H144N8O22P2Na (M+Na+) 
2061.9768, obsd 2061.9839. 
 
(37). Follow the general 
procedure A, with tetraethylene 
glycol (22 mg, 0.11 mmol) and 28 
(214 mg, 0.22 mmol), with column chromatographic purification (5% MeOH-EtOAc) 
was obtained compound 37 (91 mg, 45%) as a colorless oil: 1H NMR (600 MHz, CDCl3) 
 7.41-7.20 (m, 50H), 5.04 (dd, J = 8.8, 1.9 Hz, 2H), 5.02 (dd, J = 8.7, 1.9 Hz, 2H), 4.97 
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(d, J = 7.8 Hz, 2H), 4.95 (d, J = 7.8 Hz, 2H), 4.90 (d, J = 10.5 Hz, 2H), 4.76 (d, J = 12.1 
Hz, 2H), 4.70-4.68 (m, 3H), 4.67 (br s, 1H), 4.66-4.64 (m, 4H), 4.63 (br s, 3H), 4,62-4.69 
(m, 1H), 4.57 (s, J = 10.5 Hz, 2H), 4.04 (t, J = 7.2 Hz, 4H), 3.85-3.82 (m, 4H), 3.80 (dd, J 
= 9.5, 3.0 Hz, 2H), 3.74-3.72 (m, 2H), 3.65-3.59 (m, 6H), 3.59-3.51 (m, 6H), 3.45 (td, J = 
9.2 , 2.5Hz, 2H), 3.30-3.23 (m, 2H), 2.23-2.13 (m, 2H), 2.12-2.00 (m, 2H), 1.90-1.66 (m, 
8H), 1.56-1.42 (m, 4H); 13C NMR (125 MHz, CDCl3)  161.1, 138.4, 138.29, 138.26, 
136.5 (d, J = 6.6 Hz), 128.6, 128.50, 128.44, 128.42, 128.40, 128.36, 128.2, 127.94, 
127.91, 127.88, 127.74, 127.70, 127.67, 127.64, 98.0, 80.1, 78.2, 75.4, 74.9, 73.0, 72.21, 
72.17, 71.47 (d, J = 17.6 Hz), 70.56, 70.54. 70.52, 70.49, 68.8, 67.13, 67.09, 66.4, 45.3, 
26.2, 25.9, 24.7 (d, J = 4.0 Hz), 22.2 (d, J = 142.5 Hz); 31P NMR (202 MHz, CDCl3)  
34.23; HRMS (ESI m/z) calcd for C102H120N8O21P2Na (M+Na) + 1877.7741, obsd 
1877.7943. 
 
(38). Following general 
procedure A, with hexaethylene 
glycol (18 mg, 0.061 mmol) and 28 
(122 mg, 0.12 mmol), and thin-layer chromatographic purification (10% MeOH-EtOAc), 
was obtained compound 38 (93 mg, 79%) as a colorless oil: 1H NMR (600 MHz, CDCl3) 
 7.41-7.20 (m, 50H), 5.04 (dd, J = 8.6, 1.5 Hz, 2H), 5.02 (dd, J = 8.6, 1.5 Hz, 2H), 4.98 
(d, J = 7.9 Hz, 2H), 4.95 (d, J = 7.9 Hz, 2H), 4.90 (d, J = 10.5 Hz, 2H), 4.76 (d, J = 12.4 
Hz, 2H), 4.71-4.67 (m, 4H), 4.68-4.64 (m, 4H), 4.63 (br s, 3H), 4.61-4.58 (m, 1H), 4.57 
(s, J = 10.7 Hz, 2H), 4.05 (t, J = 7.2 Hz, 4H), 3.87-3.83 (m, 4H), 3.80 (dd, J = 9.2, 3.0 Hz, 
2H), 3.74-3.71 (m, 2H), 3.66-3.57 (m, 18H), 3.57-3.51 (m, 2H), 3.44 (td, J = 9.0 , 2.7Hz, 
177 
 
2H), 3.30-3.23 (m, 2H), 2.22-2.13 (m, 2H), 2.12-2.01 (m, 2H), 1.90-1.66 (m, 8H), 1.57-
1.43 (m, 4H); 13C NMR (125 MHz, CDCl3)  161.0, 138.3, 138.17, 138.14, 136.4 (d, J = 
7.0 Hz), 128.6, 128.43, 128.41, 128.39, 128.35, 128.2, 127.93, 127.90, 127.77, 127.75, 
127.66, 127.64, 97.8, 80.1, 78.1, 75.4, 74.6, 72.9, 72.15, 72.13, 71.37 (d, J = 17.8 Hz), 
70.56, 70.54. 70.52, 70.49, 68.8, 67.09, 67.04, 66.3, 45.3, 26.2, 25.9, 24.6 (d, J = 4.6 Hz), 
22.2 (d, J = 141.8 Hz); 31P NMR (202 MHz, CDCl3)  34.23; HRMS (ESI m/z) calcd for 
C106H128N8O23P22Na (M+2Na)2+ 994.4181, obsd 994.4166. 
 
(39). Following general 
procedure A, with octaethylene 
glycol (22 mg, 0.06 mmol) and 28 
(128 mg, 0.13 mmol), and thin layer chromatographic purification (10% MeOH-EtOAc), 
was obtained compound 39 (101 mg, 84%) as a colorless oil: 1H NMR (400 MHz, CDCl3) 
 7.24-7.43 (m, 50H), 5.06 (d, J = 12 Hz, 2H), 5.03 (d, J = 8.8 Hz, 2H), 4.99 (d, J = 8 Hz, 
2H), 4.97 (d, J = 8 Hz, 2H), 4.92 (d, J = 10.8 Hz, 2H), 4.78 (d, J = 12.4 Hz, 2H), 4.56-
4.74 (m, 12H), 4.59 (d, J = 10.4 Hz, 2H), 4.07 (t, J = 7.2 Hz, 4H), 3.87 (t, J = 4.4 Hz, 4H), 
3.82 (dd, J = 2.8, 9.2 Hz, 2H), 3.75 (br s, 2H), 3.61-3.71 (m, 26H), 3.56 (td, J = 6, 9.6 Hz, 
2H), 3.46 (t, J = 8.8 Hz, 2H), 3.29 (td, J = 6, 9.6 Hz, 2H), 2.02-2.24 (m, 4H), 1.73-1.94 
(m, 8H), 1.46-1.59 (m, 4H); 13C NMR (100 MHz, CDCl3)  161.1, 138.4, 138.26, 138.23, 
136.5 (d, J = 6 Hz), 128.6, 128.40, 128.39, 128.37, 128.32, 128.2, 127.91, 127.88, 127.85, 
127.71, 127.67, 127.6, 97.9, 80.1, 78.1, 75.4, 74.8, 72.9, 72.21, 72.17, 71.4 (d, J = 18 Hz), 
70.60. 70.58, 70.55, 69.8, 67.1, 67.0, 66.3, 45.3, 26.2, 25.9, 24.7 (d, J = 4 Hz), 22.2 (d, J 
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= 141 Hz); 31P NMR (202 MHz, CDCl3)  33.49; HRMS (ESI m/z) calcd for 
C110H137N8O25P2 (M+H+) 2031.9170, obsd 2031.9114. 
 
(40). Following general 
procedure A, with decaethylene 
glycol (28 mg, 0.061 mmol) and 28 
(123 mg, 0.12 mmol), and thin-layer chromatographic purification (15% MeOH-EtOAc), 
was obtained compound 40 (100 mg, 78%) as a colorless oil: 1H NMR (600 MHz, CDCl3) 
 7.41-7.20 (m, 50H), 5.04 (dd, J = 8.7, 1.6 Hz, 2H), 5.02 (dd, J = 8.7, 1.6 Hz, 2H), 4.97 
(d, J = 7.9 Hz, 2H), 4.95 (d, J = 7.9 Hz, 2H), 4.90 (d, J = 10.6 Hz, 2H), 4.76 (d, J = 12.2 
Hz, 2H), 4.69 (br s, 4H), 4.68-4.65 (m, 4H), 4.63 (s, 3H), 4.62-4.58 (m, 1H), 4.57 (s, J = 
10.9 Hz, 2H), 4.05 (t, J = 7.1 Hz, 4H), 3.89-3.84 (m, 4H), 3.80 (dd, J = 9.2, 3.1 Hz, 2H), 
3.74-3.71 (m, 2H), 3.70-3.58 (m, 34H), 3.58-3.52 (m, 2H), 3.45 (td, J = 9.1 , 2.3Hz, 2H), 
3.30-3.25 (m, 2H), 2.22-2.13 (m, 2H), 2.12-2.01 (m, 2H), 1.90-1.76 (m, 8H), 1.55-1.44 
(m, 4H); 13C NMR (125 MHz, CDCl3)  161.1, 138.4, 138.28, 138.26, 136.5 (d, J = 6.1 
Hz), 128.6, 128.41, 128.40, 128.38, 128.33, 128.2, 127.92, 127.89, 127.86, 127.72, 
127.68, 127.62, 97.9, 80.1, 78.2, 75.4, 74.9, 72.9, 72.23, 72.19, 71.45 (d, J = 17.6 Hz), 
70.63, 70.60. 70.58, 68.8, 67.10, 67.06, 66.4, 45.3, 26.2, 25.9, 24.7 (d, J = 4 Hz), 22.2 (d, 
J = 143 Hz); 31P NMR (202 MHz, CDCl3)  34.26; HRMS (ESI m/z) calcd for 
C114H144N8O27P23Na (M+3Na)3+ 729.3103, obsd 729.3098. 
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(41). Following general 
procedure A, with dodecaethylene 
glycol (34 mg, 0.061 mmol) and 28 
(120 mg, 0.12 mmol), and thin-layer chromatographic purification (15% MeOH-EtOAc), 
was obtained compound 41 (85 mg, 64%) as a colorless oil: 1H NMR (400 MHz, CDCl3) 
 7.41-7.11 (m, 50H), 5.04 (dd, J = 9 Hz, 1.5 Hz, 2H), 5.01 (d, J = 8.8 Hz, 1.0 Hz, 2H), 
4.98 (d, J = 7.9 Hz, 2H), 4.95 (d, J = 8.2 Hz, 2H), 4.90 (d, J = 10.6 Hz, 2H), 4.76 (d, J = 
12.2 Hz, 2H), 4.72-4.51 (m, 14H), 4.05 (t, J = 7.3 Hz, 4H), 3.89-3.82 (m, 4H), 3.80 (dd, J 
= 9.1, 3.0 Hz, 2H), 3.74-3.70 (m, 2H), 3.68-3.51 (m, 42H), 3.58-3.52 (m, 2H), 3.44 (td, J 
= 8.8 , 2.2Hz, 2H), 3.31-3.23 (m, 2H), 2.22-1.96 (m, 4H), 1.90-1.67 (m, 8H), 1.58-1.42 
(m, 4H); 13C NMR (100 MHz, CDCl3)  161.1, 138.4, 138.25, 138.23, 136.5 (d, J = 5.8 
Hz), 128.6, 128.39, 128.36, 128.32, 128.2, 127.91, 127.88, 127.86, 127.7, 127.67, 127.61, 
97.9, 80.1, 78.1, 75.4, 74.8, 72.9, 72.21, 72.17, 71.4 (d, J = 17.5 Hz), 70.55, 68.8, 67.1, 
67.04, 66.3, 45.3, 26.2, 25.9, 24.7, 22.1 (d, J = 142Hz); 31P NMR (202 MHz, CDCl3)  
34.25; HRMS (ESI m/z) calcd for C118H152N8O29P23Na (M+3Na)3+ 758.6611, obsd 
758.6596. 
General procedure B for deprotection of benzyl groups: A solution of protected bis-
phosphonate (~0.015 mmol) in distilled MeOH (2 mL) was stirred in the presence of 40% 
Pd(OH)2/C and trace amount of TFA, under balloon pressure of hydrogen, for 24 h, at 
room temperature. Filtration through Celite, then removal of solvent under vacuum 
afforded bivalent ligands BL1 - BL10. 
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BL1: Following general 
procedure B, from 24 (27 
mg, 0.015 mmol), bivalent 
ligand BL1 (12 mg, 86%) was obtained as a colorless oil: 1H NMR (400 MHz, MeOD)  
4.71 (d, J = 1.2 Hz, 2H), 3.80 (dd, J = 1.6 Hz, 2.8 Hz, 2H), 3.71 (dt, J = 10 Hz, 6 Hz, 2H), 
3.66 (dd, J = 3.2 Hz, 8.8 Hz, 2H), 3.42-3.51(m, 22H), 3.21 (t, J = 6 Hz, 4H), 2.28 (t, J = 8 
Hz, 4H), 2.13-2.21 (m, 2H), 1.90-2.03 (m, 2H), 1.87 (quint, J = 6.8 Hz, 4H), 1.74-1.83 
(m, 2H), 1.55-1.70 (m, 22H); 13C NMR (100 MHz, MeOD)  174.3, 100.1, 72.4 (d, J = 
12 Hz), 71.2, 70.9, 70.6, 70.31, 70.26, 69.6, 66.6, 38.8, 32.5, 26.6, 26.1 (d, J = 2 Hz), 
25.9 (d, J = 133 Hz), 25.3; 31P NMR (162 MHz, MeOD) δ 26.57; HRMS (ESI m/z) calcd 
for C42H82N2O22P2Na (M+Na+) 1051.4732, obsd 1051.474. 
 
BL2: Following general 
procedure B, from 25 (42 
mg, 0.016 mmol), bivalent 
ligand BL2 (24 mg, 89%) was obtained as a colorless oil: 1H NMR (400 MHz, MeOD)  
7.61-7.73 (m, 12H), 7.48-7.59 (m, 8H), 7.38-7.49 (m, 2H), 7.23-7.31 (m, 2H), 7.11-7.17 
(m, 2H), 4,47 (br s, 2H), 4.14 (t, J = 5.6 Hz, 4H), 3.81 (br, 2H), 3.61-3.71 (m, 4H), 3.51 (t, 
J = 6.4 Hz, 4H), 3.41-3.49 (m, 16H), 3.37 (br s, 2H), 2.87 (t, J = 6.4 Hz, 4H), 2.16-2.25 
(m, 2H), 1.97-2.11 (m, 2H), 1.83-1.95 (m, 4H), 1.73-1.82 (m, 8H), 1.61-1.68 (m, 12H), 
1.45-1.56 (m, 4H), 1.32-1.45 (m, 4H); 13C NMR (100 MHz, MeOD)  169.0, 162.3, 
142.0, 136.9 (d, J = 8 Hz), 132.6, 132.2, 132.1, 131.6, 131.1, 130.4, 129.3, 128.54, 
128.46, 128.38, 128.26, 128.20, 128.05, 127.95, 127.92, 100.1, 72.2 (d, J = 12 Hz), 72.0, 
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71.3, 70.8, 70.7, 70.3, 70.25, 70.22, 69.9, 68.3, 68.2, 66.4, 66.1, 39.4, 39.2, 29.0, 26.4, 
26.24, 26.16, 25.94, 25.87, 25.7, 24.8 (d, J = 3 Hz), 22.8 (d, J = 138 Hz); 31P NMR (162 
MHz, MeOD) δ 35.06, 30.58; HRMS (ESI m/z) calcd for C80H113N2O26P4Na (M+H+) 
1641.6532, obsd 1641.6533. 
 
BL3: Following general 
procedure B, from 27 
(25 mg, 0.013 mmol), 
bivalent ligand BL3 (13 mg, 96%) was obtained as a colorless oil: 1H NMR (400 MHz, 
MeOD)  7.73 (s, 2H), 4.53 (br, 2H), 4.28 (t, J = 6.8 Hz, 4H), 3.62 (br, 2H), 3.55 (dt, J = 
9.6 Hz, 6.8 Hz, 2H), 3.42-3.50 (m, 2H), 3.22-3.33 (m, 16H), 3.14 (br, 6H), 2.64 (t, J = 7.6 
Hz, 4H), 1.98-2.03 (m, 2H), 1.72-1.88 (m, 8H), 1.50-1.62 (m, 4H), 1.45 (br, 18H); 13C 
NMR (100 MHz, MeOD)  122.3, 100.2, 72.1, 71.9, 71.2, 70.8, 70.6, 70.32, 70.26, 69.4, 
66.4, 53.4, 50.0, 29.0, 26.9, 26.15, 26,13, 24.8 (d, J = 4 Hz), 22.2 (d, J = 128 Hz), 17.9; 
31P NMR (162 MHz, CDCl3) δ 29.42; HRMS (ESI m/z) calcd for C44H82N6O20P2Na 
(M+Na+) 1099.4957, obsd 1099.4971. 
 
BL4: Following general 
procedure B, from 26 (22 
mg, 0.011 mmol), bivalent 
ligand BL4 (11 mg, 93%) was obtained as a colorless oil: 1H NMR (400 MHz, MeOD)  
7.41 (s, 2H), 4.56 (d, J = 1.6 Hz, 2H), 4.23 (t, J = 6.8 Hz, 4H), 3.65 (dd, J = 1.6 Hz, 3.2 
Hz, 2H), 3.58 (dt, J = 10 Hz, 6 Hz, 2H), 3.49 (dd, J = 3.6 Hz, 9.2 Hz, 2H), 3.30-3.36 (m, 
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16H), 3.21 (br s, 2H), 3.17 (quint, J = 1.6 Hz, 4H), 2.68 (t, J = 7.6 Hz, 4H), 1,99-2.06 (m, 
2H), 1.77-1.90 (m, 8H), 1.57-1.66 (m, 4H), 1.48-1.49 (m, 18H); 13C NMR (100 MHz, 
MeOD)  137.7, 131.3, 100.2, 72.1, 71.9, 71.2, 70.1, 70.8, 70.6, 70.4, 70.28, 70.27, 68.8, 
66.4, 28.1, 26.6, 26.20, 26.16, 24.7 (d, J = 4 Hz), 22.8 (d, J = 135 Hz), 19.2; 31P NMR 
(162 MHz, MeOD)  33.57; HRMS (ESI m/z) calcd for C44H82N6O20P2Na (M+Na+) 
1099.4957, obsd 1099.4963. 
 
BL5: Following general procedure 
B, from 29 (27 mg, 0.013 mmol), 
bivalent ligand BL5 (13 mg, 88%) 
was obtained as a colorless oil:1H NMR (400 MHz, MeOD)  4.72 (d, J = 1.2 Hz, 2H), 
4.58 (t, J = 6.5 Hz, 4H), 4.22 (t, J = 7.2 Hz, 4H), 3.79-3.82 (m, 2H), 3.74 (dt, J = 10 Hz, 6 
Hz, 2H), 3.63-3.67 (m, 2H), 3.52 (t, J = 6 Hz, 4H), 3.41-3.49 (m, 18H), 2.14-2.27 (m, 
4H), 1.92-2.02 (m, 8H), 1.71-1.81 (m, 8H), 1.51-1.66 (m, 16H); 13C NMR (150 MHz, 
MeOD)  161.2, 100.2, 73.3, 72.0 (d, J = 17 Hz), 71.2, 70.8, 70.5, 70.34, 70.25, 69.8, 
66.2, 45.1, 29.0, 26.1, 26.0, 25.6, 25.5, 24.7 (d, J = 3 Hz), 22.8 (d, J = 140 Hz); 31P NMR 
(162 MHz, MeOD) δ 30.36; HRMS (ESI m/z) calcd for C44H85N8O22P2 (M+H+) 
1139.5253, obsd 1139.5271. 
 
BL6: Following general procedure B, 
from 37 (38 mg, 0.02 mmol), bivalent 
ligand BL6 (18 mg, 95%) was 
obtained as a colorless oil: 1H NMR (600 MHz, MeOD) ; 4.71 (br, 2H), 4.69 (m, 4H), 
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4.22 (t, J = 6.8 Hz, 4H), 3.91-3.86 (m, 4H), 3.80 (br, 2H), 3.76-3.70 (m, 2H), 3.69-3.57 
(m, 10H), 3.50-3.38 (m, 6H), 2.22-2.12 (m, 2H), 2.08-1.89 (m, 6H), 1.81-1.66 (m, 4H), 
1.67-1.55 (m, 4H) ; 13C NMR (150 MHz, MeOD)  162.7, 101.6, 73.8, 72.8 (d, J = 16.9); 
72.6, 72.1, 72.0, 71.6, 69.9, 67.6, 46.5, 30.4, 27.3, 26.8, 26.3, 22.9 (d, J = 142.2 Hz), 31P 
NMR (202 MHz, MeOD)  30.5; HRMS (ESI m/z) calcd for C32H60N8O21P2Na (M+Na+) 
977.3246, obsd 977.3214. 
 
BL7: Following general procedure B, 
from 38 (30 mg, 0.015 mmol), 
bivalent ligand BL7 (17 mg, 
quantitative) was obtained as a colorless oil: 1H NMR (400 MHz, MeOD)  4.73-4.62 
(m, 6H), 4.22 (t, J = 6.6 Hz, 4H), 3.93-3.86 (m, 4H), 3.79 (br s, 2H), 3.76-3.53 (m, 20H), 
3.50-3.38 (m, 6H), 2.22-2.10 (m, 2H), 2.06-1.89 (m, 6H), 1.83-1.68 (m, 4H), 1.68-1.52 
(m, 4H); 13C NMR (150 MHz, MeOD)  162.7, 101.6, 73.8, 73.4 (d, J = 15.4 Hz), 72,6, 
72.2, 71,9, 71.62, 71.56, 71.52, 69.9, 67.6, 46.5, 30.4, 27.4, 26.9, 26.2, 24.25 (d, J = 
142.1 Hz); 31P NMR (202 MHz, MeOD)  30.8; HRMS (ESI m/z) calcd for 
C36H68N8O23P2Na (M+Na+) 1065.3770, obsd 1065.3770. 
 
BL8: Following general procedure B, 
from 39 (28 mg, 0.013 mmol), 
bivalent ligand BL8 (13 mg, 88%) 
was obtained as a colorless oil: 1H NMR (400 MHz, MeOD) d, J = 1.2 Hz, 
2H), 4.68-4.71 (m, 4H), 4.24 (t, J = 6.8 Hz, 4H), 3.88-3.94 (m, 4H), 3.81-3.84 (dd, J = 
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1.6 Hz, 3.2 Hz, 2H), 3.58-3.77 (m, 28H), 3.42-3.52 (m, 6H), 2.13-2.26 (m, 2H), 1.92-2.06 
(m, 6H), 1.71-1.85 (m, 4H), 1.61-1.69 (m, 4H); 13C NMR (100 MHz, MeOD)  161.3, 
100.2, 72.4, 72.5 (d, J = 17.7 Hz), 71.2, 70.8, 70.5, 70.21, 70.17, 70.16, 70.11, 68.5, 66.2, 
45.1, 29.0, 26.0, 25.5, 24.7 (d, J = 3.7 Hz), 22.8 (d, J = 138 Hz), 17.9; 31P NMR (162 
MHz, MeOD)   30.32; HRMS (ESI m/z) calcd for C40H77N8O25P2 (M+H+) 1131.4475, 
obsd 1131.4435. 
 
BL9: Following general procedure B, 
from 40 (30 mg, 0.014 mmol), 
bivalent ligand BL9 (18 mg, 
quantitative) was obtained as a colorless oil: 1H NMR (600 MHz, MeOD)  4.71 (br s, 
2H), 4.70-4.66 (m, 4H), 4.22 (t, J = 6.9 Hz, 4H), 3.92-3.86 (m, 4H), 3.80 (br s, 2H), 3.76-
3.53 (m, 40H), 3.48-3.40 (m, 6H), 2.22-2.12 (m, 2H), 2.06-1.83 (m, 6H), 1.83-1.68 (m, 
4H), 1.68-1.58 (m, 4H); 13C NMR (100 MHz, MeOD)  162.7, 101.6, 73.8, 73.4 (d, J = 
17.7 Hz), 72.6, 72.2, 71.9, 71.61, 71.56, 71.53, 71.47, 69.9, 67.6, 46.5, 30.4, 27.4, 26.9, 
26.2 (d, J = 3.7 Hz), 24.2 (d, J = 139.9) ; 31P NMR (202 MHz, MeOD)  30.77; HRMS 
(ESI m/z) calcd for C44H84N8O27P2Na (M+Na+) 1241.4819, obsd 1241.4832. 
 
BL10: Following general procedure 
B, from 41 (30 mg, 0.014 mmol), 
bivalent ligand BL10 (18 mg, 97%) 
was obtained as a colorless oil: 1H NMR (400 MHz, MeOD)  4.71 (br s, 2H), 4.70-4.66 
(m, 4H), 4.22 (t, J = 6.9 Hz, 4H), 3.92-3.86 (m, 4H), 3.80 (br s, 2H), 3.76-3.53 (m, 44H), 
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3.48-3.40 (m, 6H), 2.22-2.12 (m, 2H), 2.06-1.83 (m, 6H), 1.83-1.55 (m, 8H); 13C NMR 
(100 MHz, MeOD)  162.7, 101.6, 73.8, 73.4 (d, J = 16.7), 72.6, 72.1, 71.9, 71.6, 71.5, 
71.49, 71.43, 71.4, 71.36, 71.33, 69.9, 67.6, 46.5, 30.4, 27.3, 26.9, 26.2, 24.2 (d, J = 
140.3) ; 31P NMR (202 MHz, MeOD)  30.17; HRMS (ESI m/z) calcd for 
C48H92N8O29P2Na (M+Na+) 1329.5343, obsd 1329.5331. 
 
B. Binding Affinity Assay 
Soluble bovine M6P/IGF2R was purified from fetal bovine serum (Life 
Technologies) according to the procedure of Byrd et al.121. The collected fractions were 
dialyzed to remove M6P, lyophilized to concentrate the receptor, and stored at -20°C. 
The purified and re-dissolved receptor was coupled to CNBr-activated Sepharose 4B 
resin, according to the manufacturer’s instructions. 
  A M6P/IGF2R-Sepharose 4B resin-based radioligand displacement assay was 
used to evaluate the ability of each of the M6P-based ligands to bind the receptor. 
Aliquots (20 μL) of receptor resin (50% slurry) were incubated with 1.5 nM 125I-PMP-
BSA in the presence of increasing concentrations of M6P-based ligands (0.1 μM to 1 mM) 
in assay buffer (50 mM HEPES, pH 7.4, 0.15 M NaCl, 0.05% Triton X-100) in a volume 
of 0.2 ml tube, for 16 h at 4°C on an end-over-end clinical mixer. As positive and 
negative controls, parallel assays were done that had increasing concentrations of M6P 
(0.1 μM to 10 mM) or G6P (1 to 10 mM), respectively. The resin pellets were collected 
by centrifugation for 1 min at 9,000 x g at 4°C, and were washed with 2 x 1 mL of ice-
cold buffer. The tips of the tubes with the resin pellets were cut and quantified in a 
WIZARD 1470 Automatic Gamma Counter (Perkin Elmer). The data were converted into 
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percent binding values based on comparison with the test ligand-free controls (designated 
as 100% radioligand binding). The competitive binding data were graphed as semi-log 
plots of percent binding vs. concentration of M6P, G6P, or the M6P-based ligands. Best-
fit curves were generated by nonlinear regression analysis using Prism GraphPad 
software (San Diego, CA), which also estimated the IC50 values (the test ligand 
concentration that displaces 50% of radioligand binding). Values for relative binding 
affinity (RBA) for the M6P-based ligands were normalized to M6P for a given 
experiment.  
  
Figure 3.23 Competitive binding analysis for bivalent ligands BL1 – BL5 
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Chapter 4  
Carbafructopyranosyl 1,2-Diamines as New Chiral Scaffolds 
I. Introduction 
A. Chiral Pool in Asymmetric Catalysis 
Naturally-occurring compounds, such as the natural phosphonates in Chapter one, 
have been great inspiration for medicinal chemists. On the other hand, natural products 
have also been magnificent resources for quite a different domain: asymmetric catalysis. 
Chiral pool-derived catalysts, ligands and auxiliaries have all contributed significantly to 
the development of numerous asymmetric transformations.1 For instance, the cinchona 
alkaloid backbone, as classically presents itself in the natural product quinine, has made 
enormous impact as the stereo-differentiating element in the Sharpless asymmetric 
hydroxylation (ADH)2, as well as the O’ Donnell-Lygo-Corey chiral phase-transfer 
catalysts (PTCs)3-5. As marked cases in the terpenoid category, the -pinene derived 
organoboron reagents, such as Alphine-boraneTM and DIP-chloride, have been widely 
utilized in asymmetric reduction.6 Furthermore, inspired by the efficiency of enzymes, 
chemists have extensively utilized amino acids in catalyst assembly.7 Notably, amino acid 
derived phosphinooxazoline (PHOX) ligands have had a major impact on a range of 
transition metal (TM)-catalyzed reactions.8 In a more biomimetic approach, Miller et al 
have developed a series of -turn-based oligopeptides with the tetrapeptide catalytic core. 
These organocatalysts have shown remarkable selectivities in various transformations, 
including the Aldol reaction, conjugate additions, epoxidations, acylations, 
phosphorylations etc.9-10  
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Their abundance and variety in nature have made carbohydrates an amazing 
source of chirality.11-20 The success of sugar based chiral catalysts can be epitomized by 
the historic tartaric acid derived ligands, such as diethyl tartrates (DET)21, TADDOLs22 
and Chiraphos23 (Fig. 4.1). Recent examples include Rajanbabu’s diphosphinite ligands 
which was built upon the bicyclic 4,6-O-benzylidene-D-glucopyranose. The nickel-ligand 
complex catalyzes hydrocyanation reactions with a range of vinylarenes, with up to 91% 
ee. 24  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Classic ligands derived from L-threose 
Figure 4.2: Some recent examples of carbohydrate derived ligands and 
catacatalysts 
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Moreover, Gomez, Claver and Godard reported a diphosphite ligand bearing a 2-
deoxy-L-fructofuranose backbone which showed excellent enantioselectivities in the Pd-
catalyzed allylic amination reactions.24 Boysen group has developed a series of -D-
glucosamine based bis(oxazoline) (glucoBox) ligands. The 3-O-Ac glucoBox was 
utilized in the total synthesis of alkaloid (-)-desoxyeseroline via an enantioselective Cu-
catalyzed cyclopropanantion of N-acyl indoles.25 Adopting the same glucosamine motif, 
Ruffo and et al have synthesized a number of bis(phosphinoamide) ligands (Trost 
ligands).26 They are exploited in the desymmetrization of meso-1,4-biscarbamate 
cyclopentene, via the Pd-promoted intramolecular allylic amination. In addition to these 
synthetically useful ligands, carbohydrate framework has also been successfully utilized 
in developing chiral organocatalysts. One of the most notable cases is Shi’s seminal work 
on the ketone-mediated asymmetric epoxidation reactions.27-29 The -D-fructopyranose 
derived exocyclic ketones proved to be highly enantioselective (up to 97%), across a 
wide range of di- or  tri-substituted alkenes  (Fig. 4.2).30-31 
B. A Chiral Pool Derived Salen Ligand Library 
In 2005, our group reported a combinatorial approach to explore novel salen 
scaffolds. A 77 library was built on the diamines derived from chiral pool (Fig. 4.3). 
Particularly, terpenoid (-pinene), amino acids (L-phenylalanine and L-phenylglycine) 
and carbohydrate (D-fructopyranose) are utilized to prepare the vicinal diamines. By 
coupling with various salicylaldehydes, a series of non-C2-symmetric salen ligands were 
prepared. They were subsequently evaluated in the Co-(III)-mediated hydrolytic kinetic 
resolution (HKR) of terminal epoxides, as a platform to introduce the double-cuvette 
ISES.32 Two hit salen scaffolds emerged from the screening. The -pinene-diamine/-
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hydroxynaphthaldehyde combination showed high selectivity for the HKR of the 
matched epoxides. This salen ligand was recently utilized to set the stereochemistry, in a 
streamlined synthesis of pseudo-enantiomeric cores of linearifolin and zaluzanin A (Fig. 
4.4).33  
 
 
 
 
 
 
 
 
 
In addition, the -D-fructopyranosyl-1,2-diamine showed great promise as a 
novel chiral motif. The salen ligand derived from this diamine and 3,5-diiodo-
salicylaldehyde exhibited the highest E-value in the HKR of propylene oxide. Moreover, 
Figure 4.3: Salicylaldehydes and diamines used in the salen ligand assembly 
Figure 4.4: Applications of -pinene derived Co(III)-salen catalyst 
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this salen series showed an interesting enantioswitch, which seems to be only dependent 
on the salicylaldehyde counterpart. Namely, changing from 3,5-diiodo-salicylaldehyde to 
3,5-di-ter-butyl-salicylaldehyde, the -D-fructopyranosyl-diamine derived ligand 
manifested opposite enantio-preference in the HKR. It was postulated that an undetected 
anomerization might cause the change of the enantiopreferences. Given the excellent 
enantioselectivity of this novel salen scaffold, we set out to explore more about these 
ligands. Specifically, we set out to make the carbocyclic version of this carbohydrate 
based diamine to lock the anomeric center of the sugar.  
C. Novel Screening Methods in Combinatorial Catalysis 
After more than 200 years of research in organic synthesis, there is no doubt that 
the discovery of new reactivity gets more and more challenging. However, search for new 
types of reactions, particularly catalytic transformations, has become increasingly 
essential for many aspects of the society, such as energy and medicine. Despite some 
great successes in recent years34, catalyst development is still a difficult process. The 
discovery of a highly efficient and selective catalyst often requires a combination of 
rational design, intuition and serendipity. In the last two decades, the combinatory 
chemistry has emerged as an approach to speed up the process. It has proved to be 
effective in catalyst discovery, via screening diverse catalytic elements including metals, 
chirality, etc.35 Recently, taking this approach, MacMillan et al discovered a Ir(III)-
mediated photoredox amine C-H arylation reaction.36 By applying an automated 
workflow system, they screened a large number of potential reactions between various 
functional groups. Out of an array of identified reactions, the C-H arylation of tertiary 
amines presents the most interesting result, owing to the pharmaceutical values of the 
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produced benzylic amine motif. Moreover, in a more dynamic combinatorial approach, 
Hartwig et al screened a variety of catalysts with diverse mixture of substrates, and then 
utilized mass spectrometry to identify the products.37 A Cu(I)-catalyzed alkyne 
hydroamination and two Ni(0)-promoted alkyne hydroarylation reactions were unveiled 
as new types of transformations (Fig. 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Novel reactivity discovered by combinatorial screening 
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Although great effort has been devoted to its development, the screening process 
is still arguably the “bottleneck” of the combinatorial catalysis.38 Recently, Glorius et al 
nicely summarized some contemporary screening methods in combinatorial catalysis.39 
Notably, by tagging substrate with a pyrene, Kozmin et al were able to screen hundreds 
of reactions using laser desorption/ionization and time-of-flight mass spectrometry.40 This 
label assisted LDI-TOF-MS technique eliminates the needs for an external matrix and 
also simplifies MS analysis. Through this novel screening method, they identified two 
interesting benzannulation reactions of siloxy alkyne; namely, the Au(III)-mediated 
annulation with 2-pyrone and Ag(I)-catalyzed cycloaddition with N-isoquinoline (Fig. 
4.6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Label assisted mass spectrometry for novel reactivity 
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Furthermore, enzyme immunoassays have shown their prowess in combinatorial 
catalysis.41-42 Recently, Taran et al utilized the sandwich enzyme-linked immunosorbant 
assay (ELISA) to uncover a novel 1,3-dipolar cycloaddition reactions.43 In this assay, one 
component was labeled with an epitope that can be recognized by a solid-supported 
monoclonal antibody (mAB), while the other component was labeled with a different 
epitope that binds to an acetylcholinesterase (AChE)-linked antibody. After the execution 
of 2816 reactions in 96-well plates, each reaction was treated with the solid-phase mAB, 
followed by the AChE-linked mAB. After several rounds of washing, the unreacted 
Figure 4.7: A new bioorthogonal chemistry disclosed by combinatorial 
immunoassay screening 
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components and the AChE-linked mAB were removed from the wells. Subsequent 
treatment with Ellman reagent (a colorimetric enzymatic substrate) lit up the wells that 
contain the hit reactions. Therefore, these cycloaddition reactions can be evaluated 
rapidly with visual screening (Fig. 4.7). After the initial screen and further optimization, 
Taran et al  disclosed a new Cu-catalyzed sydnone-alkyne cycloaddition reaction which 
was shown to be biocompartible in the fluorescent labeling of BSA.  
D. In Situ Enzymatic Screening 
In 2002, our group unveiled a conceptually new screening method: In-Situ 
Enzymatic Screening (ISES).44 By exploiting a bilayer system, we could monitor relative 
rates in real time for the allylic substitution reaction. The first Ni(0)-mediated allylic 
amination was revealed in this process (Fig. 4.8). Asymmetric version of this reaction 
was later developed, as an expeditious approach toward L-β,γ-unsaturated amino acids 
(Fig. 4.9).45  
 
 
 
 
 
 
 
 
 
 Figure 4.8: ISES for intramelecular allylic amination reactions 
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Recently, this first generation of ISES was adapted to a colorimetric method, 
utilizing the ABTS dye. The menthol byproduct from a 
(pseudo)halometalation/carbocyclization reaction diffused into the aqueous layer, where 
it was oxidized by an alcohol oxidase. The produced hydrogen peroxide was further 
oxidized to H2O by two equivalent of ABTS dye under the catalysis of peroxidase. The 
generated ABTS+· has a strong green color (405-414 = ~ 70000 M-1cm-1), which allows for 
simple visual identification (Fig. 4.10). 1152 combinations of substrates and catalysts 
were rapidly screened using this colorimetric ISES. The electron-deficient rhodium 
catalyst was found to be an efficient catalyst for the bromination-carbocyclization 
reaction. Furthermore, a thiocyanation-carbocyclization reaction was identified as a new 
transformation under palladium catalysis. 46  
ISES has the advantage that the products do not need to be installed with a 
chromophore to be detected. This is particularly useful for evaluation of product ee’s, as 
most of them are determined from HPLC traces. In 2005, our group revealed a “double 
cuvette” ISES, which not only measures the reaction rates, but also estimates the sense 
and magnitude of the enantioselection of the reaction.32 In this second generation ISES, 
we utilized two reporting enzymes which have different enantiopreferences toward the 
products.  
Figure 4.9: Asymmetric version of the Ni(0)-catalyzed allylic amination reaction 
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In this particular case, cobalt(III)-mediated HKR of propylene oxide was 
employed as a model reaction. Hydrolytica kinetic resolution of terminal epxoides, 
Figure 4.11: A schematic depiction of the Cassette-ISES 
Figure 4.10: A colorimetric ISES for higher throughput screening  
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particularly catalyzed by Co(III)-salen complexes developed by the Jacobsen group, 
proved to be a powerful synthetic tool in asymmetric synthesis and has been applied 
widely in natural product total synthesis. TBADH/HLADH pair was selected as the dual 
enzymatic screening system. For the oxidation of 1,2-propanediol  by NADP+, TBADH 
has an estimated enantioselectivity (SelTBADH) of 8.4 (vR/vS) at 40 mM concentration of 
the diol. On the other hand, HLADH oxidizes the diol with an estimated 
enantioselectivitiy (SelHLADH) of 0.34 (vR/vS), using NAD+ as the cofactor. Thus, for each 
cobalt-salen catalyst, ISES was executed in two separated cuvettes, where the produced 
diol was oxidized in different rates (TBADH vs HLADH) (Fig. 4.11). To estimate the 
enantiomeric ratios from these reaction rates and enantioselectivities, equation (1) was 
derived and validated in multiple studies.32, 47  
ሾோሿ
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II. Results and Discussion 
A. Synthesis of the Oxa- and Carbafructopyranose Derived Diamines 
 The - and -oxafructopyranosyl diamines were conveniently synthesized from 
D-fructose. Following the procedures in literature48, 4- and 5-hydroxyl groups were 
selectively protected with acetonide in 75% yield. 3-hydroxyl group was then selectively 
methylated, with MeI and NaH, in 95% yield. A TMSOTf-mediated anomeric azidation 
led to a mixture ( :  = 1 : 4) of  the - and -2-dexoy-2-azido-3-methyl-4,5-acetonide 
D-fructopyranose. Further triflation of 1-hydroxyl group, followed by TMSN3 
displacement provided the diazide 3 and 4 in excellent yields. The hydrogenation of the 
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diazides proved to be challenging. With 10 wt% of Pd/C or PtO2, the reaction proceeded 
slowly and significant decomposition was occurred during this process. Consequently, 
the hydrogenation was attempted in much faster fashion. Pleasingly, with 50 mol% PtO2 
in THF, the diazides (potentially explosive) were efficiently converted to a mixture ( :  
= 1 : 9) of - and -diamines (5 and 6) in quantitative yield (Fig. 4.12). The separation of 
these two diamines is particularly challenging, in part due to the instability of these 
diamino compounds. Therefore, the mixture of the - and -diamines was carried 
forward into the salen synthesis without further purification.   
  
 
 
 
 
 
 
 
 
 
 
 
The synthesis of the D-carbafructose derived diamines was originally started from 
(-)-quinic acid (7).49-51 7 was treated with cyclohexanone under acidic conditions to 
afford the lactone 8. Cleavage of the lactone, followed by PCC oxidation and 
Figure 4.12: Synthesis of - and -D-oxafructopyranosyl 1,2-diamines 
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concomitant -elimination gave compound 9. After the reduction and treatment with 
acetone and acid, the more stable bicyclic compound 10 was generated. Barton 
deoxygenation, followed by Grignard addition and dihydroxylation provided 11. The triol 
was selectively methylated and then cleaved using Pb(OAc)4 to yield the cyclic ketone 12. 
A standard Wittig-methylenation reaction converted the ketone to desired olefin 13 in 80% 
yield. The diazidation of the exocyclic alkene was realized adopting Snider’s procedure.52 
The Mn(OAc)3 mediated radical diazidation rendered diazide, as an “/” mixture (14:15 
= 75:25), in 80% yield. After chromatographic separation with silica column, these 
diastereomeric diazides were reduced by Pd/C catalyzed hydrogenation to give the 
respective diamines, 16 and 17, in quantitative yield (Fig. 4.13). 
 
Figure 4.13: Synthesis of - and -D-carbafructopyranosyl 1,2-diamines 
262 
 
All the four diamines were subsequently utilized to build a focused 44 library of 
salen ligands. Coupling with four different salicylaldehydes, oxa- and 
carbafructopyranosyl-1,2-diamines yielded 15 out of 16 possible salen combinations. The  
 
active cobalt catalysts were then synthesized from the reactions between these salen 
ligands and Co(OAc)2, followed by oxidation with air in the presence of 3,5-
dinitrobenzoic acid (Fig. 4.14).  
B. A New Miniaturized ISES 
The “double cuvette” ISES was successfully introduced in 2005 to screen a 77 
(42-membered) library. New reporting enzymes (LKADH, ketoreductases) were later 
recruited to expand the substrate scope.33, 47 However, the scale of this “double cuvette” 
Figure 4.14: Synthesis of an oxa- and carbafructose based salen ligand library 
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ISES is not compatible with high through screen. For each cuvette, it normally requires 4 
- 5 mg of the catalyst (0.25 mol% cat. loading) to give reliable reaction rates within a 30 
min window. With varying conditions and substrates, this method requires a large 
quantity of each catalyst. This drawback hinders a broader screening of catalysts, 
particularly of the ones with limited access. Therefore, as a proof of principle for the 
high-through compatibility, we have developed a miniaturized ISES, and utilized it to 
evaluate the newly synthesized salen library.  
 
 
 
 
 
 
 
 
 
 
Fig 4.15: Schimadzu UV-2401 instrument with 16-well quartz 
micromulticell loaded with biphasic layers 
Figure 4.16: Schematic depictions of the new miniaturized multicellular 
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By exploiting a 16 multi-microcell array the total volume of the biphasic layer 
was scaled down to 110 L from 1 mL. The “miniaturized” ISES requires 0.5 mol% 
catalyst loading to give readable rates within a short time (5 – 10 min) window. 
Consequently, the amount needed for each catalyst was reduced to < 1 mg per reaction. 
With same amount of catalysts, this newly developed platform allows ISES to evaluate 
five times more reactions than the “cuvette” setup. Furthermore, using the standard 
Shimadzu UV-2401 instrument, we were able to read up to 8 channels in one single 
experiment, representing a higher throughput screen (Fig. 4.15),.  
Since previously-employed reporting enzyme HLADH is no longer commercially 
available, we set out to find easily-accessible alternatives. Hence, we have screened an 
array of Codexis KRED (ketoreductase) enzymes towards their activities with (R)- and 
(S)-1,2-hexane diol, as well as (R)- and (S)-1,2-propane diol. Based on the reaction rates 
and selectivity factors (kS/kR, see Fig. 4.24 in the experimental section for detailed kinetic 
analysis), KRED-107, and KRED-119 were picked as the reporting enzymes for the HKR 
of hexene oxide, while KRED-23 and TBADH were used to screen the HKR of 
propylene oxide (Fig. 4.16).  
To examine the new ISES platform, the HKR reactions were also conducted under 
typical flask conditions. A comparison of the ISES estimated % ees and the HPLC 
determined % ees was compiled in Table 4.1.  A three dimensional bar graph was also 
created to compare the two sets of data. The difference between ISES conditions and 
flask conditions should be noted. Under typical ISES conditions, reactions are carried out 
in a biphasic system. The produced diols diffuse into the aqueous layer and get read out 
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by the enzymes. However, under flask conditions, the reactions are usually conducted 
without extra solvent, and the products are isolated for ee determination. As seen in Table  
  
Figure 4.17: Three dimensional bar graph of ISES screening results  
Table 4.1: Screen of a 4  4 library of salen ligands for the Co(III)-
aEach box provides the HKR data of propylene oxide (black) and hexene oxide (blue). 
The ISES estimated % ees of the produced diols are presented in brackets, followed by 
the observed % ees (chiral HPLC) and calculated E-values. ¶Difficulty was encountered in 
synthesizing appreciable quantities of this salen. #These catalysts gave ISES signals < 20 
mAbs min-1 over 35 min. §These catalysts gave a conversion < 2% after 72 h. 
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4.1 and Fig. 4.17, the estimated % ee’s correlates well with the HPLC determined % ee’s. 
Indeed, the “miniaturized” ISES decreases the reaction scale without sacrificing its 
accuracy, thereby providing a highly efficient screening tool. 
C. Preserved Enantioswitch and Boosted Enantioselectivity 
From this focused combinatorial screening, two interesting results have emerged. 
First, the salicylaldehyde-dependent enantioswitch was preserved in the 
carbafructopyranosyl series. Namely, the Co(III)-salen catalyst derived from -D-
carbafructopyranosyl diamine (17) and the sterically encumbering 3,5-di-tert-
butylsalicylaldehyde (a) gives rise to (R)-diols, whereas the catalyst based on the same 
diamine and the electronically rich 3,5-diiodosalicylaldehyde (c) gives rise to the (S)-
antipodes (Table 4.1). This observation disproves the suggestion that an “undetected 
anomerization” is the cause of the enantioswitch. In the carbafructose based ligands, the 
anomeric position is locked into - or -configuration, eliminating the possibility of 
anomerization. Therefore, this unusual enantioswitch is truly dependent on the choices of 
the pairing salicylaldehydes. This is quite interesting, considering the salicyladehyde is 
the achiral part of a salen ligand. 
Perhaps, the more exciting result is the remarkable enantioselectivity 
enhancement from the oxafructopyranose-based ligand 6c to its carbocyclic congener 
17c. Replacing the ring oxygen with CH2 renders a much more (S)-selective Co(III)-salen 
complex, with an E-value53 of 44 for the HKR of propylene oxide. Since salen ligand is 
considered as a “privileged” chiral scaffold and has been widely applied in many 
transformations54-55, this novel combination of carbohydrate-based diamine and an 
unhindered salicylaldehyde clearly represents an important combinatorial hit.  
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The most promising Co(III)-salen(17c) catalyst was subsequently examined for 
HKR across a range of distinct epoxides, using standard flask conditions. Given the 
nature of kinetic resolution, the ee’s of both remaining epoxide substrates and the formed 
diols were measured. Thus two independent selectivity factors were collected for each 
entry (Table 4.2), giving a fair judgment of the catalyst performance. Pleasingly, three 
substrates exhibited excellent resolution with E-values being around 50.56 And near 
perfect resolution (E-value = ~ 100) was obtained for another three substrates, namely O-
a0.2-1 mol% of catalyst was added to a solution of epoxide in THF or DCM or neat 
condition. The mixture was cooled to 0 oC or kept at rt and 0.5 eq water was added to 
initiate the reaction. The reaction was stirred at 0 oC  or rt until completion. bConversion 
of the reaction was determined by 1H NMR. CThe purified yield, % ee and calculated E-
value are listed consecutively.  
Table 4.2: Substrates screening using Co(III)-DNB catalyst derived from  salen 17c 
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phenylglycidol, hexene oxide and (2,3-epoxypropyl)benzene. We believe this salen 
ligand will find broad applications in various asymmetric transformations.   
D. Comparison to A Directed Evolution Based Approach 
Interestingly, the HKR result of O-phenylglycidol allows us to compare this small 
molecule-based combinatorial approach to Reetz’s Combinatorial Active-site Saturation 
Test (CAST) strategy iteratively applying the CAST method, Reetz et al have evolved A. 
niger epoxide hydrolase for the HKR of O-phenylglycidol. They were able to improve 
the E-value from 14 to 115 over 5 cycles of directed evolution, after constructing ~ 
20,000 mutants. Ultimately 9 individual residue were mutated from the wild type to 
afford the best evolved enzyme (Fig. 4.18).57  
Reetz’s approach starts from the native epoxide hydrolase. This is based on the 
knowledge that this enzyme catalyzes the HKR of epoxides. Likewise, we have selected 
the salen scaffold for our catalyst design. The evolution of the Co(III)-salen catalyst 
emanates from a 77 salen library that involves variation of diamine and salicylaldehyde 
components. The screening of the first generation catalysts rendered a similar starting 
point; namely, the Co(III)-salen(6c) catalyst showed an E-value of 13 for the HKR of (±)-
propylene oxide. In the next round “catalyst evolution”, the ring oxygen was substituted 
by a methylene group, initially as a method to support the salicylaldehyde-dependent 
enantioswitch. Nonetheless, this step boosted the selectivity to essentially the same value 
as Reetz’s enzyme. Taken together, the combinatorial approach utilized in this work is 
highly complementary to other types of methods, such as the directed evolution strategy. 
On one hand, our combinatorial assembly of diverse salen structures provides 
unprecedented and valuable ligand motifs. One the other hand, the focused screening of 
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our fructose based salen array impoves the ligand, providng an efficient approach to 
ligand optimization.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E. X-Ray Structures  and Transition State Model of HKR 
To understand the difference between the oxa- and carbafructose derived 
catalysts, we set out to characterize some of the Co(II)-salen complexes by X-ray 
crystallography. The crystals of these complexes derived from 6a, 6c, and 17c were 
successfully obtained. The x-ray crystallography studies gave very interesting results. 
Both oxacycles take a distorted boatlike conformation, whereas the corresponding 
carbacycle adopts a chairlike geometry (Fig. 4.19). It is possible this conformational 
Figure 4.18: A comparison between directed evolution based approach and a 
combinatorial salen array based approach 
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change of the fructose ring leads to the observed enantioselectivity improvement. And we 
believe that these oxafructopyranose rings twist to the boatlike structure to avoid the 
deleterious anomeric effect. Specifically, if the oxacycle was in the chairlike 
conformation, the C2-N dipole would be aligned with the ring dipole, thereby reinforcing 
the molecular dipole moment. On the contrary, when taking the boatlike geometry, C2-N 
dipole partially counteracts the ring dipole and stabilizes the molecule. However, to 
substantially support this theory and shed light on why chairlike geometry is more 
enantiodiscriminating, sophisticated density functional theory (DFT) calculations are 
inevitable in the future studies.  
 
Figure 4.19: X-ray crystal structures of the Co(II)-salen complexes and a possible 
influence of dipole-dipole interactions on the ring conformation 
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Nonetheless, using the crystal structure of Co(II)-17c complex and some observations in 
literature, we were able to build a transition state model, attempting to interpret the origin 
of the enantiopreference. First, as Blackmond and Jacobsen suggested58, we presumed the 
HKR studied here is a second-order reaction on the catalyst concentration. Thus, two 
molecules of the Co(III)-catalyst were incorporated into the transition state; one 
coordinates the epoxide oxygen, and the other delivers the nucleophile. Second, the 3D 
structure of Chin’s aziridine-Co(III)-salen complex59 was utilized as a guidance, to 
modulate the Co-O distances and the epoxide approaching angle to the cobalt-salen 
complex. Third, according to Jacobsen’s recent DFT calculation, the O-Co-O-C dihedral 
angle () has a major influence on the binding energy of a epoxide substrate, with an 
optimal range of 20 – 60o.60   
Therefore, a bimolecular transition state model was constructed, using Accelrys 
View-Pro to avoid the unfavorable van der Waals interactions. As seen in Fig. 4.20, the 
epoxide binds strongly to the Co(III)-salen complex, through a 1.99 Å Co-O coordination 
bond, very close to the distance between Co and nitrogen in Chin’s crystal structure (1.95 
Å). In addition, the oxirane ring approaches the Co center at an angle (122° ± 18°) that is 
very similar to that from the binding aziridine (123° ± 3°). Furthermore, the O-Co-O-C 
dihedral angle in our model is shown to be around 24. This is quite similar to the one 
observed in Chin’s structure (33), and very close to the global minimal on Jacobsen’s 
chart. In the meantime, the nucleophilic hydroxyl group is well positioned to the attack 
the terminal carbon through a second molecule of catalyst. Consequently, we believe this 
model should serve well in the transition state prediction for the HKR reactions. Herein, 
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(S)-hexene oxide fits in nicely underneath the -face of the OH-delivering Co-salen 
complex, elucidating the high enantio-preference of this catalyzed hydrolysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finally, it was also noted that the stepped conformation of the salen complex 
could be important for the enantioselectivity. Therefore, we employed all the three crystal 
structures to estimate these step heights. As seen in Fig 4.21, two key parameters are 
measured for each complex: (i) the crystallographic rise angle and (ii) the C2’-C2’’-
distance (designated as “hypotenuse length”). Consequently, the step heights can be 
calculated from equation (2). Indeed, the largest step height (0.76 Å) is observed in the 
Figure 4.20. Transition-state model of Co(III)-catalyst derived from 17c  in HKR of 
hexene oxide. The crystal structure of Chin’s Co(III)-aziridine complex was shown on the 
left. Transition state model was for the Co(III)-mediated HKR was shown on the right. 
Co(II)-17c complex was first modified using Spartan 2008. Consulting the crystal 
structure of Jik Chin’s Co(III)-aziridine complex, nucleophile hydroxyl group was added 
to the Co center.  (S)-Hexene oxide (preferred enantiomer) was manually docked with the 
resulting model for the HO-Co(III)-12c complex, using Accelrys ViewerPro. The distance 
between the nucleophile oxygen and the electrophile carbon is ~1.90 Å. The  Co-O 
coordination bond length is ~1.99 Å. The O-C0-O-C dihedral angle   is 24. 
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Co(II)-17c complex (Fig. 4.22), which renders the best catalyst among this series. This is 
consistent with Jacobsen’s theory and provides an additional criterion for the future 
catalyst design.  
 ൌ ݏ݅݊ሺͳͺͲ୭ െ ሻ ൈ  (2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.22 Step heights from the cystal structures of the Co(II)-
salen complexes 
 
0.24A
0.43A
0.76A
Figure 4.21: Measurment of step heigh for the Co(II)-17c complex 
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F. Streamlined Synthesis of the - and -D-Carbafructopyranosyl-1,2-Diamines 
To facilitate extensive studies of the valuable D-carbafructose derived diamines, 
we set out to develop a more streamlined synthesis, making these diamines more 
accessible. Specifically, we sought an expedient route to the key intermediate 12. The 
new route started from -methyl-D-mannopyranoside. Appel reaction could converted 
the 6-OH to the 6-iodide in excellent yield. The requisite acetonide was then selectively 
installed across the cis-configured 2,3-vicinal diol using a recipe of 2,2-
dimethoxypropane/acetone with catalytic p-TsOH. Pleasingly, C-4-O-methylation and 
dehydrohalogenation were achieved in one pot in almost quantitative yield to give the 
enol ether intermediate 19.  
Several divalent, late transition metal catalysts (HgCl2, Pd(OAc)2 and PdCl2) were 
examined, as well as variation of the solvent and temperature for the key type-II Ferrier 
rearrangement step. The optimal conditions employs 10 mol% Pd(OAc)2 in a mixture of 
acetone, dioxane and water (40:40:20) at 0°C, providing rearranged product 20 in 85 % 
yield. The temperature proved to be critical, with warming the reaction to room 
temperature resulted in unwanted side products (Figure 4.23). To remove the extra 
hydroxyl group, Barton deoxygenation was first employed. However, the projected 
phenyl thionocarbonate ester proved to be unstable. It decomposes during the silica 
column purification to yield the corresponding ,-unsaturated ketone in poor yield. 
Therefore, the route was modified and the acohol 20 was mesylated, followed by in situ 
-elimination to the ketone intermediate in 80% yield. Hydrogenation then gave desired 
product 12 in quantitative yield. The newly developed synthesis saves 6 steps and raises 
the overall yield from 7% to 39%. The new route also starts from a cheaper commercial 
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source -methyl-D-mannopyranoside ($109/100g-Aldrich) compared to (-)-quinic acid 
($192/100g-Aldrich). 
 
 
 
 
 
 
 
 
 
 In conclusion, we have developed a miniaturized ISES manifold. This new ISES 
setup allows us to screen more reactions in a higher-throughput fashion. As a proof of 
principle, this screening method was utilized to examine a library of oxa- and 
carbafructopyranosyl 1,2-diamines derived salen ligands, towards the Co(III)-mediated 
HKR reactions. The -D-carbafructopyranosyl 1,2-diamine/3,5-diiodosalicylaldehyde 
derived Co(III)-salen complex was shown to be a highly enantioselective catalyst, over 4 
times more selective than the oxafructose derived catalyst. We believe that this novel 
chiral scaffold has the great potential to be applied in other types of asymmetric 
transformations, and this miniaturized ISES will be utilized to screen different reactions.  
 
 
 
Figure 4.23: A streamlined synthesis of the key ketone intermediate 
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III. Experimental Section 
A. Organic Synthesis 
All reactions were conducted under nitrogen atmosphere using flame or oven-dried 
glassware, unless otherwise indicated. Methylene chloride was distilled from CaH2.  
Toluene, THF and Et2O were distilled from sodium benzophenone ketyl.  Methanol was 
distilled from Mg, and ethanol from Na-diethyl phthalate.  Alcohol dehydrogenase from 
Thermoanaerobium brockii (TBADH, EC 1.1.1.2), -NAD+ (sodium salt) and -NADP+ 
(sodium salt) were purchased from Sigma. KRED (ketoreductase) enzymes were 
purchased from Codexis. 3,5-Di-tert-butylsalicylaldehyde (a) was purchased from Alfa-
Aesar, 3,5-diiodosalicylaldehyde (c) from Lancaster, 1-hydroxy-2-naphthaldehyde (d) 
from TCI America, 3-tert-salicylaldehyde (b), and cobalt(II)-acetate tetrahydrate from 
Aldrich. Flash chromatography was performed using Merck silica gel 60 (230-400 mesh).  
1H NMR spectra were recorded on Bruker-DRX-Avance-400 MHz, 500 MHz and 600 
MHz instruments with chemical shifts reported relative to residual CHCl3 (7.25 ppm) and 
CH2Cl2 (5.2 ppm).  Proton-decoupled 13C NMR spectra were acquired on Bruker-DRX-
Avance-400 MHz, 500 MHz and 600 MHz instruments with chemical shifts reported 
relative to CDCl3 (77.0 ppm).  Optical rotations @589 nm were measured at 19 °C in an 
Autopol polarimeter. IR spectra were obtained using a Nicolet Avatar 360 FTIR 
spectrometer.  Mass spectra were acquired at the Nebraska Center for Mass Spectrometry 
(University of Nebraska-Lincoln). Enzyme assays and ISES were performed on a 
Shimadzu 2401 spectrophotometer, equipped with a 16-microcell sample changer with 
temperature control.  A Chiralcel OD (4.6 mm x 25 cm) chiral stationary phase was used 
for enantiomeric excess determinations by HPLC. 
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3-O-Methyl-4,5-O-isopropylidene--D-fructopyranosyl-1,2-
diazide (4):  
The starting material, 2-azido-2-deoxy-3-O-methyl-4,5-O-
isopropylidene--D-fructopyranose was prepared following the known literature 
procedure.52   
A flame dried flask was charged with the -azido alcohol 2 (2.6 g, 10 mmol, 1 equiv) 
followed by pyridine (5 mL) and CH2Cl2  (15 mL).  The flask was cooled to –20 °C and 
triflic anhydride (2.85 mL, 16.9 mmol, 1.7 equiv.) was added dropwise.  The reaction 
was stirred at –20 °C for 20 min and then warmed up to rt and stirred till all the starting 
material was consumed.  The reaction contents were diluted with ether and washed with 
1N HCl followed by saturated NaHCO3.  The ethereal layer was treated with anhydrous 
Na2SO4 and vacuum dried.  The triflate thus obtained was re-dissolved in DMF (10 mL), 
and sodium azide (2 g, 30.7 mmol, 3.1 equiv) was added to it.  The contents were stirred 
overnight at 40-50 °C and diluted with ether, then washed with water and 1N HCl and 
then finally with saturated NaHCO3.  The ethereal layer was dried with anhydrous 
Na2SO4.  Subsequent removal of ether and vacuum drying gave the diazide as a yellow 
oil (2.68 g, 94%, over two steps).  Triflate:  1H NMR (500 MHz, CDCl3) 1.36 (s, 3H), 
1.53 (s, 3H), 3.44 (d, J = 6 Hz, 1H), 3.56 (s, 3H), 4.11 (ddd, J = 2, 3, 13 Hz, 2H), 4.27- 
4.35 (m, 2H), 4.58 (d, J = 10 Hz, 1H), 4.69 (d, 10 Hz, 1H).  Diazide: 1H NMR (600 MHz, 
CDCl3)  1.32 (s, 3H), 1.51 (s, 3H), 3.39 (d, J = 7 Hz, 1H), 3.51(s, 3H), 3.54 (app s, 
2H), 4.03 (dd, J = 3, 13 Hz, 1H), 4.11 (app d, J = 13 Hz, 1H), 4.19-4.24 (unresolved, 2H);  
13C NMR (150 MHz, CDCl3)   25.8, 27.8, 54.1, 59.8, 62.1, 72.9, 76.1, 78.8, 92.3, 
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109.3;  FTIR (ATR) 2099 cm-1 (N3 stretch);  HRMS (FAB, 3-NOBA) calcd for 
C10H16O4N6 (M+Li)
+ 291.0643, obsd. 291.1398. 
 
3-O-Methyl-4,5-O-isopropylidene--D-fructopyranosyl-1,2-
diamine (6):  Diazide (200 mg, 0.7 mmol) was dissolved in THF (2 
mL) and platinum oxide (80 mg, 50 mol%) catalyst was added.  
The diazide was hydrogenated (52 psi) for 1 h and filtered through a pad of celite.  The 
celite was washed several times with CH2Cl2 and the solvent was removed in vacuo. 
TLC indicated the complete reduction of diazide to a ninhydrin positive spot (Rf = 0.3, 
95:4:1 CH2Cl2 : MeOH : NH4OH).  The diamine (mixture of anomers ~ 9:1; as seen from 
13C NMR) thereby obtained (160 mg, 98%) was of sufficient purity to be used directly 
for synthesis of salen ligands.  The -anomer:  1H NMR (400 MHz, CDCl3)  1.33 (s, 3H) 
1.52 (s, 3H), 2.67 (d, J = 13 Hz, 1H), 2.84 (d, J = 13 Hz, 1H), 3.20 (d, J = 7 Hz, 1H), 3.5 
(s, 3H), 3.83 (d, J = 13 Hz, 1H), 4.1- 4.28 (m, 3H);  13C NMR (100 MHz, CDCl3) 
26.2, 28.1, 50.3, 58.8, 59.7, 74.0, 77.2, 80.4, 85.9, 108.6;  HRMS (FAB, 3-NOBA) calcd 
for C10H20O4N2 (M+H)+ 233.1503, obsd 233.1505.  
This ~ 9:1 mixture of  - and -diamine was used to prepare -fructopyranose derived 
catalyst with 3,5-di-tert-butylsalicylaldehyde, 3-butylsalicylaldehyde 3,5-
diiodosalicylaldehyde and 2-hydroxy-1-naphthaldehyde.32  
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(3aS,4S,5R,7aR)-5-(2-hydroxypropan-2-yl)-2,2-
dimethylhexahydrobenzo[d][1,3]-dioxole-4,5-diol  (11): The starting 
material, alkene was prepared from the literature procedure.49, 51  To a 
flask containing starting alkene (300 mg, 1.41 mmol, 1 equiv), tert-butanol 
(16 mL), N-methylmorpholine N-oxide (272 mg, 2.32 mmol, 1.63 equiv), water (0.153 
mL, 8.5 mmol, 6 equiv), pyridine (0.82 mL, 10.1 mmol, 7.1 equiv), potassium osmate 
dihydrate (24 mg, 0.065 mmol, 0.045 equiv) was added.  The contents were refluxed at 
100 °C for 12 h.  The TLC indicated completion of the reaction.  The reaction was then 
quenched with satd NaHSO3 and the volatiles were removed under reduced pressure.  
The contents were extracted with EtOAc after saturating the aqueous layer with NaCl. 
The organic layer was dried with sodium sulfate and passed through a pad of silica gel, 
concentrated and dried in vacuo. The crude reaction product (290 mg, crude yield 83%) 
was carried on to the next step.  1H NMR (400 MHz, CDCl3) 1.12 (s, 3H), 1.27 (s, 3H), 
1.3 2 (s, 3H), 1.46 (s, 3H), 1.5 (m, 2H), 1.89 (br d, J = 14.4 Hz, 1H), 2.05 (m, 1H), 3.43 
(s, 1H), 3.84 (d, J = 6 Hz, 1H), 4.07 (t, J = 7.3 Hz, 1H), 4.12 (s, 1H), 4.19 (s, 1H), 4.27 
(m, 1H); 13C NMR (100 MHz, CHCl3) 5, 73.9, 75.5, 
75.8, 76.6, 80.6, 108.5. 
(3aR,4S,5R,7aR)-5-(2-hydroxypropan-2-yl)-4-methoxy-2,2-
dimethylhexahydro-benzo[d][1,3]dioxol-5-ol (21): To a solution of 
triol 11 (290 mg, 1.18 mmol, 1 equiv) in THF (6 mL) at 0 °C, NaH 
(hexanes washed, 86 mg, 3.54 mmol, 3 equiv) was added in one portion 
and stirred for 10 min.  The contents were cooled to –40 °C and iodomethane (74 L, 
1.18 mmol, 1 equiv) was added dropwise.  The contents were stirred at –40 °C for 5 h 
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and then warmed to –20 °C (NaCl/ice mixture) and stirred for 8 h.  The completion of the 
reaction was monitored by TLC.  The reaction was quenched by added satd NH4Cl and 
THF was removed under reduced pressure.  The contents were extracted with EtOAc and 
the organic layer was washed with brine, dried over anhydrous Na2SO4, concentrated and 
dried under vacuo. The crude product was chromatographed (025% EtOAc-hexanes) to 
yield the title compound (265 mg, 72 %, over two steps).  []D –41.3 (c 5.05, CHCl3);  
1H 
NMR (400 MHz, CDCl3) 
2H), 1.84 (ddd, J = 14.8, 7.9, 3.6 Hz, 1H), 2.06 (m, 1H), 3.18 (s, 1H), 3.48 (d, J = 7 Hz, 
1H), 3.58 (s, 3H), 4.16 (s, 1H), 4.24 (app t, J = 5.6 Hz, 1H), 4.30 (m, 1H);  13C NMR 
(100 MHz, CDCl3) 
108.0; HRMS (FAB) calcd for C13H24O5Li (M+Li)
+ 267.1784, obsd 267.1794.   
 
(3aR,4S,7aR)-4-methoxy-2,2-dimethyltetrahydrobenzo[d][1,3]dioxol-
5(6H)-one (12): To a stirred suspension of the diol (100 mg, 0.384 mmol, 
1 equiv) and dust of 3 Å molecular sieve in CH2Cl2 (8 mL) at rt, Pb(OAc)4 
(340 mg, 0.768 mmol, 2 equiv) was added.  The contents were stirred for 
10 min.  TLC indicated complete conversion of the diol to the product, ketone.  The 
reaction was quenched by adding satd. NaHCO3 and extracted with ether.  The organic 
layer was then washed with brine, dried over anhyd Na2SO4.  Removal of solvent under 
reduced pressure yielded the title compound S5 (77 mg, quantitative). []19D –69.6 (c 1.1, 
CHCl3);  1H NMR (400 MHz, CDCl3)  1.33 (s, 3H), 1.43 (s, 3H), 2.09-2.14 (m, 1H), 
2.21-2.30 (m, 2H), 2.46-2.55 (m, 1H), 3.41(s, 3H), 4.31 (dd, J = 6.8, 4.6 Hz, 1H), 4.41-
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4.48 (m, 1H);  13C NMR (100 MHz, CDCl3) 23,70, 24.38, 26.72, 32.68, 58.80, 72.29, 
78.05, 84.23, 109.22, 207.53; HRMS (FAB) calcd for C10H17O4 (M+H)
+ 201.1127, obsd 
201.1119. 
 
(3aR,4R,7aR)-4-methoxy-2,2-dimethyl-5-
methylenehexahydrobenzo[d][1,3]dioxole (13): To a stirred ice-cold 
solution of Ph3PCH3Br (1.32 g, 2.14 mmol, 1.5 equiv), was added 1.3 M 
BuLi in hexanes (1.5 mL, 2.0 mmol, 1.4 equiv) slowly.  The resulting yellow solution 
was stirred for 10 min at 0 °C, and the ethereal solution of the ketone (288 mg, 1.44 
mmol, 1 equiv) was added slowly.  Immediate precipitation appeared, the resulting 
suspension was stirred overnight, and quenched with 1 M NaOH. The product was 
extracted with ether, washed with brine and dried over Na2SO4.  Removal of solvent 
under reduced pressure provided the crude product.  The product was purified by column 
chromatography on silica gel to yield the terminal olefin 9 (228 mg, 80%) as a clear 
liquid.  []19D –96.2 (c 1.0, CHCl3);  1H NMR (400 MHz, CDCl3)  1.26 (d, J = 2.5 Hz, 
3H), 1.41 (d, J = 2.6 Hz, 3H), 1.77-1.81 (m, 1H), 1.86-1.92 (m, 1H), 2.11-2.14 (m, 1H), 
2.20-2.27 (m, 1H), 3.30 (d, J = 2.8 Hz, 3H), 3.61 (dt, J = 3.8, 1.1 Hz, 1H), 3.93-3.97 (m, 
1H), 4.23-4.26 (m, 1H), 4.92 (d J = 1.08 Hz, 3H);  13C NMR (100 MHz, CDCl3)  25,32, 
25.78, 26.15, 27.49, 57.25, 73.48, 79.43, 83.23, 108.18, 111.20, 142.53;  HRMS (CI) 
calcd for C11H19O3 (M+H)
+ 199.1334, obsd 199.1338. 
 
282 
 
(3aR,4R,5S,7aR)-5-azido-5-(azidomethyl)-4-methoxy-2,2-dimethylhexahydro-
benzo[d][1,3]dioxole (-diazide) (15):   
A dry flask was charged with NaN3 (442 mg, 6.8 mmol, 5 equiv), Mn(OAc)3.2H2O (1.1 g, 
4.1 mmol, 3 equiv) and CH3CN (7 mL) and nitrogen gas was bubbled through the 
mixture.  Then the mixture was cooled down to –20 °C and 13 (270 mg, 1.36 mmol, 1 
equiv) was added to it dropwise.  The reaction was initiated by the slow addition of TFA 
(0.21 mL).  The reaction mixture was slowly warmed up to rt.  After 3 h, aqueous 
NaHSO3 solution was added and the reaction mixture was extracted with CH2Cl2. The 
organic layer was washed with satd Na2CO3 and dried. Column chromatography (10% 
Et2O in hexanes) gave two fractions with very close Rf values, with 80% yield.   
Fraction 1 yield the -diazide 15 as a clear oil (84 mg, 22%);  [ ]19D –
84.2 (c 1.05, CHCl3);  1H NMR (400 MHz, CDCl3
1.48 (s, 3H), 1.59 (m, 1H), 1.71 (dt, J = 14, 5.5 Hz, 1H), 1.92 (m, 2H), 
3.22 (d, J = 7.3 Hz, 1H), 3.53(s, 3H), 3.55 (d, J = 12.1 Hz, 1H), 3.62 (d, J = 12.1 Hz, 
1H), 4.13 (dd, J = 7.2, 5.4 Hz 1H), 4.25 (m, 1H);  13C NMR (100 MHz, CDCl3) 
26.2, 26.3, 28.4, 55.3, 60.2, 65.8, 73.9, 79.7, 82.5, 108.5;  HRMS (FAB) calcd for 
C13H19N6O3 (M+H)+ 283.1519, obsd 283.1530.   
 
Fraction 2 yielded the -diazide 14 as a clear oil (221 mg, 58%);  
[ ]19D –110.3 (c 1.0, CHCl3);  1H NMR (400 MHz, CDCl3
(s, 3H), 1.49 (s, 3H), 1.64 (m, 2H), 1.83 (m, 1H), 2.03 (m, 1H), 3.18 (d, J = 13.4 Hz, 1H), 
3.35 (d, J = 7.1 Hz, 1H), 3.55 (s, 3H), 3.68 (d, J = 13.4 Hz, 1H), 3.90 (app t, J = 6.8 Hz 
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1H), 4.21 (m, 1H);  13C NMR (100 MHz, CDCl3) 22.6, 25.4, 26.1, 28.2, 51.2, 60.4, 
66.2, 73.3, 79.2, 85.2, 108.8;  HRMS (FAB) calcd for C11H18N6O3Li (M+Li)+ 289.1600, 
obsd 289.1596.   
 
(3aR,4R,5S,7aR)-5-(aminomethyl)-4-methoxy-2,2-
dimethylhexahydrobenzo-[d][1,3]dioxol-5-amine (-diamine) (17): 
-Diazide 15 (321 mg, 1.14 mmol) was dissolved in EtOH (10 mL) 
and 32 mg of 10% Pd/C was added.  The resulting suspension was hydrogenated at 52 psi 
for 12 h, resulting total reduction to give the -diamine 17 (262 mg, 100%).  []19D –61.5 
(c 0.76, CHCl3);  1H NMR (400 MHz, CDCl3)  1.30 (br s, 4H), 1.33 (s, 3H), 1.5 (s, 3H), 
1.54 (dt, J = 13.5, 4.6 Hz, 2H), 1.87 (br d, J = 13.2 Hz, 1H), 2.04 (tt, J = 13.3, 4.7Hz, 
1H), 2.6 (d, J = 12.7 Hz, 1H), 2.63 (d, J = 12.7 Hz, 1H), 3.08 (d, J = 7.2, Hz, 1H), 3.51 
(s, 3H), 4.16 (app t, J = 6.8 Hz, 1H), 4.26 (m, 1H);  13C NMR (100 MHz, CDCl3
26.4, 27.7, 28.4, 51.7, 56.0, 60.0, 74.4, 80.2, 84.1, 107.7; HRMS (FAB) calcd for 
C13H23N2O3 (M+H)
+ 231.1709, obsd 231.1700. 
 
-diamine (16): -Diazide 14 (168 mg, 0.6 mmol) was dissolved in 
EtOH (5 mL) and 20 mg of 10% Pd/C was added.  The resulting 
suspension was hydrogenated at 52 psi for 12 h, resulting total reduction to give -
diamine (135 mg, 100%). []19D –54.7 (c 0.35, CHCl3); 1H NMR (400 MHz, CDCl3) 1.30 
(br s, 3 H), 1.37-1.47 (m, 4 H), 1.48 (s, 3 H), 1.54 (dt, J = 13.6, 4 Hz, 1 H), 1.60-1.70 (m, 
1 H), 1.92 (qt, J = 4, 15.6 Hz, 1 H), 2.42 (d, J = 13.2 Hz, 1 H), 2.67 (d, J = 13.2 Hz, 1 H), 
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3.14 (d, J = 7.2 Hz, 1 H), 3.51 (s, 3 H), 3.96 (dd, J = 5.6, 7.6 Hz, 1 H), 4.20-4.24 (m, 1 
H); HRMS (ESI) calcd for C13H23N2O3 (M+H)
+ 231.1709, obsd 231.1706 
 
6-(iodomethyl)-4-methoxy-2,2-dimethyltetrahydro-3aH-
[1,3]dioxolo[4,5-c]pyran-7-ol (22): Methyl--D-mannopyranose (9 g, 
46.3 mmol) was suspended in 200 mL toluene at 80 °C, from that 
suspension was added triphenylphosphine (13.9 g, 53.3 mmol) and imidazole (10.88 g, 
160 mmol) and kept stirring for 10 min at that temperature.  Then iodine (17.2 g, 66.7 
mmol) was added in portions over 0.5 h.  The resulting suspension was vigorously stirred 
at 80 °C for 2 h and solution became dark brown.  The solution was cooled and the 
product was extracted into H2O (3×200 mL), the aqueous layer was washed with 200 mL 
of toluene and concentrated under vacuum.  The crude was purified by column 
chromatography with pure ethyl acetate (Rf 0.45 in 50% ethylacetate in acetone) and pure 
product (11.3 g, 37.0 mmol, 80%) was obtained as white solid.  []19D +64.3 (c 1.1, 
EtOH);  1H NMR (400 MHz, D2O)  3.37 (dd, J = 10.9, 7.1 Hz, 1H), 3.45 (ddd, J = 9.4, 
7.1, 2.2 Hz, 1H), 3.57 (app t, J = 9.5, 9.4 Hz, 1H), 3.63 (dd, J= 10.9, 2.2 Hz, 1H), 3.76 
(dd,  = 9.5, 3.5 Hz, 1H), 3.93 (dd, J=3.4, 1.7 Hz, 1H), 4.73 (d, J = 1.4 Hz, 1H);  13C NMR 
(100 MHz, D2O)  6.1, 55, 69.8, 70.05, 70.6, 71.5, 101.1;  HMRS (FAB) Calcd for 
C7H13IO5Li (M+Li)+ 310.9968, obsd 310.9961.   
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6-(Iodomethyl)-4-methoxy-2,2-dimethyltetrahydro-3aH-
[1,3]dioxolo[4,5-c] pyran-7-ol (18): To a solution of 22 (7.5 g, 24.6 
mmol, 1 equiv) in 120 mL acetone at 0 °C was added p-
toluenesulfonic acid (936 mg, 4.92 mmol, 20%), followed by dropwise addition of 
dimethoxylpropane (9.1 mL, 73.8 mmol, 3 equiv) via syringe pump.  The resulting 
solution was kept stirring for 3 h upon which time all the starting materials disappeared.  
The reaction was quenched by Et3N (1.37 mL, 9.84 mmol, 40%) and organic solvent was 
evaporated under reduced pressure.  The resulting residue were re-suspended in 60 mL 
water and extracted with EtOAc (3 × 60 mL).  The organic layer was washed with brine 
and dried under Na2SO4, filtered and evaporated, resulted in pale yellowish liquid as 
clean product (8.5 g, 95%) without the need for further purification.  []19D +33.4 (c 1.1, 
CHCl3);  1H NMR (400 MHz, CDCl3)  1.34 (s, 3H), 1.51(s, 3H), 3.30 (dd, J=10.5, 
7.1Hz, 1H), 3.4d (ddd, J=9.2, 7.1, 2.4Hz, 1H), 3,46 (s, 3H), 3.49 (ddd, J=9.4, 6.9, 3.4Hz 
1H), 3.58(dd, J=10.6, 2.5Hz, 1H), 4.10-4.12 (m, 2H), 4.91 (s, 1H);  13C NMR (100 MHz, 
CDCl3)  6.81, 26.06, 27.97, 55,55, 68.95, 73.06, 75.69, 78.35, 98.33, 109.78; HMRS 
(FAB) Calcd for C10H18IO5 (M+H)+ 345.0121 obsd 345.0204.   
 
6-(iodomethyl)-4,7-dimethoxy-2,2-dimethyltetrahydro-3aH-
[1,3]dioxolo[4,5-c] Pyran (23): To a solution of 18 (160 mg, 0.47 
mmol) in 3 mL THF at 0 °C was added imidazole (6.8 mg, 0.1 mmol) 
and NaH (240 mg, 60% suspension in mineral oil, 6 mmol), followed by slow addition of 
MeI (62 µL, 1 mmol). The resulting solution was kept stirring at 0 oC for 3 h, upon which 
time TLC showed complete consumption of the starting material.  The reaction is 
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quenched by saturated NH4Cl and extracted with Et2O.  Organic phase was dried, filtered 
and evaporated.  The crude product was purified by silica column chromatography to 
afford 23 as a clear oil (134 mg, 80%). 1H NMR (400 MHz, CDCl3)  1.31 (s, 3H), 1.51 
(s, 3H), 3.07 (dd, J = 9.6, 6.9 Hz, 1H), 3.27 (dd, J = 10.3, 7.4 Hz, 1H), 3.35 (ddd, J = 9.6, 
7.4, 2.2Hz, 1H), 3.43 (s, 3H), 3.50 (s, 3H), 4.06 (d, J = 5.7Hz, 1H), 4.14 (app t, 1H);  13C 
NMR (100 MHz, CDCl3)  7.15, 26.18, 27.93, 55.91, 59.25, 67.91, 75.76, 78.09, 81.65, 
98.21, 109.29;  HRMS ESI calcd for C11H19O5INa (M+Na)+ 381.0175, obsd 381.0164.   
 
(3aR,4S,7S,7aR)-7-Hydroxy-4-methoxy-2,2-
dimethyltetrahydrobenzo[d][1,3]dioxol-5(6H)-one (19): Two step 
procedure from 18: To 150 mg 23 (0.42 mmol) in 5 mL DMF was 
added 0.7 mL DBU (0.46 mmol) at rt. The resulting mixture was stirred at 80 °C for 
overnight.  The reaction mixture was cooled down and 60 mL EtOAc and 30 mL of 
saturated NaHCO3 solution were added.  The layers were separated and the organic layer 
was washed with water (3×60 mL), then with brine. The resulting organic phase was 
dried with Na2SO4 and evaporated under reduced pressure to give the product in 60% 
yield:  []19D +49.1 (c 1.1, CHCl3);  1H NMR (400 MHz, CDCl3)  1.33 (s, 3H), 1.48 (s, 
3H), 3.46 (d, J = 0.7 Hz, 3H), 3.49 (d, J = 0.7Hz, 3H), 3.81 (dd, J = 0.8, 4.6 Hz, 1H), 4.16 
(ddd, J = 7.2, 3.8, 0.5 Hz, 1H), 4.26 (dd, J = 7.1, 6.0 Hz, 1H), 4.43 (d, J = 0.8 Hz, 1H), 
4.64 (d, J = 0.8 Hz, 1H), 4.86 (s, 1H);  13C NMR (100 MHz, CDCl3)  24.74, 26.89, 
56.25, 57.91, 74.58, 75.86, 77.97, 93.22, 100.23, 109.80, 151.94;  HMRS (FAB) Calcd 
for C11H18O5Li (M+Li)+ 237.031, obsd 237.1316. 
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For the one-pot process: 1.3 g 18 (3.78 mmol) was dissolved in 40 mL DMF, cooled to 
0oC and 0.47 mL MeI (7.56 mmol) was added, followed by 51 mg imidazole (0.76 mmol, 
20%) and 272 mg NaH (11.3 mmol, washed with hexane to remove mineral oil).  The 
reaction mixture was kept stirring at 0 oC for 3 h, TLC shows all SM converted to alkene 
product and iodide intermediate.  The reaction mixture was left stirring at rt for overnight. 
TLC showed a single spot as the eliminated product. Work-up: The reaction mixture was 
added 60 mL EtOAc and 30 mL of saturated NaHCO3 solution. The layers were 
separated and the organic layer was washed with water (3 × 60 mL), then with brine. The 
resulting organic phase was dried with Na2SO4 and evaporated under reduced pressure to 
give 19 as a colorless oil (0.85 g, 98%).   
 
(3aR,4S,7S,7aR)-7-hydroxy-4-methoxy-2,2-
dimethyltetrahydrobenzo[d][1,3]dioxol-5(6H)-one (20): 19 (5.21 g, 
22.6 mmol) was dissolved in 120 mL solvent containing 2:2:1 volume 
ratio of acetone, dioxane and H2O.  The solution was cooled to 0 oC, Pd(OAc)2 (10 mol %) 
was added in portions.  Reaction mixture was kept at 0 °C for 12 h and the TLC showed 
complete consumption of the starting material. Reaction mixture was diluted with 
saturated NaCl and extracted with EtOAc (3 × 60 mL).  The resulting organic phase was 
dried with Na2SO4, filtered and evaporated under reduced pressure.  The residue was 
purified by column chromatography (Rf  0.25 at 50% EA in hexanes) and 4.15 g product 
were obtained (85% total yield, which contains about 8% of the 5-epimer).  For the major 
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epimer:  []19D -32.9 (c 1.0, CHCl3);  1H NMR (400 MHz, CDCl3)  1.30 (s, 3H), 1.41 (s, 
3H), 2.42 (dd, J = 18.3, 6.2 Hz, 1H), 2.75 (dd, J = 18.3, 5.0 Hz, 1H), 3.45 (s, 3H), 3.56-
3.63 (m, 1H), 3.70 (d, J = 5.2 Hz, 1H), 4.27 (app. t, J = 6.9, 5.4Hz, 1H), 4.39 (dd, J = 7.0, 
5.3Hz, 1H), 5.51-5.55 (m, 2H);  13C NMR (100 MHz, CDCl3)  24.26, 26.73, 41.86, 
59.00, 67.50, 76.71, 77.04, 83.89, 109.77, 204.70;  HRMS FAB calcd for C10H17O5 
(M+H)+ 217.1076, obsd 217.1073.   
 
(3aR,4S,7aR)-4-methoxy-2,2-dimethyl-3a,4-
dihydrobenzo[d][1,3]dioxol-5(7aH)-one (24): To a solution of 20 (692 
mg, 3.2 mmol) in 10 mL of CH2Cl2 at 0 oC, were added diisopropyethyl 
amine (1.11 mL, 6.4 mmol) and 1 crystal of DMAP. Then MsCl (371 L, 
4.8 mmol) was added dropwise and the resulting solution was stirred at rt until SM 
disappeared.  The reaction was quenched by addition of saturated NH4Cl and extracted 
with CH2Cl2, column chromatography purification afforded 24 as a clear oil (480 mg, 76% 
yield). []19D –84.4 (c 0.65, CHCl3);  1H NMR (400 MHz, CDCl3)  1.35 (d, J = 4.26 Hz, 
3H), 1.40 (d, J = 4.38 Hz, 3H), 3.45 (d, J = 4.5 Hz, 3H), 3.82 (app.t, J = 4.4, 5.2 Hz, 1H), 
4.47 (m, 1H), 4.73 (m, 1H), 5.99 (dd, J = 10.25, 4.53 Hz, 1H), 6.64-6.69 (m, 1H);  13C 
NMR (100 MHz, CDCl3)   26.29, 27.82, 59.17, 71.12, 76.68, 81.07, 110.96, 128.08, 
143.32, 194.96;  HRMS FAB calcd for C10H14LiO4 (M+Li)+ 205.1052, obsd 205.1046.   
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(3aR,4S,7aR)-4-methoxy-2,2-dimethyltetrahydrobenzo[d][1,3]dioxol-
5(6H)-one (12): To a solution of 24 (200 mg, 1.0 mmol) in EtOAc (10 mL) 
was added 20% Pd(OH)2/C (20 wt%, 40 mg).  The resulting mixture was 
hydrogenated at 20 psi for 1 h, the catalyst was then filtered off a pad of celite and 
washed with EtOAc. The filtrate was evaporated to give the ketone 8 as a colorless oil 
(202 mg, 100% yield). []19D –69.6 (c 1.1, CHCl3);  1H NMR (400 MHz, CDCl3)  1.33 
(s, 3H), 1.43 (s, 3H), 2.09-2.14 (m, 1H), 2.21-2.30 (m, 2H), 2.46-2.55 (m, 1H), 3.41(s, 
3H), 4.31 (dd, J = 6.8, 4.6 Hz, 1H), 4.41-4.48 (m, 1H);  13C NMR (100 MHz, CDCl3)  
23,70, 24.38, 26.72, 32.68, 58.80, 72.29, 78.05, 84.23, 109.22, 207.53;  HRMS reported 
above.  
 
General procedure for salen synthesis: 
The oxa-fructopyranose diamine derived salens (5a-5d, 6a-6d) were synthesized 
following previous procedures.32 For the synthesis of the carba-fructopyranose diamine 
derived salens (16a-16d, 17a-17d), a general procedure is described using 16a as an 
example. To an oven-dried RB flask was added diamine 16 (388 mg, 1.68 mmol, 1 equiv), 
3,5-di-tert-butylsalicylaldehyde (789 mg, 3.37 mmol, 2 equiv) and freshly distilled 
ethanol (5 mL). The reaction mixture was heated at 60 °C for 12 h. TLC indicated 
completion of the reaction. The reaction was concentrated in vacuo. The residue was 
purified by silica column chromatography (eluting with EtOAc/Hexanes: 0-30%) to 
afford salen 16a as a yellow solid (729 mg, 63%). In some cases, the salen ligands 
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crystallized out during the reaction, therefore, the products were purified by simple 
trituration with cold ethanol.  
 
2,4-di-tert-butyl-6-((E)-((((3aR,4R,5R,7aR)-5-
((E)-(3,5-di-tert-butyl-2-
hydroxybenzylidene)amino)-4-methoxy-2,2-
dimethylhexahydrobenzo[d][1,3]dioxol-5-
yl)methyl)imino)methyl)phenol (16a): Following 
the general procedure for salen synthesis, a mixture of -diamine (388 mg, 1.68 mmol) 
and 3,5-di-tert-butylsalicylaldehyde (789 mg, 3.37 mmol) in ethanol (5 mL) was heated 
at 60 °C for 12 h.  The product 16a (729 mg, 63%) was obtained as yellow solid after 
column chromatography purification.  []19D  +127.8 (c 0.7, CH2Cl2);   1H NMR (400 
MHz, CD3Cl3
(s, 3H), 1.87-1.96 (m, 1 H), 1.97-2.10 (m, 2 H), 2.16-2.26 (m, 1 H), 3.52 (d, J = 7.2 Hz, 1 
H), 3.66 (s, 3 H), 3.82 (d, J = 13.2 Hz, 1 H), 4.05 (d, J = 12.8 Hz, 1 H), 4.27 (dd, J = 4.4, 
6.8 Hz, 1 H), 4.45 (dd, J = 2.8, 8.0 Hz, 1 H), 7.09 (d, J = 2.4 Hz, 1 H), 7.12 (d, J = 2.4 
Hz, 1 H), 7.40 (d, J = 1.6 Hz, 2 H), 8.42 (s, 1 H), 8.54 (s, 1 H), 13.45 (s, 1 H), 14.25 (s, 1 
H);  13C NMR (100 MHz, CD3Cl3
34.1, 35.1, 59.5, 61.4, 65.4, 73.8, 79.6, 86.4, 108.6, 117.8, 117.9, 126.1, 126.5, 127.0, 
127.2, 136.66, 136.70, 139.8, 140.1, 158.0, 158.4, 163.9, 168.5;  HMRS (ESI) Calcd for 
C41H62N2O5Na (M+Na)+ 685.4556 obsd 685.4531. 
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2-(tert-butyl)-6-((E)-((((3aR,4R,5R,7aR)-5-((E)-(3-(tert-
butyl)-2-hydroxybenzylidene)amino)-4-methoxy-2,2-
dimethylhexahydrobenzo[d][1,3]dioxol-5-
yl)methyl)imino)methyl)phenol (16b): Following the general 
procedure for salen synthesis, a mixture of -diamine (212 mg, 0.92 mmol) and 3-tert-
butylsalicylaldehyde (328 mg, 1.84 mmol) in ethanol (5 mL) was heated at 60 °C for 12 h.  
The product (380 mg, 70%) was obtained as pale yellow solid after column 
chromatography purification.  []19D  +161.4 (c 2.5, CH2Cl2);   1H NMR (400 MHz, 
CD3Cl3 - 1.94 (m, 1 H), 
1.98 (dt, J = 14.8, 4 Hz, 1 H), 2.03-2.10 (m, 1 H), 2.15-2.23 (m, 1 H), 3.53 (d, J = 7.2 Hz, 
1 H), 3.63 (s, 3 H), 3.81 (dd, J = 0.8, 13.2 Hz, 1 H), 4.02 (d, J = 13.2 Hz, 1 H), 4.25 (dd, 
J = 5.2, 6.4 Hz, 1 H), 4.43 (dd, J = 4.4, 9.2 Hz, 1 H), 6.80 (dt, J = 1.6, 7.6 Hz, 2 H), 7.08 
(dd, J = 1.6, 7.6 Hz, 1 H), 7.11 (dd, J = 2.0, 8.0 Hz, 1 H), 7.32 (t, J = 0.8 Hz, 1 H), 7.34 
(br s, 1 H), 8.38 (s, 1 H), 8.49 (s, 1 H), 13.59 (s, 1 H), 14.43 (s, 1 H);  13C NMR (100 
MHz, CD3Cl3
73.7, 79.4, 85.9, 108.6, 117.6, 117.9, 118.5, 118.6, 129.4, 129.7, 129.9, 130.3, 137.4, 
137.5, 160.2, 160.8, 163.6, 168.2; HMRS (ESI) Calcd for C33H46N2O5Na (M+Na)+ 
573.3304 obsd 573.3302. 
 
2-((E)-((((3aR,4R,5R,7aR)-5-((E)-(2-hydroxy-3,5-
diiodobenzylidene)amino)-4-methoxy-2,2-
dimethylhexahydrobenzo[d][1,3]dioxol-5-
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yl)methyl)imino)methyl)-4,6-diiodophenol (16c): Following the general procedure for 
salen synthesis, a mixture of -diamine (128 mg, 1.97 mmol) and 3,5-
diiodosalicylaldehyde (1.46 g, 3.93 mmol) in ethanol (5 mL) was heated at 60 °C for 12 h.  
The product (1.01 g, 65%) was obtained as yellow solid after column chromatography 
purification.  []19D  +137.5 (c 0.8, CH2Cl2);   1H NMR (400 MHz, CD3Cl3) 1.37 (s, 3 H), 
1.49 (s, 3 H), 1.86-1.94 (m, 2 H), 1.98-2.04 (m, 1 H), 2.16-2.23 (m, 1 H), 3.37 (d, J = 7.2 
Hz, 1 H), 3.56 (s, 3 H), 3.81 (d, J = 13.6 Hz, 1 H), 3.98 (d, J = 13.6 Hz, 1 H), 4.17 (dd, J 
= 5.2, 6.8 Hz, 1 H), 4.37 (dd, J = 3.2, 4.8 Hz, 1 H), 7.45 (d, J = 2 Hz, 1 H), 4.46 (d, J = 2 
Hz, 1 H), 8.02 (s, 1 H), 8.03 (s, 1 H), 8.09 (s, 1 H), 8.11 (d, J = 2.4 Hz, 1 H), 13.99 (s, 1 
H), 15.06 (d, J = 2.4 Hz, 1 H);   13C NMR (100 MHz, CD3Cl3
58.1, 61.0, 65.7, 73.4, 78.3, 79.4, 79.8, 85.3, 87.2, 89.2, 108.9, 119.2, 119.7, 140.1, 140.6, 
149.1, 149.3, 160.3, 160.9, 162.6, 165.9; HMRS (ESI) Calcd for C25H26N2O5I4Na 
(M+Na)+ 964.7918 obsd 964.7901. 
 
2-((E)-((((3aR,4R,5R,7aR)-5-((E)-((1-hydroxynaphthalen-
2-yl)methylene)amino)-4-methoxy-2,2-
dimethylhexahydrobenzo[d][1,3]dioxol-5-
yl)methyl)imino)methyl)naphthalen-1-ol (16d): Following 
the general procedure for salen synthesis, a mixture of -diamine 16 (122 mg, 1.87 mmol) 
and 2-hydroxy-1-naphthaldehyde (643 mg, 3.74 mmol) in ethanol (5 mL) was refluxed at 
60 °C for 12 h.  The product (488 mg, 64%) was obtained as yellow solid after column 
chromatography purification.  [ ]19D  +1386 (c 1.0, CH2Cl2);   1H NMR (400 MHz, 
CD3Cl3 -2.04 (m, 2 H), 2.18-2.27 (m, 1 H), 2.29-2.41 
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(m, 1 H), 3.53 (d, J = 7.6 Hz, 1 H), 3.73 (d, J = 13.6 Hz, 1 H), 3.79 (s, 3 H), 3.88 (d, J = 
13.6 Hz, 1 H), 4.17 (dd, J = 5.2, 7.2 Hz, 1 H), 4.40 (dd, J = 3.2, 4.8 Hz, 1 H), 6.71 (d, J 
= 8.8 Hz, 1 H), 6.79 (d, J = 8.8 Hz, 1 H), 6.88 (dd, J = 8.8 Hz, 1 H), 6.92 (dd, J = 8.8 Hz, 
1 H), 7.41- 7.47 (m, 1 H), 4.47-7.49 (m, 1 H), 7.52-7.59 (m, 3 H), 7.63 (d, J = 10.8 Hz, 1 
H), 7.84 (d, J = 10.8 Hz,1 H), 7.96 (br s, 1 H), 8.40 (d, J = 8.0 Hz, 1 H), 8.49 (d, J = 8.0 
Hz, 1 H), 13.97 (br s, 1 H), 13.03 (d, J = 10.8 Hz, 1 H); 13C NMR (100 MHz, CD3Cl3
22.7, 24.6, 26.3, 28.2, 55.1, 61.1, 62.9, 73.3, 79.2, 85.4,108.9, 110.2, 114.9, 116.6, 124.5, 
125.0, 125.3, 125.5, 127.25, 127.29, 127.4, 127.6, 128.3, 129.8, 129.9, 130.4, 136.8, 
137.7, 157.5, 165.3, 169.8, 177.3; HMRS (ESI) Calcd for C33H34N2O5Na (M+Na)+ 
561.2365 obsd 561.2388. 
2,4-di-tert-butyl-6-((E)-(((3aR,4S,5S,7aR)-5-((E)-3,5-di-
tert-butyl-2-hydroxybenzylideneamino)-4-methoxy-2,2-
dimethylhexahydrobenzo[d][1,3]dioxol-5-
yl)methylimino)methyl)phenol (17a): Following the 
-
diamine 17 (207 mg, 0.9 mmol, 1 equiv) and 3,5-di-tert-
butylsalicylaldehyde (380 mg, 1.62 mmol, 1.8 equiv) in 
ethanol (5 mL) was heated at 60 °C for 12 h.  The product (429 mg, 80%) was obtained 
as pale yellow solid after addition of cold 10% water in EtOH.  []19D  -125.3 (c 1.6, 
CH2Cl2);   1H NMR (400 MHz, CD3Cl3
(s, 9H), 1.45 (s, 9H), 1.57 (s, 3H), 1.77-1.87 (m, 1H), 2.01-2.04 (m, 3H), 3.59 (d, J = 7.9 
Hz, 1H), 3.63 (d, J = 12.1 Hz, 1H), 3.67 (s, 3H), 4.13 (d, J = 12.1 Hz, 1H), 4.22 (dd, J = 
7.9, 5.2 Hz, 1H), 4.31 (t, J = 4.7 Hz, 1H), 7.11 (dd, J = 6.8, 2.4 Hz, 2H), 7.34 (d, J = 2.4 
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Hz, 1H), 7.39 (dd, J = 6.4, 2.4 Hz, 2H), 7.59 (d, J = 2.4 Hz, 1H), 8.41 (s, 1H), 8.70 (s, 
1H), 13.56 (s, 1H), 13.95 (s, 1H);  13C NMR (100 MHz, CD3Cl3
26.6, 28.4, 29.35, 29.43, 31.5, 31.6, 34.1, 35.1, 61, 64.5, 65.3, 74.4, 80.2, 83.2, 108.2, 
117.8, 118.1, 126, 126.6, 127.2, 127.3, 136.8, 139.9, 140.2, 158.1, 158.4, 166.6, 167.9;  
HMRS (FAB) Calcd for C41H63N2O5 (M+H)+ 663.4659 obsd 663.4727. 
 
2-(tert-butyl)-6-((E)-((((3aR,4R,5S,7aR)-5-((E)-(3-(tert-
butyl)-2-hydroxybenzylidene)amino)-4-methoxy-2,2-
dimethylhexahydrobenzo[d][1,3]dioxol-5-
yl)methyl)imino)methyl)phenol (17b): Following the 
-
diamine (177 mg, 0.77 mmol, 1 equiv) and 3-tert-butylsalicylaldehyde (274 mg, 1.54 
mmol, 2 equiv)  in ethanol (5 mL) was heated at 60 °C for 12 h.  The product (347 mg, 
82%) was obtained as pale yellow solid after column chromatography purification. []19D  
-59.1 (c 0.7, CH2Cl2);   1H NMR (400 MHz, CDCl3
9H), 1.58 (s, 3H), 1.74-1.85 (m, 1H), 2.01-2.12 (m, 3H), 3.59 (d, J = 8.0 Hz, 1H), 3.64 (d, 
J = 11.6 Hz, 1H), 3.66 (s, 3H), 4.14 (d, J = 12.0 Hz, 1H), 4.22 (dd, J = 5.2, 8.0 Hz, 1H), 
4.34 (t, J = 2.4 Hz, 1H), 6.81 (d, J = 7.6, 1 H), 6.85 (d, J = 7.6, 1 H), 7.13 (dd, J = 1.6, 
6.0 Hz, 1 H), 7.15 (dd, J = 1.6, 6.0 Hz, 1 H), 7.35 (dt, J = 1.6, 7.6 Hz, 2 H), 8.41 (s, 1 H), 
8.71 (s, 1 H), 13.8 (s, 1 H), 14.16 (s, 1 H);  13C NMR (100 MHz, CD3Cl3
28.4, 28.6, 29.3, 29.4, 34.9, 60.9, 64.4, 65.3, 74.4, 80.2, 83.0, 117.8, 118.0, 118.6. 118.9, 
129.7, 129.8, 129.9, 130.4, 137.56, 137.59, 160.4, 160.8, 166.3, 167.7; HMRS (ESI) 
Calcd for C33H46N2O5Na (M+Na)+ 573.3304 obsd 573.3301. 
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2-((E)-(((3aR,4S,5S,7aR)-5-((E)-2-hydroxy-3,5-
diiodobenzylideneamino)-4-methoxy-2,2-
dimethylhexahydrobenzo[d][1,3]dioxol-5-
yl)methylimino)methyl)-4,6-diiodophenol (17c): Following 
the general procedure for salen preparation, a mixture of -
diamine 17 (65 mg, 0.28 mmol) and 3,5-
diiodosalicylaldehyde (190 mg, 0.51 mmol, 1.8 equiv) in ethanol (3 mL) was heated at 
50 °C overnight, the product (211 mg, 88%) was obtained as yellow solid after washing 
with cold Ethanol.  []19D –138.4 (c 1.0, CHCl3);  1H NMR (400 MHz, CD3Cl3) 1.33 (s, 
3H), 1.53 (s, 3H), 1.86-1.88 (m, 1H), 1.95-1.97 (m, 2H), 2.06-2.08 (m, 1H), 3.41 (d, J = 
7.7 Hz, 3H), 3.59 (s, 3H), 3.98 (d, J = 12.5 Hz, 1H), 3.83 (d, J = 12.5  Hz, 1H), 4.8 (dd, J 
= 7.5, 5.4 Hz, 1H), 4.28 (br s, 1H), 7.48 (d, J = 1.9 Hz, 1H), 7.51 (d, J = 1.9 Hz, 1H), 
8.04 (d, J = 1.9 Hz, 1H), 8.05 (d, J = 1.9 Hz, 1H), 8.12 (s, 1H), 8.37 (d, J = 1.73 Hz, 1H), 
14.05 (s, 1H), 14.83 (s, 1H); 13C NMR (100 MHz, CD3Cl3)  21.8, 26.3, 27.4, 28.4, 60.8, 
63.9, 65.3, 73.7, 78.6, 79.3, 79.7, 83.9, 87.3, 88.9, 108.4, 119.4, 119.6, 139.9, 140.6, 
149.0, 149.2, 160.3, 162.3, 163.8, 165.4; HMRS (FAB) Calcd for C25H27N2O5I4 (M+H)+ 
942.8021 obsd 942.8115. 
2-((E)-((((3aR,4R,5S,7aR)-5-((E)-((1-
hydroxynaphthalen-2-yl)methylene)amino)-4-methoxy-
2,2-dimethylhexahydrobenzo[d][1,3]dioxol-5-
yl)methyl)imino)methyl)naphthalen-1-ol (17d): 
Following the general procedure for salen synthesis, a 
-diamine (60 mg, 0.26 mmol) and 2-hydroxy-1-naphthaldehyde (89 mg, 
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0.52 mmol) in ethanol (2 mL) was heated at 60 °C for 12 h.  The product (106 mg, 73%) 
was obtained as a brown solid after column chromatography purification. []19D  +488 (c 
1, CH2Cl2);   1H NMR (400 MHz, CDCl3) -2.01 (m, 
1H), 2.03-2.22 (m, 3H), 3.47 (d, J = 6.8 Hz, 1H), 3.74 (d, J = 10.4 Hz, 1H), 3.76 (s, 3 H), 
3.88 (d, J = 12.8 Hz , 1H), 4.26-4.32 (m, 2 H), 6.71 (d, J = 8.8 Hz, 1 H), 6.79 (d, J = 8.8 
Hz, 1 H), 6.91 (d, J = 12.4 Hz, 1 H), 6.94 (d, J = 12.4 Hz, 1 H), 7.40-7.45 (m, 1 H), 7.46-
7.51 (m, 1 H), 7.52- 7.61 (m, 3 H), 7.64 (d, J = 7.6 Hz, 1 H), 7.88 (s, 1 H), 7.92 (d, J = 
10.4 Hz, 1 H), 8.46 (d, J = 8.0 Hz, 1 H), 8.50 (d, 8.0 Hz, 1 H), 13.68 (d, J = 10.4 Hz, 1 
H), 13.95 (s, 1 H);  13C NMR (100 MHz, CD3Cl3) 21.4, 25.5, 26.4, 28.4, 60.7, 61.5, 62.6, 
73.7, 79.4, 82.5, 124.7, 125.2, 125.4, 125.6, 127.30, 127.31, 127.4, 127.9, 128.2, 129.9, 
130.0, 130.6, 136.9, 137.7, 158.9, 164.7, 170.7, 178.0; HMRS (ESI) Calcd for 
C33H34N2O5Na (M+Na)+ 561.2365 obsd 561.2363. 
General Procedure for Synthesis of Co(III)-Salen Catalysts (illustrated for 16a): 
To a stirred solution of salen ligand (16a) (116 mg, 0.17 mmol, 1 equiv.) in 1 mL CH2Cl2, 
a methanolic (1 mL) solution of cobalt (II) acetate tetrahydrate (42 mg, 0.17 mmol, 1.0 
equiv.), was added via cannula, under Ar. The Co(II)-salen complex precipitated out as a 
red solid. After filtration, the Co(II) complex was taken up in CH2Cl2 or toluene (2 mL) 
and stirred with 3,5-dinitrobenzoic acid (1 equiv.) open to the air. The oxidation could be 
followed by TLC [formation of a greenish-brown spot of lower Rf {Co-(III) complex} 
from the visibly red, higher Rf spot characteristic of the Co-(II) salen]. When TLC 
indicated the completion of the reaction (2-12 h), the solvent was evaporated, and the 
Co(III)-salen complex further dried in vacuo. The Co-(III)-salen complexes were 
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generally used directly for HKR experiments, under ISES (bilayer) conditions or under 
typical neat or one-phase flask conditions. 
Table 4.3: HR-MS characterization of Co(III)-salen catalysts. 
Catalyst Molecular Formula Calcd 
obsd HR-MS 
(EI) 
Co(III)-16a-3,5-DNB C41H60N2O5Co 719.3834 719.3824 
Co(III)-16b-3,5-DNB C33H44N2O5Co 607.2582 607.2563 
Co(III)-16c-3,5-DNB C25H24N2O5I4Co 998.7196 998.7170 
Co(III)-16d-3,5-DNB C33H32N2O5Co 595.1643 595.1635 
Co(III)-17a-3,5-DNB C41H60N2O5Co 719.3834 719.3833 
Co(III)-17b-3,5-DNB C33H44N2O5Co 607.2582 607.2604 
Co(III)-17c-3,5-DNB C25H24N2O5I4Co 998.7196 998.7200 
Co(III)-17d-3,5-DNB C33H32N2O5Co 595.1643 595.1644 
 
B.  Miniaturized ISES (In Situ Enzymatic Screening) Experiments 
A general procedure for the minituarized ISES to estimate both relative reaction 
rates and sense and magnitude of enantioselectivity is presented below.  Cobalt-(III)-
salen mediated HKR of (±)-propylene oxide and (±)-hexene oxide were chosen as model 
reactions. A new reporting system was developed in this work, so that more readily 
available enzymes might be used by chemists seeking to perform these ISES assays. To 
establish a new set of reporting enzymes for these model reactions, commercially 
available nicotinamide-dependent ketoreductases from Codexis (so-called KREDs)  were 
screened for catalytic efficiency and enantioselectivity for the oxidation of the 1,2-diol 
products of these model HKR reactions (Note: One motivation here was the reduced 
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availability of the most utilized reporting enzyme heretofore; namely native HLADH = 
horse liver alcohol DH).  As a result of these screening studies, TBADH (selective for R-
1,2-propanediol) and KRED 23 (selective for S-1,2-propanediol) were selected as 
reporting enzymes for the HKR of (±)-propylene oxide. Correspondingly, KRED 107 and 
KRED 119 were selected as reporting enzymes for the HKR of (±)-hexene oxide.  The 
details of the characterization of these new KRED reporting enzymes are provided 
herewith. 
KRED Reporting Enzyme Characterization 
1) KRED 107: The enantioselectivity of KRED 107 was estimated by comparing 
the initial velocities of (R)- vs. (S)-1,2-hexanediol oxidation at fixed initial concentrations 
between 1.25 and 100 mM at 25 °C.  Each velocity measurement was performed in 
duplicate. The assay well contained the following: 2.2 mM NADP+ (3.5 μL from a 125 
mM stock), 0.045 U of KRED 107, and various concentrations of either (R)- or (S)-1,2-
hexanediol. In all cases, the final volume was adjusted to 0.2 mL using 50 mM sodium 
pyrophosphate buffer, pH 8.8. 2) KRED 119: The enantioselectivity of KRED 119 was 
estimated in the same manner as for KRED 107, as described above. 3). KRED 23: The 
enantioselectivity of KRED 23 was estimated by comparing the rates of (R)- vs. (S)-1,2-
propanediol oxidation at fixed initial concentrations between 3 and 140 mM at 25 °C. 
Each velocity measurement was performed in duplicate. The assay well contained the 
following: 7.2 mM NAD+ (5 μL from a 220 mM stock), 10 μL of a KRED 23 stock 
solution (2 mg in 250 μL buffer)  and various concentrations of either (R)- or (S)-1,2-
propanediol. In all cases, the final volume was adjusted to 150 μL using 50 mM sodium 
pyrophosphate buffer, pH 8.8. 
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Previously, we estimated during HKR-ISES experiments that the diol 
concentration is in the range of 2.5-70 mM.  So, generally selectivity parameters 
appropriate for ISES screening are chosen based upon enantioselectivities observed in 
this concentration range.  For KRED 119, a selectivity factor of 6.5 in favor of the (R)-
1,2-hexanediol was used for ISES estimations.  This corresponds to the selectivity 
observed in the standard assay cuvette at approximately 40 mM diol concentration. 
KRED 107 proved to be the most difficult reporting enzyme to parametrize, owing to its 
very high preference for the (S)-antipode of 1,2-hexanediol.   In the end, iterative analysis 
of candidate fitting factors led us to assign a selectivity factor of 59 for this reporting 
enzyme (corresponds approximately to the selectivity of this reporting enzyme on the 
lower end of the aforementioned concentration window). Selectivity factors of 8.4 (vS/vR) 
for TBADH2 and 6.5 (vS/vR) for KRED 23 were employed for 1,2-propanediol reporting.  
The complete set of enantiomeric diol screening data (rate vs. concentration) for each of 
the selected KRED screening enzymes is provided in Fig. 4.24.  
Enzyme Standardization 
Stock Solutions. The following stock solutions were made for enzyme 
standardization: 40 mM -NADP+, 130 mM -NAD+, 0.016mg/L TBADH, 0.016 
mg/L KRED 23, 0.002 mg/L KRED 107 and 0.002 mg/L KRED 119 in 25 mM 
sodium phosphate buffer (pH 7.0), 2 M (R)-1,2-propanediol in water. Enzyme units were 
calculated by measuring the rate of formation of NADPH or NADH at 340 nm (vide 
infra). In each case, one S.I. unit is taken as the amount of enzyme catalyzing the 
formation of one mol of NADPH per minute. 
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Standardization of TBADH. The assay cuvette contained the following 
components: 2.2 mM (5 L of 40 mM stock solution), -NADP+, 5 L of TBADH stock 
solution, 71 L of 50 mM sodium pyrophosphate buffer (pH 8.8), and 200 mM (9 L of 
2 M stock) of (R)-1,2-propanediol. The reaction was initiated by the addition of the (R)-
1,2-propanediol, which typically gave a rate of 0.709 abs/min at 25oC at 340 nm 
Figure 4.24:  Enantioselectivities of the new reporting enzymes 
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wavelength.  This was indicative of 0.028 U/L for the TBADH stock solution for the 
oxidation of (R)-1,2-propanediol. 
Standardization of KRED 23. The assay cuvette contained the following 
components: 7.2 mM (5 L of 130 mM stock solution) -NAD+, 5 L of KRED 23 stock 
solution, 71 L of 50 mM sodium pyrophosphate buffer (pH 8.8), and 200 mM (9 L of 
2 M stock) of (R)-1,2-propanediol. The reaction was initiated by the addition of the (R)-
1,2-propanediol, which typically gave a rate of 0.540 abs/min at 25oC at 340 nm 
wavelength.  This is indicative of 0.016 U/L for the KRED 23 stock solution for the 
oxidation of (R)-1,2-propanediol. 
Standardization of KRED 107. The assay cuvette contained the following 
components: 2.2 mM (5 L of 40 mM stock solution), -NADP+, 5 L of KRED 107 
stock solution, 81 L of 50 mM sodium pyrophosphate buffer (pH 8.8), and 200 mM (9 
L of 2 M stock) of (R)-1,2-hexanediol. The reaction was initiated by the addition of the 
(R)-1,2-hexanediol, which typically gave a rate of 0.124 abs/min at 25oC at 340 nm 
wavelength.  This is indicative of 0.00398 U/L for the KRED 107 stock solution for the 
oxidation of (R)-1,2-hexanediol. 
Standardization of KRED 119. The assay cuvette contained the following 
components: 2.2 mM (5 L of 40 mM stock solution) -NADP+, 5 L of KRED 119 
stock solution, 81 L of 50 mM sodium pyrophosphate buffer (pH 8.8), and 200 mM (9 
L of 2 M stock) of (R)-1,2-hexanediol. The reaction was initiated by the addition of the 
(R)-1,2-hexanediol, which typically gave a rate of 0.291 abs/min at 25oC at 340 nm 
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wavelength.  This was indicative of 0.00935 U/L for the KRED 119 stock solution for 
the oxidation of (R)-1,2-hexanediol. 
Layer Composition 
Quartz cuvettes with nominal 1 mL volumes were used in all previous ISES 
experiments. Here, for the first time, we describe a general procedure utilizing a 16 
multimicrocell array for “cassette” in situ enzymatic screening. For every catalyst, a four 
well “cassette screen” was performed over the two different substrates: propylene oxide 
and hexene oxide. For propylene oxide, well A contains TBADH and well B contains 
KRED 23. For hexene oxide, well C contains KRED 107 and well D contains KRED 119. 
Organic Layer in Wells A and B.  Both well A and B had the following 
composition: 10 L propylene oxide (8.3 mg, 0.14 mmol), 10 L of CHCl3 and 0.25 mol% 
catalyst. The total organic layer volume was maintained to 20 L. Organic Layer in 
Wells C and D. Both well C and D had the following composition: 10 L hexene oxide 
(8.3 mg, 0.08 mmol), 10 L of CHCl3 and 0.25 mol% catalyst. The total organic layer 
volume was maintained to 20 L. 
Aqueous Layer in Well A.  0.1 U of TBADH (3.6 L from a stock solution (0.028 
U/L)), 2.2 mM -NADP+ (5 L from a 40 mM stock solution) and 81.4 L of 50 mM 
sodium pyrophosphate buffer, pH 8.8. The total volume of the aqueous layer was 
maintained at 90 L. Aqueous Layer in Well B.  0.1 U of KRED 23 (6.2 L from a stock 
solution (0.016 u/L)), 7.2 mM -NAD+ (5 L of 130 mM stock solution) and 78.8 L of 
50 mM sodium pyrophosphate buffer (pH 8.8). The total volume of the aqueous layer 
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was maintained at 90 L. Aqueous Layer in Well C. 0.0374 U of KRED 107 (9.4 L 
from a stock solution (0.00398 U/L)), 2.2 mM -NADP+ (5 L from a 40 mM stock 
solution) and 75.6 L of 50 mM sodium pyrophosphate buffer, pH 8.8. The total volume 
of the aqueous layer was maintained at 90 L. Aqueous Layer in Well D. 0.0374 U of 
KRED 119 (4 L from a stock solution (0.00935 U/L)), 2.2 mM -NADP+ (5 L from a 
40 mM stock solution) and 81 L of 50 mM sodium pyrophosphate buffer, pH 8.8. The 
total volume of the aqueous layer was maintained at 90 L. 
Step by Step Protocol  
It was found practical to load the aqueous layers first. Routinely 90 L aqueous 
layers were loaded into individuate wells of 16-well quartz multimicrocell either with a 
microsyringe or with a multichannel pipetter. The quartz cell was gently tapped to keep 
the layers evenly distributed in the solid quartz apparatus,  then cooled on ice. Then the 
organic layers were prepared by briefly vortexing the catalyst stock in CHCl3 with (±)-
propylene oxide or (±)-hexene oxide in iced microcentrifuge tubes. The low volume (20 
L) organic layer was  then loaded to each well, most easily by rapidly syringing below 
the aqueous layer.  Catalyst screens were run at room temperature in duplicate, with ISES 
rates taken as the average of the two ΔOD340/time values obtained, for the appropriate 
time window (vide infra). 
C.  HKR Reactions Under Flask Conditions 
General Procedure for HKR of Epoxides: Two different general procedures were 
adapted based on the boiling points of the epoxides.  In some cases, the epoxide was 
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opened with phenyl selenide anion.  This latter protocol may be of advantage (i) to 
decrease the volatility of leftover epoxides, (ii) to introduce a UV chromophore (for UV 
detection – HPLC) and/or (iii) to improve enantiomeric peak resolution in chiral-HPLC.  
Procedure for Epoxide Opening by Phenylselenide:  Phenylselenide anion was 
prepared by slow addition of 3 equiv NaBH4 into an ice-cold suspension of 1.5 equiv of 
diphenyl diselenide in ethanol (5-7 mL).  The resulting mixture was heated at 40 °C for 
20 – 40 min, until the solution became colorless.  Then, either purified epoxide or the 
reaction mixture out of HKR was added to the ethanolic solution of phenyl selenide at 
0 °C.  The resulting reaction was slowly allowed to warm to rt and stirring was continued 
for 8 - 10 h at rt.  The reaction was quenched with ~1 mL of NH4Cl.  The mixture was 
diluted with dichloromethane and dried over anhydrous Na2SO4.  The crude product was 
obtained after filtration and the removal of the solvent. Silica gel column 
chromatography was used to isolate seleno-alcohol (and the diol, in cases, where the 
mixture of both epoxide and diol was added to phenyl selenide anion). Mosher Ester 
Analysis:  For some seleno-alcohols, enantiomeric excess was estimated via a classical 
Mosher esterification procedure [CH2Cl2, NEt3 (10 equiv), DMAP (cat.), S-Mosher acid 
chloride] followed by 1H NMR analysis. 
General Procedure A (Direct Treatment of the HKR Reaction Mixture with 
Phenyl Selenide):  This procedure was adapted for propylene oxide, hexene oxide, 1, 2-
epoxy-3-phenylpropane, butadiene monoxide and 1,2-epoxy-7-octene.  Here, we 
describe a general procedure for propylene oxide.   
Propylene oxide (Table 4.2, entry 1):   
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In this case catalyst Co(III)-17c-3,5-DNB (29.4 mg, 0.026 mmol, 1 mol%) 
was mixed with 1,2-epoxypropane (1.52 g, 26.1 mmol) and cooled to 0 °C. 
The reaction was initiated by 213 µL (0.5 equiv) of water and the stirring was continued 
for 12 h at 0 °C. For this substrate, the reaction mixture was added to the phenyl selenide 
solution at 0 °C. Workup and column chromatography provided selenoalcohol (2.06 g, 
38%, 030% ether in pentane) and 1,2-propanediol (786 mg, 42%, 500% ether in 
EtOAc).   
1-(Phenylseleno)-2-propanol:  NMR data matched reported data.7 The sign of the 
rotation was dependent on the solvent: in ethanol, []19obsd +4.5 (for 54% ee of R), []19D 
+8.3 (calcd); in CH2Cl2 []19obsd -28.1 (for 54% ee of R), []19D -52.1 (calcd).  The 
enantiomeric excess of the 1-(phenylseleno)-2-propanol was estimated by derivatization 
as its R-Mosher ester - 1H NMR, 3.02 (dd, 1H, R-enantiomer) & 2.93 (dd, 1H, S-
enantiomer).   
1,2-Propanediol:  The diol was derivatized to its bis-(p-bromobenzoate) ester and the 
enantiomeric excess was measured in chiral HPLC (Chiralcel OD, hexanes:i-PrOH 97:3, 
flow rate 1mL/min) tR 9.9 min (R), 10.8 min (S). 
1,2-Epoxyhexane (Table 4.2, entry 3):   
General Procedure A was followed, starting from 1,2-epoxyhexane 
(100 mg, 1.0 mmol), catalyst Co(III)-17c-3,5-DNB (5 mg, 0.005 
mmol, 0.5 mol%) and 9 µL (0.5 equiv) of water at 0 °C for 30 h.  1H NMR of a small 
aliquot of the reaction showed a 53% reaction conversion.  Direct ring-opening with 
phenyl selenide anion was performed.  Workup and column chromatography, provided 
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both the seleno-alcohol (116 mg, 45%, using 20% EtOAc in hexanes) and 1,2-hexanediol 
(57 mg, 48%, using 10% methanol in EtOAc).  
1-(phenylseleno)-2-hexanol: 1H NMR (400 MHz, CDCl3) δ 0.87 (t, J = 6.4 Hz, 3H), 
1.26-1.32 (m, 3H), 1.38-1.42 (m, 1H), 1.50-1.55 (m, 2H), 2.34 (br s, 1H), 2.85-2.90 (m, 
1H), 3.12-3.16 (m, 1H), 3.63-3.67 (m, 1H), 7.24-7.26 (m, 3H), 7.51-7.53 (m, 2H); 
[α]19obsd -29.5 (for 99% ee of R), [α]19D -29.8, calcd (c = 1.1, CHCl3). The enantiomers of 
the seleno alcohol were separable using Chiralcel OD column. For this alcohol 
(hexanes/i-PrOH 98:2, flow rate 1 mL/min), minor isomer, tR = 10.5 min (S) and major 
isomer, tR = 11.6 min (R). 
1,2-Hexanediol: 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.4 Hz, 3H), 1.23-1.41 (m, 
6H), 2.69 (br s, 2H), 3.43-3.68 (m, 3H); [α]23obsd -33.93 (for 91% ee of S), [α]23D -37.28, 
calcd (c = 0.75, EtOH), [lit.8 [α]D = + 15.7 (c = 1.0, EtOH, for R-diol); lit.9 [α]D  = – 22.1 
(c = 1.0, EtOH, for S-diol), lit.10 (S)-diol is -17.5° (c = 1.3, EtOH), lit.11 (S)-diol is -17.0° 
(c = 1.09, EtOH), lit.12 (R)-diol is +22.0 (c = 1.1, EtOH)].  The 1,2-diol was derivatized 
as its bis-p-bromobenzoate ester and the enantiomeric excess was determined using the 
same chiral column (hexanes/i-PrOH 97:3, flow rate 1 mL/min) for minor isomer, tR = 
6.9 min (R) and for major isomer, tR = 8.0 min (S).   
1,2-Epoxy-3-phenylpropane (Table 4.2, entry 4):  
General Procedure A was followed, starting from epoxy-3-
phenylpropane (315 mg, 2.3 mmol), catalyst Co(III)-17c-3,5-DNB 
(24.8 mg, 0.023 mmol, 1 mol%) and 22 µL (0.5 equiv) of water at 0 °C for 12 h.  1H 
NMR of a small aliquot of the reaction showed a 49% reaction conversion.  Direct ring-
307 
 
opening with phenyl selenide anion ensued.  After workup and column chromatography 
were obtained both the seleno-alcohol (329 mg, 48%, 050% ether in pentane) and 3-
phenyl-1,2-propanediol (175 mg, 49%, 500% ether in EtOAc).   
1-(Phenylseleno)-3-phenyl-2-propanol: 1H NMR (400 MHz, CDCl3) δ 2.36 (d, J = 3.6 
Hz, 1H), 2.86-2.88 (m, 2H), 2.91-2.96 (m, 1H), 3.10-3.14 (m, 1H), 3.92-3.96 (m, 1H), 
7.17-7.30 (m, 8H), 7.47-7.50 (m, 2H); [α]19obsd -24.6 (for 76% ee of R), [α]19D -32.4, 
calcd (c = 1.0, CHCl3). The seleno-alcohol was resolved on Chiral column. For the 
seleno-alcohol (hexane/ i-PrOH 97:3, flow rate: 1 mL/min), major isomer, tR = 17.1 min 
(R) and minor isomer, tR = 19.3 min (S).   
3-Phenylpropane-1,2-diol: 1H NMR (400 MHz, CDCl3) δ 2.68-2.78 (m, 2H), 3.44-3.48 
(m, 2H), 3.63 (d, J = 10.8 Hz, 2H), 3.89 (d, J = 5.6 Hz, 1H), 7.18-7.31 (m, 5H); [α]19obsd -
21.5 (for 92% ee of S), [α]19D -23.3, calcd (c = 1.0, CHCl3), [lit.12 [α]D -18.6, (c = 1.3, 
CHCl3) for S-diol), lit.13 [α]20D +20.4, (c = 1.0, CHCl3) for R-diol), lit.14 [α]20D +15.0, (c = 
1.0, CHCl3) for R-diol), lit.15 [α]D -29.0, (c = 1.2, EtOH) for S-diol)]. 1,2-diol was 
resolved on Chiral column. For 1,2-diol (hexane/i-PrOH 92:8, flow rate: 1 mL/min), 
minor isomer, tR = 12.1 min (R) and major isomer, tR = 13.2 min (S). 
1,2-Epoxy-7-octene (Table 4.2, entry 6):   
General Procedure A was followed, starting from 1,2-epoxy-7-
octene (126 mg, 1.0 mmol), catalyst Co(III)-17c-3,5-DNB (5 
mg, 0.005 mmol, 0.5 mol% loading) and 9 µL (0.5 equiv) of water at rt for 30 h.  Direct 
ring-opening with phenyl selenide anion ensued.  After workup and column 
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chromatography, were obtained both the seleno-alcohol (119 mg, 42%, using 20% 
EtOAc in hexanes) and oct-7-ene-1,2-diol (71 mg, 49%, using pure EtOAc).  
1-(Phenylseleno)-oct-7-ene-2-ol: 1H NMR (400 MHz, CDCl3) δ 1.34-1.38 (m, 4H), 
1.50-1.53 (m, 2H), 2.02 (d, J = 6.8 Hz, 2H), 2.38 (d, J = 4Hz, 1H), 2.84-2.90 (m, 1H), 
3.11-3.15 (m, 1H), 3.65 (bs, 1H), 4.90-4.50 (m, 2H), 5.77-5.78 (m, 1H), 7.25-7.27 (m, 
3H), 7.50-7.53 (m, 2H); [α]19obsd -36.4 (for 99% ee of R), [α]19D -36.7, calcd (c = 1.1, 
CHCl3). The enantiomeric excess of this seleno alcohol was estimated by chiral HPLC 
(Chiralcel OD, hexanes/i-PrOH 97 :3, flow rate 1 mL/min, 254 nm), tRmajor = 11.6 min (R) 
and tRminor = 13.8 min (S). 
Oct-7-ene-1,2-diol: 1H NMR (400 MHz, CDCl3) δ 1.29-1.46 (m, 6H), 2.01-2.06 (m, 2H), 
3.05 (br s, 2H), 3.37-3.41 (m, 1H), 3.60-3.65 (m, 2H), 4.90-4.99 (m, 2H), 5.72-5.82 (m, 
1H); [α]19obsd -2.6 (for 81% ee of S), [α]19D -3.2, calcd (c = 1.0, CHCl3).   
The enantiomeric excess of 7-octen-1,2-diol was determined by derivatization as its bis-
(p-bromobenzoate) ester and chiral HPLC analysis (Chiralcel OD column, hexanes/i-
PrOH, 97:3, flow rate 1 mL/min, 254 nm), tRminor = 15.0 min (R); tRmajor = 16.2 min (S). 
General Procedure B (Separation of the Epoxide and Diol HKR Products):   
(Illustrated for 3-phenoxy-1,2-epoxypropane).  This procedure is applicable to all 
remaining epoxides.   
3-Phenoxy-1,2-epoxypropane (Table 4.2, entry 2): 
Catalyst Co(III)-17c-3,5-DNB (5 mg, 0.005 mmol, 0.5 mol% 
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loading) was mixed with 3-phenoxy-1,2-epoxypropane (150 mg, 1 mmol) and 300 µL of 
CH2Cl2.  The mixture was cooled to 0 °C, and the reaction was initiated by adding 9 µL 
(0.5 equiv) of water and stirring was continued for 20 h at rt.  After the reaction, silica 
gel column chromatography provided the unreacted 3-phenoxy-1,2-epoxypropanee (71 
mg, 47%, using 50% ether in pentane) and 3-phenoxy-1,2-propanediol (77 mg, 46%, 
using 10% methanol in ether).   
3-Phenoxy-1,2-epoxypropane: 1H NMR (400 MHz, CDCl3) δ 2.73-2.79 (m, 1H), 2.89-
2.91 (t, J = 4.8 Hz, 1H), 3.33-3.37 (m, 1H), 3.94-4.04 (m, 1H), 4.19-4.25 (m, 1H), 6.88-
7.00 (m, 3H), 7.23-7.33 (m, 2H); [α]19obsd +22.3 (for 97% ee of S), [α]19D +23.0, calcd (c 
= 1.4, CHCl3). The enantiomers of this epoxide were separable using Chiralcel OD 
column. For the epoxide (hexanes:i-PrOH 87 :13, flow rate 1 mL/min), minor isomer, tR 
= 8.2 min (R) and major isomer, tR = 12.4 min (S).   
3-Phenoxy-1,2-propanediol: 1H NMR (400 MHz, CDCl3) δ 2.54 (br s, 1H), 3.03 (br s, 
1H), 3.71-3.84 (m, 2H), 4.01-4.11 (m, 3H), 6.88-6.98 (m, 3H), 7.23-7.30 (m, 2H); 
[α]19obsd -9.1 (for 92% ee of R), [α]19D -9.9, calcd (c = 1.4, CHCl3), [lit.16 [α]23D -10.0 (c = 
1.9, EtOH)]. The enantiomers of the diol were also separable using Chiralcel OD column. 
For the diol (hexanes:i-PrOH 90:10, flow rate 1 mL/min), major isomer, tR = 15.6 min (R) 
and minor isomer, tR = 33.7 min (S).   
6-[(tert-Butoxycarbonyl)-amino]-1,2-epoxyhexane (Table 4.2, entry 5):  
Following General Procedure B, catalyst Co(III)-17c-3,5-
DNB (5 mg, 0.05 mmol, 1 mol% loading) with 6-[(tert-
butoxycarbonyl)-amino]-1,2-epoxyhexane (107 mg, 0.5 mmol), 200 µL of THF and 
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water (4 µL, 0.2 mmol, 0.44 equiv) at rt for 35 h, provided the unreacted epoxide (59 mg, 
55%, using pure ether) and the diol (47 mg, 40%, using 30% methanol in ether) after 
silica gel column chromatography.   
6-[(tert-Butoxycarbonyl)-amino]-1,2-epoxyhexane: 1H NMR (400 MHz, CDCl3) δ 1.46 
(s, 9H), 1.48-1.60 (m, 6H), 2.43-2.45 (m, 1H), 2.71-2.74 (m, 1H), 3.10-3.11 (m, 1H), 
3.68 (m, 2H), 4.54 (br s, 1H); [α]19obsd +5.1 (for 72% ee of R), [α]19D +7.2, calcd (c = 1.1, 
CHCl3).  The enantiomeric excess of the epoxide was determined by converting the 
epoxide to 6-[(tert-butoxycarbonyl)-amino]-1-(phenylseleno)-2-hexanol.   
6-[(tert-Butoxycarbonyl)-amino]-1-(phenylseleno)-2-hexanol: 1H NMR (400 MHz, 
CDCl3) δ 1.42 (s, 9H), 1.45-1.57 (m, 6H), 2.42 (br s, 1H), 2.84-2.89 (m, 1H), 3.08-3.13 
(m, 3H), 3.64-3.66 (m, 1H), 4.50 (br s, 1H), 7.24-7.27 (m, 3H), 7.50-7.52 (m, 2H), 
[α]19obsd -10.5 (for 72% ee of R), [α]19D -14.6, calcd (c = 0.3, CHCl3). The enantiomers of 
the seleno-alcohol were resolved on a Chiralcel OD column (92:8 hexanes:i-PrOH, flow 
rate: 1 mL/min), tRmajor = 16.0 min (R) and tRminor = 18.6 min (S).   
6-[(tert-Butoxycarbonyl)-amino]-1,2-hexanediol: 1H NMR (400 MHz, CDCl3) δ 1.43 (s, 
9H), 1.45-1.61 (m, 6H), 1.97 (br s, 1H), 2.16 (br s, 1H), 3.12-3.13 (m, 2H), 3.41-3.47 (m, 
1H), 3.61-3.71 (m, 2H), 4.54 (br s, 1H); [α]19obsd -9.7 (for 92% ee of S), [α]19D -10.5, 
calcd (c = 1.0, CHCl3). The diol was derivatized to its bis(p-bromobenzoate) and the 
enantiomers of the diol derivative were resolved using Chiralcel OD column (95:5 
hexanes:i-PrOH, flow rate 1 mL/min), tRminor = 24.9 min (R) and tRmajor = 29.8 min (S).   
4-Benzyloxy-1,2-epoxybutane (Table 4.2, entry 7):   
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Following General Procedure B, catalyst Co(III)-17c-3,5-
DNB (5 mg, 0.005 mmol, 0.5 mol% loading), 4-benzyloxy-
1,2-epoxybutane17 (178 mg, 1.0 mmol), 400 µL of CH2Cl2 and 9 µL of water at rt for 20 
h provided the unreacted epoxide (121 mg, 68%, using 25% ether in pentane) and the 
product diol (51 mg, 26%, 0100% EtOAc in ether), after silica gel column 
chromatography. 
4-Benzyloxy-1,2-epoxybutane: 1H NMR (400 MHz, CDCl3) δ 1.77-1.84 (m, 1H), 1.89-
1.95 (m, 1H), 2.54-2.56 (m, 1H), 2.79-2.82 (m, 1H), 3.07-3.12 (m, 1H), 3.63-3.67 (m, 
2H), 4.56 (s, 2H), 7.28-7.38 (m, 5H); [α]23obsd +6.40 (for 39% ee of R), [α]23D +16.41, 
calcd (c = 1.0, CHCl3), [lit.18 [α]D +16.6, (c = 3.0, CHCl3) for R-epoxide and [α]D -13.9, 
(c = 2.0, CHCl3) for S-epoxide, lit.19 [α]D +16.9, (c = 2.51, CHCl3) for R-epoxide and 
[α]D -14.5, (c = 2.51, CHCl3) for S-epoxide].  The enantiomeric excess of the epoxide 
was determined by converting the epoxide to 4-benzyloxy-1-phenylseleno-2-butanol with 
phenyl selenide.   
4-Benzyloxy-1-phenylseleno-2-butanol: 1H NMR (400 MHz, CDCl3) δ 1.85-1.89 (m, 
2H), 2.97-3.09 (m, 2H), 3.16 (br s, 1H), 3.62-3.68 (m, 2H), 3.93-3.96 (br s, 1H), 4.49 (s, 
2H), 7.22-7.32 (m, 8H), 7.49-7.52 (m, 2H).  The enantiomeric excess was determined 
from HPLC using Chiralcel OD column (95:5 hexanes:i-PrOH, flow rate 1 mL/min), 
tRmajor = 9.3 min (R) and tRminor = 13.9 min (S).   
4-Benzyloxy-1,2-butanediol: 1H NMR (400 MHz, CDCl3) δ 1.71-1.82 (m, 2H), 2.59 (br 
s, 1H), 3.25 (br s, 1H), 3.46-3.50 (m, 1H), 3.59-3.69 (m, 3H), 3.70-3.91 (m, 1H), 4.50 (s, 
2H), 7.25-7.36 (m, 5H); [α]23obsd -16.46 (for 86% ee of S), [α]23D -19.14, calcd (c = 0.65, 
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EtOH), [lit.16 [α]23D -22.5, (c = 1.1, EtOH) for S-diol].  The enantiomers were resolved in 
chiral HPLC. (Chiralcel OD column, hexanes:i-PrOH 95:5, flow rate 1 mL/min), tRminor = 
21.2 min (R) and tRmajor = 23.2 min (S). 
 
5-[(tert-butyldiphenylsilyl)oxy]-1,2-epoxypentane (Table 4.2, entry 8):  
Following General Procedure B, the catalyst Co(III)-17c-
3,5-DNB (10 mg, 0.01 mmol, 1 mol% loading) was mixed 
with 5-[(t-butyldiphenylsilyl)oxy]-1,2-epoxypentane17 (343 mg, 1 mmol) and 500 µL of 
THF.  The mixture was cooled to 0 °C, and the reaction initiated by adding 9 µL (0.5 
equiv) of water and stirring continued for 50 h at rt.  After the reaction, silica gel column 
chromatography provided the unreacted epoxide (214 mg, 63%, using ether) and 5-[(tert-
butyldiphenylsilyl)oxy]-1,2-pentanediol (104 mg, 29%, using 10% methanol in ether).20   
5-[(tert-Butyldiphenylsilyl)oxy]-1,2-epoxypentane: 1H NMR (400 MHz, CDCl3) δ 1.04 
(s, 9H), 1.65-1.71 (m, 4H), 2.44-2.46 (m, 1H), 2.71-2.73 (m, 1H), 2.90-2.91 (m, 1H), 
3.68-3.71 (m, 2H), 7.25-7.41 (m, 8H), 7.64-7.66 (m, 2H); [α]19obsd +1.0 (for 33 ee of R), 
[α]19D +3.15, calcd (c = 1.0, CHCl3), [lit.20 [α]D -3.41, (c = 1.12, CHCl3) for S-epoxide, 
lit.21 [α]20D -2.71, (c = 1.1, CHCl3) for S-epoxide]. The enantiomeric excess of the 
epoxide was determined by converting the epoxide to 5-[(tert-butyldiphenylsilyl)oxy]-1-
(phenylseleno)-pentane-2-ol.   
5-[(tert-Butyldiphenylsilyl)oxy]-1-(phenylseleno)-2-pentanol: 1H NMR (400 MHz, 
CDCl3) δ 1.01 (s, 9H), 1.57-1.71 (m, 4H), 2.75 (d, J = 3.6 Hz, 1H), 2.90-2.95 (m, 1H), 
3.08-3.12 (m, 1H), 3.65 (t, J = 4.0 Hz, 2H), 3.68-3.74 (m, 1H), 7.23-7.26 (m, 3H), 7.34-
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7.41 (m, 6H), 7.50-7.53 (m, 2H), 7.64 (dd, J = 1.6, 8.0 Hz, 4H).  The enantiomeric excess 
was estimated using chiral HPLC (Chiralcel OD, hexanes:iPrOH 98:2, flow rate: 1 
mL/min), tRminor = 17.7 min (S) and tRmajor = 19.0 min (R).   
5-(tert-Butyldiphenylsilyloxy)-pentane-l,2-diol: 1H NMR (400 MHz, CDCl3) δ1.01 (s, 
9H), 1.58-1.73 (m, 4H), 2.16-2.19 (br s, 1H), 3.02 (br s, 1H), 3.42-3.47 (m, 1H), 3.63-
3.87 (m, 4H), 7.25-7.41 (m, 8H), 7.64-7.66 (m, 2H); [α]19obsd -2.8 (for 90% ee of S), 
[α]19D -3.0, calcd (c = 1.2, CHCl3); [lit20. [α]D -1.27, c = 1.73, CHCl3 for S-diol; lit.21 
[α]20D -1.0, (c = 1.03, CH2Cl2) for S-diol; lit.22 [α]19D +1.0, (c = 0.39, CHCl3) for R-diol].  
The diol was derivatized as its bis(p-bromobenzoate) ester, and the enantiomers were 
resolved on a Chiralcel OD column (hexanes:i-PrOH 96:4, flow rate: 1 mL/min), tRminor = 
7.3 min (R) and tRmajor = 8.8 min (S).   
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V. NMR Spectra  
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